id	sid	tid	token	lemma	pos
ghmj-960	1	1	knowledge	knowledge	NOUN
ghmj-960	1	2	,	,	PUNCT
ghmj-960	1	3	attitudes	attitude	NOUN
ghmj-960	1	4	,	,	PUNCT
ghmj-960	1	5	and	and	CCONJ
ghmj-960	1	6	hiv	hiv	PROPN
ghmj-960	1	7	/	/	SYM
ghmj-960	1	8	aids	aids	PROPN
ghmj-960	1	9	risk	risk	NOUN
ghmj-960	1	10	behaviors	behavior	NOUN
ghmj-960	1	11	of	of	ADP
ghmj-960	1	12	myanmar	myanmar	PROPN
ghmj-960	1	13	migrant	migrant	ADJ
ghmj-960	1	14	workers	worker	NOUN
ghmj-960	1	15	in	in	ADP
ghmj-960	1	16	thailand	thailand	PROPN
ghmj-960	1	17	ghmj	ghmj	PROPN
ghmj-960	1	18	(	(	PUNCT
ghmj-960	1	19	global	global	ADJ
ghmj-960	1	20	health	health	PROPN
ghmj-960	1	21	management	management	NOUN
ghmj-960	1	22	journal	journal	PROPN
ghmj-960	1	23	)	)	PUNCT
ghmj-960	1	24	2023	2023	NUM
ghmj-960	1	25	,	,	PUNCT
ghmj-960	1	26	vol	vol	NOUN
ghmj-960	1	27	.	.	PROPN
ghmj-960	1	28	6	6	NUM
ghmj-960	1	29	,	,	PUNCT
ghmj-960	1	30	no	no	INTJ
ghmj-960	1	31	.	.	NOUN
ghmj-960	1	32	2	2	NUM
ghmj-960	1	33	indonesian	indonesian	ADJ
ghmj-960	1	34	scholars	scholar	NOUN
ghmj-960	1	35	’	'	PUNCT
ghmj-960	1	36	alliance	alliance	NOUN
ghmj-960	1	37	open	open	ADJ
ghmj-960	1	38	access	access	NOUN
ghmj-960	1	39	review	review	NOUN
ghmj-960	1	40	prevalence	prevalence	NOUN
ghmj-960	1	41	,	,	PUNCT
ghmj-960	1	42	pathophysiology	pathophysiology	NOUN
ghmj-960	1	43	,	,	PUNCT
ghmj-960	1	44	and	and	CCONJ
ghmj-960	1	45	treatment	treatment	NOUN
ghmj-960	1	46	of	of	ADP
ghmj-960	1	47	urticaria	urticaria	NOUN
ghmj-960	1	48	post	post	ADJ
ghmj-960	1	49	-	-	ADJ
ghmj-960	1	50	covid-19	covid-19	ADJ
ghmj-960	1	51	vaccination	vaccination	NOUN
ghmj-960	1	52	:	:	PUNCT
ghmj-960	1	53	a	a	DET
ghmj-960	1	54	systematic	systematic	ADJ
ghmj-960	1	55	review	review	NOUN
ghmj-960	1	56	ardhina	ardhina	PROPN
ghmj-960	1	57	nugrahaeni	nugrahaeni	PROPN
ghmj-960	1	58	1	1	NUM
ghmj-960	1	59	,	,	PUNCT
ghmj-960	1	60	rani	rani	PROPN
ghmj-960	1	61	tiyas	tiyas	PROPN
ghmj-960	1	62	budiyanti	budiyanti	PROPN
ghmj-960	1	63	2	2	NUM
ghmj-960	1	64	1	1	NUM
ghmj-960	1	65	center	center	NOUN
ghmj-960	1	66	for	for	ADP
ghmj-960	1	67	health	health	NOUN
ghmj-960	1	68	policy	policy	NOUN
ghmj-960	1	69	and	and	CCONJ
ghmj-960	1	70	management	management	NOUN
ghmj-960	1	71	,	,	PUNCT
ghmj-960	1	72	faculty	faculty	NOUN
ghmj-960	1	73	of	of	ADP
ghmj-960	1	74	medicine	medicine	NOUN
ghmj-960	1	75	,	,	PUNCT
ghmj-960	1	76	public	public	ADJ
ghmj-960	1	77	health	health	NOUN
ghmj-960	1	78	,	,	PUNCT
ghmj-960	1	79	and	and	CCONJ
ghmj-960	1	80	nursing	nursing	NOUN
ghmj-960	1	81	,	,	PUNCT
ghmj-960	1	82	gadjah	gadjah	PROPN
ghmj-960	1	83	mada	mada	PROPN
ghmj-960	1	84	university	university	PROPN
ghmj-960	1	85	,	,	PUNCT
ghmj-960	1	86	yogyakarta	yogyakarta	PROPN
ghmj-960	1	87	,	,	PUNCT
ghmj-960	1	88	indonesia	indonesia	PROPN
ghmj-960	1	89	.	.	PROPN
ghmj-960	1	90	2	2	NUM
ghmj-960	1	91	faculty	faculty	NOUN
ghmj-960	1	92	of	of	ADP
ghmj-960	1	93	public	public	ADJ
ghmj-960	1	94	health	health	NOUN
ghmj-960	1	95	,	,	PUNCT
ghmj-960	1	96	universitas	universita	NOUN
ghmj-960	1	97	diponegoro	diponegoro	PROPN
ghmj-960	1	98	,	,	PUNCT
ghmj-960	1	99	semarang	semarang	PROPN
ghmj-960	1	100	,	,	PUNCT
ghmj-960	1	101	indonesia	indonesia	PROPN
ghmj-960	1	102	.	.	PUNCT
ghmj-960	2	1	*	*	PUNCT
ghmj-960	2	2	corresponding	correspond	VERB
ghmj-960	2	3	author	author	NOUN
ghmj-960	2	4	’s	’s	PART
ghmj-960	2	5	email	email	NOUN
ghmj-960	2	6	:	:	PUNCT
ghmj-960	2	7	ardhinanugrahaeni@gmail.com	ardhinanugrahaeni@gmail.com	X
ghmj-960	2	8	doi	doi	NOUN
ghmj-960	2	9	:	:	PUNCT
ghmj-960	2	10	10.35898	10.35898	NUM
ghmj-960	2	11	/	/	SYM
ghmj-960	2	12	ghmj-62960	ghmj-62960	ADJ
ghmj-960	2	13	abstract	abstract	ADJ
ghmj-960	2	14	background	background	NOUN
ghmj-960	2	15	:	:	PUNCT
ghmj-960	2	16	vaccination	vaccination	NOUN
ghmj-960	2	17	for	for	ADP
ghmj-960	2	18	covid-19	covid-19	PROPN
ghmj-960	2	19	has	have	AUX
ghmj-960	2	20	been	be	AUX
ghmj-960	2	21	intensively	intensively	ADV
ghmj-960	2	22	developed	develop	VERB
ghmj-960	2	23	since	since	SCONJ
ghmj-960	2	24	the	the	DET
ghmj-960	2	25	end	end	NOUN
ghmj-960	2	26	of	of	ADP
ghmj-960	2	27	2020	2020	NUM
ghmj-960	2	28	.	.	PUNCT
ghmj-960	3	1	its	its	PRON
ghmj-960	3	2	use	use	NOUN
ghmj-960	3	3	must	must	AUX
ghmj-960	3	4	also	also	ADV
ghmj-960	3	5	obtain	obtain	VERB
ghmj-960	3	6	an	an	DET
ghmj-960	3	7	emergency	emergency	NOUN
ghmj-960	3	8	use	use	NOUN
ghmj-960	3	9	authorization	authorization	NOUN
ghmj-960	3	10	(	(	PUNCT
ghmj-960	3	11	eua	eua	PROPN
ghmj-960	3	12	)	)	PUNCT
ghmj-960	3	13	permit	permit	NOUN
ghmj-960	3	14	.	.	PUNCT
ghmj-960	4	1	some	some	PRON
ghmj-960	4	2	of	of	ADP
ghmj-960	4	3	the	the	DET
ghmj-960	4	4	vaccines	vaccine	NOUN
ghmj-960	4	5	have	have	AUX
ghmj-960	4	6	been	be	AUX
ghmj-960	4	7	used	use	VERB
ghmj-960	4	8	including	include	VERB
ghmj-960	4	9	sinovac	sinovac	PROPN
ghmj-960	4	10	,	,	PUNCT
ghmj-960	4	11	astra	astra	PROPN
ghmj-960	4	12	zeneca	zeneca	PROPN
ghmj-960	4	13	,	,	PUNCT
ghmj-960	4	14	moderna	moderna	PROPN
ghmj-960	4	15	,	,	PUNCT
ghmj-960	4	16	pfizer	pfizer	PROPN
ghmj-960	4	17	,	,	PUNCT
ghmj-960	4	18	johnson	johnson	PROPN
ghmj-960	4	19	&	&	CCONJ
ghmj-960	4	20	johnson	johnson	PROPN
ghmj-960	4	21	,	,	PUNCT
ghmj-960	4	22	and	and	CCONJ
ghmj-960	4	23	sinopharm	sinopharm	NOUN
ghmj-960	4	24	.	.	PUNCT
ghmj-960	5	1	in	in	ADP
ghmj-960	5	2	fact	fact	NOUN
ghmj-960	5	3	,	,	PUNCT
ghmj-960	5	4	there	there	PRON
ghmj-960	5	5	are	be	VERB
ghmj-960	5	6	many	many	ADJ
ghmj-960	5	7	effects	effect	NOUN
ghmj-960	5	8	that	that	PRON
ghmj-960	5	9	have	have	AUX
ghmj-960	5	10	developed	develop	VERB
ghmj-960	5	11	after	after	ADP
ghmj-960	5	12	the	the	DET
ghmj-960	5	13	covid-19	covid-19	PROPN
ghmj-960	5	14	vaccination	vaccination	NOUN
ghmj-960	5	15	administration	administration	NOUN
ghmj-960	5	16	like	like	ADP
ghmj-960	5	17	local	local	ADJ
ghmj-960	5	18	reactions	reaction	NOUN
ghmj-960	5	19	,	,	PUNCT
ghmj-960	5	20	systemic	systemic	ADJ
ghmj-960	5	21	reactions	reaction	NOUN
ghmj-960	5	22	,	,	PUNCT
ghmj-960	5	23	and	and	CCONJ
ghmj-960	5	24	other	other	ADJ
ghmj-960	5	25	reactions	reaction	NOUN
ghmj-960	5	26	.	.	PUNCT
ghmj-960	6	1	in	in	ADP
ghmj-960	6	2	addition	addition	NOUN
ghmj-960	6	3	,	,	PUNCT
ghmj-960	6	4	one	one	NUM
ghmj-960	6	5	of	of	ADP
ghmj-960	6	6	them	they	PRON
ghmj-960	6	7	is	be	AUX
ghmj-960	6	8	urticaria	urticaria	NOUN
ghmj-960	6	9	.	.	PUNCT
ghmj-960	7	1	however	however	ADV
ghmj-960	7	2	,	,	PUNCT
ghmj-960	7	3	the	the	DET
ghmj-960	7	4	existing	exist	VERB
ghmj-960	7	5	literature	literature	NOUN
ghmj-960	7	6	has	have	AUX
ghmj-960	7	7	focused	focus	VERB
ghmj-960	7	8	poorly	poorly	ADV
ghmj-960	7	9	on	on	ADP
ghmj-960	7	10	urticaria	urticaria	NOUN
ghmj-960	7	11	caused	cause	VERB
ghmj-960	7	12	by	by	ADP
ghmj-960	7	13	covid-19	covid-19	PROPN
ghmj-960	7	14	vaccines	vaccine	NOUN
ghmj-960	7	15	.	.	PUNCT
ghmj-960	8	1	aims	aim	NOUN
ghmj-960	8	2	:	:	PUNCT
ghmj-960	8	3	this	this	DET
ghmj-960	8	4	research	research	NOUN
ghmj-960	8	5	explores	explore	VERB
ghmj-960	8	6	the	the	DET
ghmj-960	8	7	prevalence	prevalence	NOUN
ghmj-960	8	8	,	,	PUNCT
ghmj-960	8	9	pathophysiology	pathophysiology	NOUN
ghmj-960	8	10	,	,	PUNCT
ghmj-960	8	11	and	and	CCONJ
ghmj-960	8	12	treatment	treatment	NOUN
ghmj-960	8	13	of	of	ADP
ghmj-960	8	14	urticaria	urticaria	NOUN
ghmj-960	8	15	post	post	ADJ
ghmj-960	8	16	-	-	ADJ
ghmj-960	8	17	covid19	covid19	ADJ
ghmj-960	8	18	vaccination	vaccination	NOUN
ghmj-960	8	19	.	.	PUNCT
ghmj-960	9	1	methods	method	NOUN
ghmj-960	9	2	:	:	PUNCT
ghmj-960	9	3	this	this	DET
ghmj-960	9	4	study	study	NOUN
ghmj-960	9	5	conducted	conduct	VERB
ghmj-960	9	6	a	a	DET
ghmj-960	9	7	systematic	systematic	ADJ
ghmj-960	9	8	review	review	NOUN
ghmj-960	9	9	based	base	VERB
ghmj-960	9	10	on	on	ADP
ghmj-960	9	11	the	the	DET
ghmj-960	9	12	guideline	guideline	NOUN
ghmj-960	9	13	which	which	PRON
ghmj-960	9	14	is	be	AUX
ghmj-960	9	15	preferred	prefer	VERB
ghmj-960	9	16	reporting	reporting	NOUN
ghmj-960	9	17	items	item	NOUN
ghmj-960	9	18	for	for	ADP
ghmj-960	9	19	systematic	systematic	ADJ
ghmj-960	9	20	reviews	review	NOUN
ghmj-960	9	21	and	and	CCONJ
ghmj-960	9	22	meta	meta	NOUN
ghmj-960	9	23	-	-	PUNCT
ghmj-960	9	24	analyses	analysis	NOUN
ghmj-960	9	25	(	(	PUNCT
ghmj-960	9	26	prisma	prisma	PROPN
ghmj-960	9	27	)	)	PUNCT
ghmj-960	9	28	.	.	PUNCT
ghmj-960	10	1	we	we	PRON
ghmj-960	10	2	searched	search	VERB
ghmj-960	10	3	scopus	scopus	NOUN
ghmj-960	10	4	,	,	PUNCT
ghmj-960	10	5	proquest	proquest	PROPN
ghmj-960	10	6	,	,	PUNCT
ghmj-960	10	7	ebsco	ebsco	PROPN
ghmj-960	10	8	,	,	PUNCT
ghmj-960	10	9	and	and	CCONJ
ghmj-960	10	10	google	google	PROPN
ghmj-960	10	11	scholar	scholar	NOUN
ghmj-960	10	12	databases	database	NOUN
ghmj-960	10	13	from	from	ADP
ghmj-960	10	14	2020	2020	NUM
ghmj-960	10	15	until	until	ADP
ghmj-960	10	16	2022	2022	NUM
ghmj-960	10	17	for	for	ADP
ghmj-960	10	18	identifying	identify	VERB
ghmj-960	10	19	the	the	DET
ghmj-960	10	20	data	datum	NOUN
ghmj-960	10	21	regarding	regard	VERB
ghmj-960	10	22	urticaria	urticaria	PROPN
ghmj-960	10	23	post	post	ADJ
ghmj-960	10	24	-	-	ADJ
ghmj-960	10	25	covid-19	covid-19	ADJ
ghmj-960	10	26	vaccination	vaccination	NOUN
ghmj-960	10	27	.	.	PUNCT
ghmj-960	11	1	in	in	ADP
ghmj-960	11	2	a	a	DET
ghmj-960	11	3	nutshell	nutshell	NOUN
ghmj-960	11	4	,	,	PUNCT
ghmj-960	11	5	9	9	NUM
ghmj-960	11	6	studies	study	NOUN
ghmj-960	11	7	were	be	AUX
ghmj-960	11	8	included	include	VERB
ghmj-960	11	9	in	in	ADP
ghmj-960	11	10	the	the	DET
ghmj-960	11	11	systematic	systematic	ADJ
ghmj-960	11	12	review	review	NOUN
ghmj-960	11	13	.	.	PUNCT
ghmj-960	12	1	results	result	NOUN
ghmj-960	12	2	:	:	PUNCT
ghmj-960	12	3	only	only	ADV
ghmj-960	12	4	28	28	NUM
ghmj-960	12	5	%	%	NOUN
ghmj-960	12	6	of	of	ADP
ghmj-960	12	7	urticarial	urticarial	ADJ
ghmj-960	12	8	rashes	rash	NOUN
ghmj-960	12	9	incident	incident	NOUN
ghmj-960	12	10	among	among	ADP
ghmj-960	12	11	all	all	DET
ghmj-960	12	12	cutaneous	cutaneous	ADJ
ghmj-960	12	13	adverse	adverse	ADJ
ghmj-960	12	14	reactions	reaction	NOUN
ghmj-960	12	15	after	after	ADP
ghmj-960	12	16	postcovid-19	postcovid-19	PROPN
ghmj-960	12	17	,	,	PUNCT
ghmj-960	12	18	it	it	PRON
ghmj-960	12	19	was	be	AUX
ghmj-960	12	20	higher	high	ADJ
ghmj-960	12	21	among	among	ADP
ghmj-960	12	22	females	female	NOUN
ghmj-960	12	23	and	and	CCONJ
ghmj-960	12	24	people	people	NOUN
ghmj-960	12	25	aged	age	VERB
ghmj-960	12	26	45	45	NUM
ghmj-960	12	27	-	-	SYM
ghmj-960	12	28	49	49	NUM
ghmj-960	12	29	years	year	NOUN
ghmj-960	12	30	old	old	ADJ
ghmj-960	12	31	,	,	PUNCT
ghmj-960	12	32	and	and	CCONJ
ghmj-960	12	33	people	people	NOUN
ghmj-960	12	34	with	with	ADP
ghmj-960	12	35	allergy	allergy	NOUN
ghmj-960	12	36	histories	history	NOUN
ghmj-960	12	37	.	.	PUNCT
ghmj-960	13	1	the	the	DET
ghmj-960	13	2	most	most	ADV
ghmj-960	13	3	frequent	frequent	ADJ
ghmj-960	13	4	reaction	reaction	NOUN
ghmj-960	13	5	is	be	AUX
ghmj-960	13	6	urticarial	urticarial	ADJ
ghmj-960	13	7	following	follow	VERB
ghmj-960	13	8	the	the	DET
ghmj-960	13	9	covid-19	covid-19	PROPN
ghmj-960	13	10	vaccine	vaccine	NOUN
ghmj-960	13	11	administration	administration	NOUN
ghmj-960	13	12	.	.	PUNCT
ghmj-960	14	1	this	this	DET
ghmj-960	14	2	concerns	concern	NOUN
ghmj-960	14	3	hypersensitivity	hypersensitivity	NOUN
ghmj-960	14	4	reaction	reaction	NOUN
ghmj-960	14	5	related	relate	VERB
ghmj-960	14	6	to	to	ADP
ghmj-960	14	7	immunoglobulin	immunoglobulin	NOUN
ghmj-960	14	8	e	e	PROPN
ghmj-960	14	9	(	(	PUNCT
ghmj-960	14	10	ige	ige	PROPN
ghmj-960	14	11	)	)	PUNCT
ghmj-960	14	12	mediated	mediate	VERB
ghmj-960	14	13	,	,	PUNCT
ghmj-960	14	14	immunoglobulin	immunoglobulin	NOUN
ghmj-960	14	15	g	g	PROPN
ghmj-960	14	16	(	(	PUNCT
ghmj-960	14	17	igg	igg	PROPN
ghmj-960	14	18	)	)	PUNCT
ghmj-960	14	19	,	,	PUNCT
ghmj-960	14	20	and	and	CCONJ
ghmj-960	14	21	sensitizing	sensitize	VERB
ghmj-960	14	22	excipients	excipient	NOUN
ghmj-960	14	23	in	in	ADP
ghmj-960	14	24	covid-19	covid-19	PROPN
ghmj-960	14	25	vaccines	vaccine	NOUN
ghmj-960	14	26	.	.	PUNCT
ghmj-960	15	1	conclusion	conclusion	NOUN
ghmj-960	15	2	:	:	PUNCT
ghmj-960	15	3	this	this	DET
ghmj-960	15	4	systematic	systematic	ADJ
ghmj-960	15	5	review	review	NOUN
ghmj-960	15	6	raises	raise	VERB
ghmj-960	15	7	the	the	DET
ghmj-960	15	8	concern	concern	NOUN
ghmj-960	15	9	of	of	ADP
ghmj-960	15	10	hypersensitivity	hypersensitivity	NOUN
ghmj-960	15	11	reaction	reaction	NOUN
ghmj-960	15	12	that	that	PRON
ghmj-960	15	13	related	relate	VERB
ghmj-960	15	14	to	to	ADP
ghmj-960	15	15	igemediated	igemediate	VERB
ghmj-960	15	16	,	,	PUNCT
ghmj-960	15	17	igg	igg	PROPN
ghmj-960	15	18	,	,	PUNCT
ghmj-960	15	19	and	and	CCONJ
ghmj-960	15	20	sensitizing	sensitize	VERB
ghmj-960	15	21	excipients	excipient	NOUN
ghmj-960	15	22	in	in	ADP
ghmj-960	15	23	covid-19	covid-19	PROPN
ghmj-960	15	24	vaccines	vaccine	NOUN
ghmj-960	15	25	.	.	PUNCT
ghmj-960	16	1	urticaria	urticaria	NOUN
ghmj-960	16	2	is	be	AUX
ghmj-960	16	3	the	the	DET
ghmj-960	16	4	most	most	ADV
ghmj-960	16	5	frequent	frequent	ADJ
ghmj-960	16	6	reaction	reaction	NOUN
ghmj-960	16	7	after	after	ADP
ghmj-960	16	8	the	the	DET
ghmj-960	16	9	covid-19	covid-19	PROPN
ghmj-960	16	10	vaccine	vaccine	NOUN
ghmj-960	16	11	administration	administration	NOUN
ghmj-960	16	12	.	.	PUNCT
ghmj-960	17	1	attention	attention	NOUN
ghmj-960	17	2	to	to	ADP
ghmj-960	17	3	medical	medical	ADJ
ghmj-960	17	4	history	history	NOUN
ghmj-960	17	5	and	and	CCONJ
ghmj-960	17	6	immunology	immunology	NOUN
ghmj-960	17	7	/	/	SYM
ghmj-960	17	8	allergy	allergy	NOUN
ghmj-960	17	9	consultation	consultation	NOUN
ghmj-960	17	10	might	might	AUX
ghmj-960	17	11	be	be	AUX
ghmj-960	17	12	advantageous	advantageous	ADJ
ghmj-960	17	13	to	to	PART
ghmj-960	17	14	assess	assess	VERB
ghmj-960	17	15	the	the	DET
ghmj-960	17	16	risk	risk	NOUN
ghmj-960	17	17	of	of	ADP
ghmj-960	17	18	allergy	allergy	NOUN
ghmj-960	17	19	and	and	CCONJ
ghmj-960	17	20	the	the	DET
ghmj-960	17	21	guidance	guidance	NOUN
ghmj-960	17	22	of	of	ADP
ghmj-960	17	23	the	the	DET
ghmj-960	17	24	vaccine	vaccine	NOUN
ghmj-960	17	25	.	.	PUNCT
ghmj-960	18	1	keywords	keyword	NOUN
ghmj-960	18	2	:	:	PUNCT
ghmj-960	18	3	urticaria	urticaria	NOUN
ghmj-960	18	4	,	,	PUNCT
ghmj-960	18	5	post	post	ADJ
ghmj-960	18	6	-	-	ADJ
ghmj-960	18	7	covid-19	covid-19	ADJ
ghmj-960	18	8	vaccination	vaccination	NOUN
ghmj-960	18	9	,	,	PUNCT
ghmj-960	18	10	mrna	mrna	PROPN
ghmj-960	18	11	vaccines	vaccine	NOUN
ghmj-960	18	12	,	,	PUNCT
ghmj-960	18	13	whole	whole	ADJ
ghmj-960	18	14	inactivated	inactivated	ADJ
ghmj-960	18	15	virus	virus	NOUN
ghmj-960	18	16	,	,	PUNCT
ghmj-960	18	17	hypersensitivity	hypersensitivity	NOUN
ghmj-960	18	18	reactions	reaction	NOUN
ghmj-960	18	19	.	.	PUNCT
ghmj-960	19	1	received	receive	VERB
ghmj-960	19	2	:	:	PUNCT
ghmj-960	19	3	9	9	NUM
ghmj-960	19	4	may	may	PROPN
ghmj-960	19	5	2023	2023	NUM
ghmj-960	19	6	;	;	PUNCT
ghmj-960	19	7	revised	revise	VERB
ghmj-960	19	8	:	:	PUNCT
ghmj-960	19	9	8	8	NUM
ghmj-960	19	10	june	june	PROPN
ghmj-960	19	11	2023	2023	NUM
ghmj-960	19	12	;	;	PUNCT
ghmj-960	19	13	accepted	accept	VERB
ghmj-960	19	14	:	:	PUNCT
ghmj-960	19	15	18	18	NUM
ghmj-960	19	16	july	july	PROPN
ghmj-960	19	17	2023	2023	NUM
ghmj-960	19	18	©	©	PROPN
ghmj-960	19	19	yayasan	yayasan	PROPN
ghmj-960	19	20	aliansi	aliansi	PROPN
ghmj-960	19	21	cendekiawan	cendekiawan	PROPN
ghmj-960	19	22	indonesia	indonesia	PROPN
ghmj-960	19	23	thailand	thailand	PROPN
ghmj-960	19	24	(	(	PUNCT
ghmj-960	19	25	indonesian	indonesian	ADJ
ghmj-960	19	26	scholars	scholar	NOUN
ghmj-960	19	27	’	’	PART
ghmj-960	19	28	alliance	alliance	NOUN
ghmj-960	19	29	)	)	PUNCT
ghmj-960	19	30	.	.	PUNCT
ghmj-960	20	1	this	this	PRON
ghmj-960	20	2	is	be	AUX
ghmj-960	20	3	an	an	DET
ghmj-960	20	4	open	open	ADJ
ghmj-960	20	5	-	-	PUNCT
ghmj-960	20	6	access	access	NOUN
ghmj-960	20	7	following	follow	VERB
ghmj-960	20	8	creative	creative	ADJ
ghmj-960	20	9	commons	common	NOUN
ghmj-960	20	10	license	license	NOUN
ghmj-960	20	11	deed	deed	NOUN
ghmj-960	20	12	attribution	attribution	NOUN
ghmj-960	20	13	-	-	PUNCT
ghmj-960	20	14	noncommercial	noncommercial	ADJ
ghmj-960	20	15	-	-	PUNCT
ghmj-960	20	16	sharealike	sharealike	ADJ
ghmj-960	20	17	4.0	4.0	NUM
ghmj-960	20	18	international	international	ADJ
ghmj-960	20	19	(	(	PUNCT
ghmj-960	20	20	cc	cc	NOUN
ghmj-960	20	21	by	by	ADP
ghmj-960	20	22	-	-	PUNCT
ghmj-960	20	23	nc	nc	PROPN
ghmj-960	20	24	-	-	PUNCT
ghmj-960	20	25	sa	sa	PROPN
ghmj-960	20	26	4.0	4.0	NUM
ghmj-960	20	27	)	)	PUNCT
ghmj-960	20	28	1	1	NUM
ghmj-960	20	29	.	.	PUNCT
ghmj-960	21	1	introduction	introduction	NOUN
ghmj-960	21	2	the	the	DET
ghmj-960	21	3	coronavirus	coronavirus	NOUN
ghmj-960	21	4	(	(	PUNCT
ghmj-960	21	5	covid-19	covid-19	PROPN
ghmj-960	21	6	)	)	PUNCT
ghmj-960	21	7	outbreak	outbreak	NOUN
ghmj-960	21	8	spread	spread	VERB
ghmj-960	21	9	rapidly	rapidly	ADV
ghmj-960	21	10	throughout	throughout	ADP
ghmj-960	21	11	the	the	DET
ghmj-960	21	12	entire	entire	ADJ
ghmj-960	21	13	world	world	NOUN
ghmj-960	21	14	and	and	CCONJ
ghmj-960	21	15	became	become	VERB
ghmj-960	21	16	a	a	DET
ghmj-960	21	17	new	new	ADJ
ghmj-960	21	18	challenge	challenge	NOUN
ghmj-960	21	19	for	for	ADP
ghmj-960	21	20	controlling	control	VERB
ghmj-960	21	21	the	the	DET
ghmj-960	21	22	pandemic	pandemic	ADJ
ghmj-960	21	23	and	and	CCONJ
ghmj-960	21	24	reducing	reduce	VERB
ghmj-960	21	25	its	its	PRON
ghmj-960	21	26	impact	impact	NOUN
ghmj-960	21	27	.	.	PUNCT
ghmj-960	22	1	it	it	PRON
ghmj-960	22	2	has	have	AUX
ghmj-960	22	3	affected	affect	VERB
ghmj-960	22	4	more	more	ADJ
ghmj-960	22	5	than	than	ADP
ghmj-960	22	6	600	600	NUM
ghmj-960	22	7	million	million	NUM
ghmj-960	22	8	people	people	NOUN
ghmj-960	22	9	worldwide	worldwide	ADV
ghmj-960	22	10	since	since	SCONJ
ghmj-960	22	11	declaring	declare	VERB
ghmj-960	22	12	in	in	ADP
ghmj-960	22	13	march	march	PROPN
ghmj-960	22	14	2020	2020	NUM
ghmj-960	22	15	by	by	ADP
ghmj-960	22	16	the	the	DET
ghmj-960	22	17	world	world	PROPN
ghmj-960	22	18	health	health	PROPN
ghmj-960	22	19	organization	organization	NOUN
ghmj-960	22	20	.	.	PUNCT
ghmj-960	23	1	vaccination	vaccination	NOUN
ghmj-960	23	2	is	be	AUX
ghmj-960	23	3	presently	presently	ADV
ghmj-960	23	4	a	a	DET
ghmj-960	23	5	safe	safe	ADJ
ghmj-960	23	6	and	and	CCONJ
ghmj-960	23	7	effective	effective	ADJ
ghmj-960	23	8	way	way	NOUN
ghmj-960	23	9	to	to	PART
ghmj-960	23	10	control	control	VERB
ghmj-960	23	11	covid-19	covid-19	PROPN
ghmj-960	23	12	.	.	PUNCT
ghmj-960	24	1	covid-19	covid-19	PROPN
ghmj-960	24	2	vaccination	vaccination	NOUN
ghmj-960	24	3	development	development	NOUN
ghmj-960	24	4	started	start	VERB
ghmj-960	24	5	at	at	ADP
ghmj-960	24	6	mailto:ardhinanugrahaeni@gmail.com	mailto:ardhinanugrahaeni@gmail.com	PROPN
ghmj-960	24	7	https://doi.org/10.35898/ghmj-62960	https://doi.org/10.35898/ghmj-62960	PROPN
ghmj-960	24	8	nugrahaeni	nugrahaeni	PROPN
ghmj-960	24	9	&	&	CCONJ
ghmj-960	24	10	budiyanti	budiyanti	PROPN
ghmj-960	24	11	ghmj	ghmj	PROPN
ghmj-960	24	12	(	(	PUNCT
ghmj-960	24	13	global	global	ADJ
ghmj-960	24	14	health	health	PROPN
ghmj-960	24	15	management	management	NOUN
ghmj-960	24	16	journal	journal	PROPN
ghmj-960	24	17	)	)	PUNCT
ghmj-960	24	18	2023	2023	NUM
ghmj-960	24	19	,	,	PUNCT
ghmj-960	24	20	vol	vol	NOUN
ghmj-960	24	21	.	.	PROPN
ghmj-960	24	22	6	6	NUM
ghmj-960	24	23	,	,	PUNCT
ghmj-960	24	24	no	no	INTJ
ghmj-960	24	25	.	.	NOUN
ghmj-960	24	26	2	2	NUM
ghmj-960	24	27	58	58	NUM
ghmj-960	24	28	the	the	DET
ghmj-960	24	29	end	end	NOUN
ghmj-960	24	30	of	of	ADP
ghmj-960	24	31	2020	2020	NUM
ghmj-960	24	32	.	.	PUNCT
ghmj-960	25	1	it	it	PRON
ghmj-960	25	2	holds	hold	VERB
ghmj-960	25	3	emergency	emergency	NOUN
ghmj-960	25	4	use	use	NOUN
ghmj-960	25	5	authorization	authorization	NOUN
ghmj-960	25	6	(	(	PUNCT
ghmj-960	25	7	eua	eua	PROPN
ghmj-960	25	8	)	)	PUNCT
ghmj-960	25	9	permit	permit	NOUN
ghmj-960	25	10	.	.	PUNCT
ghmj-960	26	1	according	accord	VERB
ghmj-960	26	2	to	to	ADP
ghmj-960	26	3	the	the	DET
ghmj-960	26	4	world	world	PROPN
ghmj-960	26	5	health	health	NOUN
ghmj-960	26	6	organization	organization	NOUN
ghmj-960	26	7	(	(	PUNCT
ghmj-960	26	8	who	who	PRON
ghmj-960	26	9	)	)	PUNCT
ghmj-960	26	10	,	,	PUNCT
ghmj-960	26	11	numerous	numerous	ADJ
ghmj-960	26	12	covid-19	covid-19	PROPN
ghmj-960	26	13	vaccines	vaccine	NOUN
ghmj-960	26	14	administered	administer	VERB
ghmj-960	26	15	such	such	ADJ
ghmj-960	26	16	as	as	ADP
ghmj-960	26	17	viral	viral	ADJ
ghmj-960	26	18	vectors	vector	NOUN
ghmj-960	26	19	(	(	PUNCT
ghmj-960	26	20	johnson	johnson	PROPN
ghmj-960	26	21	&	&	CCONJ
ghmj-960	26	22	johnson	johnson	PROPN
ghmj-960	26	23	's	's	PART
ghmj-960	26	24	janssen	janssen	PROPN
ghmj-960	26	25	and	and	CCONJ
ghmj-960	26	26	astrazeneca	astrazeneca	PROPN
ghmj-960	26	27	)	)	PUNCT
ghmj-960	26	28	,	,	PUNCT
ghmj-960	26	29	mrna	mrna	PROPN
ghmj-960	26	30	(	(	PUNCT
ghmj-960	26	31	pfizer	pfizer	NOUN
ghmj-960	26	32	and	and	CCONJ
ghmj-960	26	33	moderna	moderna	PROPN
ghmj-960	26	34	)	)	PUNCT
ghmj-960	26	35	,	,	PUNCT
ghmj-960	26	36	and	and	CCONJ
ghmj-960	26	37	inactivated	inactivated	ADJ
ghmj-960	26	38	virus	virus	NOUN
ghmj-960	26	39	(	(	PUNCT
ghmj-960	26	40	sinovac	sinovac	NOUN
ghmj-960	26	41	and	and	CCONJ
ghmj-960	26	42	sinopharm	sinopharm	NOUN
ghmj-960	26	43	)	)	PUNCT
ghmj-960	26	44	.	.	PUNCT
ghmj-960	27	1	adverse	adverse	ADJ
ghmj-960	27	2	events	event	NOUN
ghmj-960	27	3	following	follow	VERB
ghmj-960	27	4	immunization	immunization	NOUN
ghmj-960	27	5	(	(	PUNCT
ghmj-960	27	6	aefi	aefi	NOUN
ghmj-960	27	7	)	)	PUNCT
ghmj-960	27	8	are	be	AUX
ghmj-960	27	9	medical	medical	ADJ
ghmj-960	27	10	events	event	NOUN
ghmj-960	27	11	after	after	ADP
ghmj-960	27	12	immunization	immunization	NOUN
ghmj-960	27	13	.	.	PUNCT
ghmj-960	28	1	some	some	DET
ghmj-960	28	2	people	people	NOUN
ghmj-960	28	3	might	might	AUX
ghmj-960	28	4	have	have	VERB
ghmj-960	28	5	side	side	ADJ
ghmj-960	28	6	effects	effect	NOUN
ghmj-960	28	7	following	follow	VERB
ghmj-960	28	8	covid-19	covid-19	PROPN
ghmj-960	28	9	vaccination	vaccination	NOUN
ghmj-960	28	10	.	.	PUNCT
ghmj-960	29	1	common	common	ADJ
ghmj-960	29	2	side	side	NOUN
ghmj-960	29	3	effects	effect	NOUN
ghmj-960	29	4	consist	consist	VERB
ghmj-960	29	5	of	of	ADP
ghmj-960	29	6	pain	pain	NOUN
ghmj-960	29	7	or	or	CCONJ
ghmj-960	29	8	redness	redness	NOUN
ghmj-960	29	9	at	at	ADP
ghmj-960	29	10	the	the	DET
ghmj-960	29	11	injection	injection	NOUN
ghmj-960	29	12	site	site	NOUN
ghmj-960	29	13	,	,	PUNCT
ghmj-960	29	14	fever	fever	NOUN
ghmj-960	29	15	,	,	PUNCT
ghmj-960	29	16	headache	headache	NOUN
ghmj-960	29	17	,	,	PUNCT
ghmj-960	29	18	muscle	muscle	NOUN
ghmj-960	29	19	aches	ache	VERB
ghmj-960	29	20	,	,	PUNCT
ghmj-960	29	21	and	and	CCONJ
ghmj-960	29	22	fatigue	fatigue	NOUN
ghmj-960	29	23	.	.	PUNCT
ghmj-960	30	1	dermatologic	dermatologic	ADJ
ghmj-960	30	2	reactions	reaction	NOUN
ghmj-960	30	3	after	after	ADP
ghmj-960	30	4	administering	administer	VERB
ghmj-960	30	5	covid-19	covid-19	PROPN
ghmj-960	30	6	vaccinations	vaccination	NOUN
ghmj-960	30	7	became	become	VERB
ghmj-960	30	8	reality	reality	NOUN
ghmj-960	30	9	.	.	PUNCT
ghmj-960	31	1	urticaria	urticaria	NOUN
ghmj-960	31	2	is	be	AUX
ghmj-960	31	3	a	a	DET
ghmj-960	31	4	main	main	ADJ
ghmj-960	31	5	skin	skin	NOUN
ghmj-960	31	6	condition	condition	NOUN
ghmj-960	31	7	that	that	PRON
ghmj-960	31	8	is	be	AUX
ghmj-960	31	9	mast	mast	VERB
ghmj-960	31	10	cell	cell	NOUN
ghmj-960	31	11	-	-	PUNCT
ghmj-960	31	12	driven	drive	VERB
ghmj-960	31	13	disease	disease	NOUN
ghmj-960	31	14	.	.	PUNCT
ghmj-960	32	1	it	it	PRON
ghmj-960	32	2	shows	show	VERB
ghmj-960	32	3	angioedema	angioedema	ADV
ghmj-960	32	4	,	,	PUNCT
ghmj-960	32	5	wheels	wheel	NOUN
ghmj-960	32	6	(	(	PUNCT
ghmj-960	32	7	hives	hive	NOUN
ghmj-960	32	8	)	)	PUNCT
ghmj-960	32	9	,	,	PUNCT
ghmj-960	32	10	or	or	CCONJ
ghmj-960	32	11	both	both	PRON
ghmj-960	32	12	.	.	PUNCT
ghmj-960	33	1	the	the	DET
ghmj-960	33	2	active	active	ADJ
ghmj-960	33	3	skin	skin	NOUN
ghmj-960	33	4	mast	mast	NOUN
ghmj-960	33	5	cells	cell	NOUN
ghmj-960	33	6	discharge	discharge	VERB
ghmj-960	33	7	histamine	histamine	NOUN
ghmj-960	33	8	and	and	CCONJ
ghmj-960	33	9	other	other	ADJ
ghmj-960	33	10	mediators	mediator	NOUN
ghmj-960	33	11	like	like	ADP
ghmj-960	33	12	cytokines	cytokine	NOUN
ghmj-960	33	13	and	and	CCONJ
ghmj-960	33	14	platelet	platelet	NOUN
ghmj-960	33	15	-	-	PUNCT
ghmj-960	33	16	activating	activate	VERB
ghmj-960	33	17	factor	factor	NOUN
ghmj-960	33	18	(	(	PUNCT
ghmj-960	33	19	paf	paf	PROPN
ghmj-960	33	20	)	)	PUNCT
ghmj-960	33	21	.	.	PUNCT
ghmj-960	34	1	the	the	DET
ghmj-960	34	2	signals	signal	NOUN
ghmj-960	34	3	of	of	ADP
ghmj-960	34	4	mast	mast	NOUN
ghmj-960	34	5	cell	cell	NOUN
ghmj-960	34	6	activating	activate	VERB
ghmj-960	34	7	in	in	ADP
ghmj-960	34	8	urticaria	urticaria	NOUN
ghmj-960	34	9	are	be	AUX
ghmj-960	34	10	various	various	ADJ
ghmj-960	34	11	.	.	PUNCT
ghmj-960	35	1	these	these	PRON
ghmj-960	35	2	include	include	VERB
ghmj-960	35	3	autoantibodies	autoantibody	NOUN
ghmj-960	35	4	and	and	CCONJ
ghmj-960	35	5	t	t	NOUN
ghmj-960	35	6	-	-	PUNCT
ghmj-960	35	7	cell	cell	NOUN
ghmj-960	35	8	-	-	PUNCT
ghmj-960	35	9	driven	drive	VERB
ghmj-960	35	10	cytokines	cytokine	NOUN
ghmj-960	35	11	(	(	PUNCT
ghmj-960	35	12	zuberbier	zuberbier	NOUN
ghmj-960	35	13	,	,	PUNCT
ghmj-960	35	14	et	et	PROPN
ghmj-960	35	15	al	al	PROPN
ghmj-960	35	16	.	.	PROPN
ghmj-960	35	17	,	,	PUNCT
ghmj-960	35	18	2022	2022	NUM
ghmj-960	35	19	)	)	PUNCT
ghmj-960	35	20	.	.	PUNCT
ghmj-960	36	1	however	however	ADV
ghmj-960	36	2	,	,	PUNCT
ghmj-960	36	3	this	this	DET
ghmj-960	36	4	research	research	NOUN
ghmj-960	36	5	aims	aim	VERB
ghmj-960	36	6	to	to	PART
ghmj-960	36	7	explore	explore	VERB
ghmj-960	36	8	the	the	DET
ghmj-960	36	9	prevalence	prevalence	NOUN
ghmj-960	36	10	,	,	PUNCT
ghmj-960	36	11	cause	cause	NOUN
ghmj-960	36	12	,	,	PUNCT
ghmj-960	36	13	prevention	prevention	NOUN
ghmj-960	36	14	,	,	PUNCT
ghmj-960	36	15	and	and	CCONJ
ghmj-960	36	16	treatment	treatment	NOUN
ghmj-960	36	17	of	of	ADP
ghmj-960	36	18	urticaria	urticaria	NOUN
ghmj-960	36	19	post	post	ADJ
ghmj-960	36	20	-	-	ADJ
ghmj-960	36	21	covid-19	covid-19	ADJ
ghmj-960	36	22	vaccination	vaccination	NOUN
ghmj-960	36	23	.	.	PUNCT
ghmj-960	37	1	2	2	X
ghmj-960	37	2	.	.	X
ghmj-960	37	3	methods	method	NOUN
ghmj-960	37	4	the	the	DET
ghmj-960	37	5	research	research	NOUN
ghmj-960	37	6	was	be	AUX
ghmj-960	37	7	a	a	DET
ghmj-960	37	8	systematic	systematic	ADJ
ghmj-960	37	9	review	review	NOUN
ghmj-960	37	10	using	use	VERB
ghmj-960	37	11	the	the	DET
ghmj-960	37	12	prisma	prisma	PROPN
ghmj-960	37	13	model	model	NOUN
ghmj-960	37	14	.	.	PUNCT
ghmj-960	38	1	the	the	DET
ghmj-960	38	2	scope	scope	NOUN
ghmj-960	38	3	of	of	ADP
ghmj-960	38	4	this	this	DET
ghmj-960	38	5	research	research	NOUN
ghmj-960	38	6	includes	include	VERB
ghmj-960	38	7	the	the	DET
ghmj-960	38	8	prevalence	prevalence	NOUN
ghmj-960	38	9	,	,	PUNCT
ghmj-960	38	10	pathophysiology	pathophysiology	NOUN
ghmj-960	38	11	,	,	PUNCT
ghmj-960	38	12	and	and	CCONJ
ghmj-960	38	13	treatment	treatment	NOUN
ghmj-960	38	14	of	of	ADP
ghmj-960	38	15	urticaria	urticaria	NOUN
ghmj-960	38	16	after	after	ADP
ghmj-960	38	17	post	post	ADJ
ghmj-960	38	18	-	-	ADJ
ghmj-960	38	19	covid-19	covid-19	ADJ
ghmj-960	38	20	vaccination	vaccination	NOUN
ghmj-960	38	21	.	.	PUNCT
ghmj-960	39	1	the	the	DET
ghmj-960	39	2	keywords	keyword	NOUN
ghmj-960	39	3	that	that	PRON
ghmj-960	39	4	were	be	AUX
ghmj-960	39	5	used	use	VERB
ghmj-960	39	6	are	be	AUX
ghmj-960	39	7	“	"	PUNCT
ghmj-960	39	8	urticaria	urticaria	ADJ
ghmj-960	39	9	”	"	PUNCT
ghmj-960	39	10	“	"	PUNCT
ghmj-960	39	11	and	and	CCONJ
ghmj-960	39	12	”	"	PUNCT
ghmj-960	39	13	cause	cause	NOUN
ghmj-960	39	14	”	"	PUNCT
ghmj-960	39	15	“	"	PUNCT
ghmj-960	39	16	and	and	CCONJ
ghmj-960	39	17	”	"	PUNCT
ghmj-960	39	18	“	"	PUNCT
ghmj-960	39	19	prevalence	prevalence	NOUN
ghmj-960	39	20	”	"	PUNCT
ghmj-960	39	21	“	"	PUNCT
ghmj-960	39	22	and	and	CCONJ
ghmj-960	39	23	”	"	PUNCT
ghmj-960	39	24	treatment	treatment	NOUN
ghmj-960	39	25	”	"	PUNCT
ghmj-960	39	26	“	"	PUNCT
ghmj-960	39	27	and	and	CCONJ
ghmj-960	39	28	”	"	PUNCT
ghmj-960	39	29	“	"	PUNCT
ghmj-960	39	30	covid-19	covid-19	PROPN
ghmj-960	39	31	vaccination	vaccination	NOUN
ghmj-960	39	32	”	"	PUNCT
ghmj-960	39	33	.	.	PUNCT
ghmj-960	40	1	we	we	PRON
ghmj-960	40	2	used	use	VERB
ghmj-960	40	3	the	the	DET
ghmj-960	40	4	preferred	preferred	ADJ
ghmj-960	40	5	reporting	reporting	NOUN
ghmj-960	40	6	items	item	NOUN
ghmj-960	40	7	for	for	ADP
ghmj-960	40	8	systematic	systematic	ADJ
ghmj-960	40	9	reviews	review	NOUN
ghmj-960	40	10	and	and	CCONJ
ghmj-960	40	11	meta	meta	NOUN
ghmj-960	40	12	-	-	PUNCT
ghmj-960	40	13	analyses	analysis	NOUN
ghmj-960	40	14	(	(	PUNCT
ghmj-960	40	15	prisma	prisma	PROPN
ghmj-960	40	16	)	)	PUNCT
ghmj-960	40	17	flowchart	flowchart	NOUN
ghmj-960	40	18	and	and	CCONJ
ghmj-960	40	19	form	form	VERB
ghmj-960	40	20	the	the	DET
ghmj-960	40	21	basis	basis	NOUN
ghmj-960	40	22	for	for	ADP
ghmj-960	40	23	the	the	DET
ghmj-960	40	24	inclusion	inclusion	NOUN
ghmj-960	40	25	or	or	CCONJ
ghmj-960	40	26	exclusion	exclusion	NOUN
ghmj-960	40	27	criteria	criterion	NOUN
ghmj-960	40	28	of	of	ADP
ghmj-960	40	29	the	the	DET
ghmj-960	40	30	articles	article	NOUN
ghmj-960	40	31	.	.	PUNCT
ghmj-960	41	1	the	the	DET
ghmj-960	41	2	inclusion	inclusion	NOUN
ghmj-960	41	3	criteria	criterion	NOUN
ghmj-960	41	4	were	be	AUX
ghmj-960	41	5	articles	article	NOUN
ghmj-960	41	6	related	relate	VERB
ghmj-960	41	7	to	to	ADP
ghmj-960	41	8	urticaria	urticaria	PROPN
ghmj-960	41	9	post	post	ADJ
ghmj-960	41	10	-	-	ADJ
ghmj-960	41	11	covid-19	covid-19	ADJ
ghmj-960	41	12	vaccination	vaccination	NOUN
ghmj-960	41	13	that	that	PRON
ghmj-960	41	14	has	have	AUX
ghmj-960	41	15	been	be	AUX
ghmj-960	41	16	published	publish	VERB
ghmj-960	41	17	in	in	ADP
ghmj-960	41	18	scopus	scopus	PROPN
ghmj-960	41	19	,	,	PUNCT
ghmj-960	41	20	proquest	proquest	PROPN
ghmj-960	41	21	,	,	PUNCT
ghmj-960	41	22	ebsco	ebsco	PROPN
ghmj-960	41	23	,	,	PUNCT
ghmj-960	41	24	and	and	CCONJ
ghmj-960	41	25	google	google	PROPN
ghmj-960	41	26	scholar	scholar	NOUN
ghmj-960	41	27	databases	database	NOUN
ghmj-960	41	28	from	from	ADP
ghmj-960	41	29	2020	2020	NUM
ghmj-960	41	30	until	until	ADP
ghmj-960	41	31	2022	2022	NUM
ghmj-960	41	32	and	and	CCONJ
ghmj-960	41	33	open	open	ADJ
ghmj-960	41	34	access	access	NOUN
ghmj-960	41	35	.	.	PUNCT
ghmj-960	42	1	the	the	DET
ghmj-960	42	2	articles	article	NOUN
ghmj-960	42	3	should	should	AUX
ghmj-960	42	4	be	be	AUX
ghmj-960	42	5	related	relate	VERB
ghmj-960	42	6	to	to	ADP
ghmj-960	42	7	the	the	DET
ghmj-960	42	8	prevalence	prevalence	NOUN
ghmj-960	42	9	,	,	PUNCT
ghmj-960	42	10	pathophysiology	pathophysiology	NOUN
ghmj-960	42	11	,	,	PUNCT
ghmj-960	42	12	and	and	CCONJ
ghmj-960	42	13	treatment	treatment	NOUN
ghmj-960	42	14	of	of	ADP
ghmj-960	42	15	urticaria	urticaria	NOUN
ghmj-960	42	16	post	post	PROPN
ghmj-960	42	17	-	-	PROPN
ghmj-960	42	18	covid-19	covid-19	PROPN
ghmj-960	42	19	.	.	PUNCT
ghmj-960	43	1	the	the	DET
ghmj-960	43	2	exclusion	exclusion	NOUN
ghmj-960	43	3	criteria	criterion	NOUN
ghmj-960	43	4	were	be	AUX
ghmj-960	43	5	data	datum	NOUN
ghmj-960	43	6	that	that	PRON
ghmj-960	43	7	had	have	VERB
ghmj-960	43	8	unclear	unclear	ADJ
ghmj-960	43	9	characteristics	characteristic	NOUN
ghmj-960	43	10	,	,	PUNCT
ghmj-960	43	11	review	review	NOUN
ghmj-960	43	12	articles	article	NOUN
ghmj-960	43	13	,	,	PUNCT
ghmj-960	43	14	and	and	CCONJ
ghmj-960	43	15	not	not	PART
ghmj-960	43	16	full	full	ADJ
ghmj-960	43	17	paper	paper	NOUN
ghmj-960	43	18	articles	article	NOUN
ghmj-960	43	19	.	.	PUNCT
ghmj-960	44	1	the	the	DET
ghmj-960	44	2	authors	author	NOUN
ghmj-960	44	3	initially	initially	ADV
ghmj-960	44	4	collected	collect	VERB
ghmj-960	44	5	the	the	DET
ghmj-960	44	6	identified	identify	VERB
ghmj-960	44	7	records	record	NOUN
ghmj-960	44	8	from	from	ADP
ghmj-960	44	9	four	four	NUM
ghmj-960	44	10	databases	database	NOUN
ghmj-960	44	11	source	source	NOUN
ghmj-960	44	12	including	include	VERB
ghmj-960	44	13	scopus	scopus	NOUN
ghmj-960	44	14	,	,	PUNCT
ghmj-960	44	15	proquest	proquest	PROPN
ghmj-960	44	16	,	,	PUNCT
ghmj-960	44	17	ebsco	ebsco	PROPN
ghmj-960	44	18	,	,	PUNCT
ghmj-960	44	19	and	and	CCONJ
ghmj-960	44	20	google	google	PROPN
ghmj-960	44	21	scholar	scholar	NOUN
ghmj-960	44	22	.	.	PUNCT
ghmj-960	45	1	we	we	PRON
ghmj-960	45	2	checked	check	VERB
ghmj-960	45	3	for	for	ADP
ghmj-960	45	4	duplicates	duplicate	NOUN
ghmj-960	45	5	using	use	VERB
ghmj-960	45	6	stata	stata	NOUN
ghmj-960	45	7	and	and	CCONJ
ghmj-960	45	8	screened	screen	VERB
ghmj-960	45	9	the	the	DET
ghmj-960	45	10	resulting	result	VERB
ghmj-960	45	11	studies	study	NOUN
ghmj-960	45	12	based	base	VERB
ghmj-960	45	13	on	on	ADP
ghmj-960	45	14	titles	title	NOUN
ghmj-960	45	15	and	and	CCONJ
ghmj-960	45	16	abstracts	abstract	NOUN
ghmj-960	45	17	afterward	afterward	ADV
ghmj-960	45	18	.	.	PUNCT
ghmj-960	46	1	we	we	PRON
ghmj-960	46	2	screened	screen	VERB
ghmj-960	46	3	independently	independently	ADV
ghmj-960	46	4	the	the	DET
ghmj-960	46	5	studies	study	NOUN
ghmj-960	46	6	based	base	VERB
ghmj-960	46	7	on	on	ADP
ghmj-960	46	8	their	their	PRON
ghmj-960	46	9	full	full	ADJ
ghmj-960	46	10	texts	text	NOUN
ghmj-960	46	11	and	and	CCONJ
ghmj-960	46	12	excluded	exclude	VERB
ghmj-960	46	13	the	the	DET
ghmj-960	46	14	ineligible	ineligible	ADJ
ghmj-960	46	15	studies	study	NOUN
ghmj-960	46	16	.	.	PUNCT
ghmj-960	47	1	the	the	DET
ghmj-960	47	2	authors	author	NOUN
ghmj-960	47	3	independently	independently	ADV
ghmj-960	47	4	extracted	extract	VERB
ghmj-960	47	5	the	the	DET
ghmj-960	47	6	data	datum	NOUN
ghmj-960	47	7	from	from	ADP
ghmj-960	47	8	the	the	DET
ghmj-960	47	9	eligible	eligible	ADJ
ghmj-960	47	10	studies	study	NOUN
ghmj-960	47	11	.	.	PUNCT
ghmj-960	48	1	these	these	DET
ghmj-960	48	2	data	datum	NOUN
ghmj-960	48	3	include	include	VERB
ghmj-960	48	4	the	the	DET
ghmj-960	48	5	author	author	NOUN
ghmj-960	48	6	,	,	PUNCT
ghmj-960	48	7	title	title	NOUN
ghmj-960	48	8	,	,	PUNCT
ghmj-960	48	9	year	year	NOUN
ghmj-960	48	10	,	,	PUNCT
ghmj-960	48	11	method	method	NOUN
ghmj-960	48	12	,	,	PUNCT
ghmj-960	48	13	and	and	CCONJ
ghmj-960	48	14	resume	resume	NOUN
ghmj-960	48	15	.	.	PUNCT
ghmj-960	49	1	the	the	DET
ghmj-960	49	2	eligibility	eligibility	ADJ
ghmj-960	49	3	criteria	criterion	NOUN
ghmj-960	49	4	of	of	ADP
ghmj-960	49	5	studies	study	NOUN
ghmj-960	49	6	included	include	VERB
ghmj-960	49	7	102	102	NUM
ghmj-960	49	8	articles	article	NOUN
ghmj-960	49	9	out	out	ADP
ghmj-960	49	10	of	of	ADP
ghmj-960	49	11	430	430	NUM
ghmj-960	49	12	articles	article	NOUN
ghmj-960	49	13	.	.	PUNCT
ghmj-960	50	1	after	after	ADP
ghmj-960	50	2	reviewing	review	VERB
ghmj-960	50	3	the	the	DET
ghmj-960	50	4	full	full	ADJ
ghmj-960	50	5	-	-	PUNCT
ghmj-960	50	6	text	text	NOUN
ghmj-960	50	7	articles	article	NOUN
ghmj-960	50	8	,	,	PUNCT
ghmj-960	50	9	93	93	NUM
ghmj-960	50	10	articles	article	NOUN
ghmj-960	50	11	were	be	AUX
ghmj-960	50	12	excluded	exclude	VERB
ghmj-960	50	13	and	and	CCONJ
ghmj-960	50	14	only	only	ADV
ghmj-960	50	15	9	9	NUM
ghmj-960	50	16	articles	article	NOUN
ghmj-960	50	17	were	be	AUX
ghmj-960	50	18	included	include	VERB
ghmj-960	50	19	.	.	PUNCT
ghmj-960	51	1	figure	figure	NOUN
ghmj-960	51	2	1	1	NUM
ghmj-960	51	3	.	.	PUNCT
ghmj-960	52	1	search	search	NOUN
ghmj-960	52	2	results	result	NOUN
ghmj-960	52	3	from	from	ADP
ghmj-960	52	4	various	various	ADJ
ghmj-960	52	5	databases	database	NOUN
ghmj-960	52	6	records	record	NOUN
ghmj-960	52	7	identified	identify	VERB
ghmj-960	52	8	through	through	ADP
ghmj-960	52	9	database	database	NOUN
ghmj-960	52	10	searching	search	VERB
ghmj-960	52	11	(	(	PUNCT
ghmj-960	52	12	n	n	NOUN
ghmj-960	52	13	=	=	SYM
ghmj-960	52	14	430	430	NUM
ghmj-960	52	15	)	)	PUNCT
ghmj-960	52	16	full	full	ADJ
ghmj-960	52	17	text	text	NOUN
ghmj-960	52	18	articles	article	NOUN
ghmj-960	52	19	assessed	assess	VERB
ghmj-960	52	20	for	for	ADP
ghmj-960	52	21	eligibility	eligibility	NOUN
ghmj-960	52	22	(	(	PUNCT
ghmj-960	52	23	n	n	NOUN
ghmj-960	52	24	=	=	SYM
ghmj-960	52	25	102	102	NUM
ghmj-960	52	26	)	)	PUNCT
ghmj-960	52	27	articles	article	NOUN
ghmj-960	52	28	were	be	AUX
ghmj-960	52	29	eliminated	eliminate	VERB
ghmj-960	52	30	(	(	PUNCT
ghmj-960	52	31	n	n	NOUN
ghmj-960	52	32	=	=	SYM
ghmj-960	52	33	328	328	NUM
ghmj-960	52	34	)	)	PUNCT
ghmj-960	52	35	articles	article	NOUN
ghmj-960	52	36	were	be	AUX
ghmj-960	52	37	involved	involve	VERB
ghmj-960	52	38	(	(	PUNCT
ghmj-960	52	39	n	n	NOUN
ghmj-960	52	40	=	=	SYM
ghmj-960	52	41	9	9	X
ghmj-960	52	42	)	)	PUNCT
ghmj-960	52	43	articles	article	NOUN
ghmj-960	52	44	excluded	exclude	VERB
ghmj-960	52	45	after	after	ADP
ghmj-960	52	46	full	full	ADJ
ghmj-960	52	47	text	text	NOUN
ghmj-960	52	48	review	review	NOUN
ghmj-960	52	49	(	(	PUNCT
ghmj-960	52	50	n	n	NOUN
ghmj-960	52	51	=	=	SYM
ghmj-960	52	52	93	93	NUM
ghmj-960	52	53	)	)	PUNCT
ghmj-960	52	54	59	59	NUM
ghmj-960	52	55	ghmj	ghmj	NOUN
ghmj-960	52	56	(	(	PUNCT
ghmj-960	52	57	global	global	ADJ
ghmj-960	52	58	health	health	PROPN
ghmj-960	52	59	management	management	NOUN
ghmj-960	52	60	journal	journal	PROPN
ghmj-960	52	61	)	)	PUNCT
ghmj-960	52	62	2023	2023	NUM
ghmj-960	52	63	,	,	PUNCT
ghmj-960	52	64	vol	vol	NOUN
ghmj-960	52	65	.	.	PROPN
ghmj-960	53	1	6	6	NUM
ghmj-960	53	2	,	,	PUNCT
ghmj-960	53	3	no	no	NOUN
ghmj-960	53	4	.	.	NOUN
ghmj-960	53	5	2	2	NUM
ghmj-960	53	6	nugrahaeni	nugrahaeni	PROPN
ghmj-960	53	7	&	&	CCONJ
ghmj-960	53	8	budiyanti	budiyanti	PROPN
ghmj-960	53	9	table	table	NOUN
ghmj-960	53	10	1	1	NUM
ghmj-960	53	11	.	.	PUNCT
ghmj-960	54	1	information	information	NOUN
ghmj-960	54	2	of	of	ADP
ghmj-960	54	3	the	the	DET
ghmj-960	54	4	included	include	VERB
ghmj-960	54	5	articles	article	NOUN
ghmj-960	54	6	author	author	NOUN
ghmj-960	54	7	title	title	NOUN
ghmj-960	54	8	year	year	NOUN
ghmj-960	54	9	method	method	NOUN
ghmj-960	54	10	resume	resume	NOUN
ghmj-960	54	11	burlando	burlando	PROPN
ghmj-960	54	12	m	m	PROPN
ghmj-960	54	13	,	,	PUNCT
ghmj-960	54	14	herzum	herzum	PROPN
ghmj-960	54	15	a	a	PROPN
ghmj-960	54	16	,	,	PUNCT
ghmj-960	54	17	micalizzi	micalizzi	ADP
ghmj-960	54	18	c	c	PROPN
ghmj-960	54	19	,	,	PUNCT
ghmj-960	54	20	cozzani	cozzani	PROPN
ghmj-960	54	21	e	e	NOUN
ghmj-960	54	22	,	,	PUNCT
ghmj-960	54	23	parodi	parodi	ADJ
ghmj-960	54	24	a.	a.	NOUN
ghmj-960	54	25	cutaneous	cutaneous	ADJ
ghmj-960	54	26	reactions	reaction	NOUN
ghmj-960	54	27	to	to	ADP
ghmj-960	54	28	covid-19	covid-19	PROPN
ghmj-960	54	29	vaccine	vaccine	NOUN
ghmj-960	54	30	at	at	ADP
ghmj-960	54	31	the	the	DET
ghmj-960	54	32	dermatology	dermatology	NOUN
ghmj-960	54	33	primary	primary	ADJ
ghmj-960	54	34	care	care	NOUN
ghmj-960	54	35	2021	2021	NUM
ghmj-960	54	36	the	the	DET
ghmj-960	54	37	data	datum	NOUN
ghmj-960	54	38	among	among	ADP
ghmj-960	54	39	patients	patient	NOUN
ghmj-960	54	40	with	with	ADP
ghmj-960	54	41	skin	skin	NOUN
ghmj-960	54	42	reactions	reaction	NOUN
ghmj-960	54	43	after	after	SCONJ
ghmj-960	54	44	covid-19	covid-19	PROPN
ghmj-960	54	45	administration	administration	NOUN
ghmj-960	54	46	were	be	AUX
ghmj-960	54	47	collected	collect	VERB
ghmj-960	54	48	retrospectively	retrospectively	ADV
ghmj-960	54	49	from	from	ADP
ghmj-960	54	50	march	march	PROPN
ghmj-960	54	51	2021	2021	NUM
ghmj-960	54	52	to	to	ADP
ghmj-960	54	53	june	june	PROPN
ghmj-960	54	54	2021	2021	NUM
ghmj-960	54	55	in	in	ADP
ghmj-960	54	56	dermatology	dermatology	NOUN
ghmj-960	54	57	primary	primary	NOUN
ghmj-960	54	58	only	only	ADV
ghmj-960	54	59	15	15	NUM
ghmj-960	54	60	%	%	NOUN
ghmj-960	54	61	of	of	ADP
ghmj-960	54	62	patients	patient	NOUN
ghmj-960	54	63	developed	develop	VERB
ghmj-960	54	64	cutaneous	cutaneous	ADJ
ghmj-960	54	65	reactions	reaction	NOUN
ghmj-960	54	66	following	follow	VERB
ghmj-960	54	67	covid-19	covid-19	PROPN
ghmj-960	54	68	administration	administration	NOUN
ghmj-960	54	69	.	.	PUNCT
ghmj-960	55	1	most	most	ADJ
ghmj-960	55	2	of	of	ADP
ghmj-960	55	3	them	they	PRON
ghmj-960	55	4	were	be	AUX
ghmj-960	55	5	either	either	CCONJ
ghmj-960	55	6	mild	mild	ADJ
ghmj-960	55	7	or	or	CCONJ
ghmj-960	55	8	moderate	moderate	ADJ
ghmj-960	55	9	.	.	PUNCT
ghmj-960	56	1	ten	ten	NUM
ghmj-960	56	2	of	of	ADP
ghmj-960	56	3	twenty	twenty	NUM
ghmj-960	56	4	-	-	PUNCT
ghmj-960	56	5	one	one	NUM
ghmj-960	56	6	patients	patient	NOUN
ghmj-960	56	7	developed	develop	VERB
ghmj-960	56	8	urticarial	urticarial	ADJ
ghmj-960	56	9	reactions	reaction	NOUN
ghmj-960	56	10	following	follow	VERB
ghmj-960	56	11	covid19	covid19	PROPN
ghmj-960	56	12	administration	administration	PROPN
ghmj-960	56	13	.	.	PUNCT
ghmj-960	57	1	four	four	NUM
ghmj-960	57	2	of	of	ADP
ghmj-960	57	3	them	they	PRON
ghmj-960	57	4	appeared	appear	VERB
ghmj-960	57	5	within	within	ADP
ghmj-960	57	6	24	24	NUM
ghmj-960	57	7	hours	hour	NOUN
ghmj-960	57	8	and	and	CCONJ
ghmj-960	57	9	the	the	DET
ghmj-960	57	10	rest	rest	NOUN
ghmj-960	57	11	after	after	ADP
ghmj-960	57	12	24	24	NUM
ghmj-960	57	13	hours	hour	NOUN
ghmj-960	57	14	grieco	grieco	PROPN
ghmj-960	57	15	t	t	PROPN
ghmj-960	57	16	,	,	PUNCT
ghmj-960	57	17	ambrosio	ambrosio	PROPN
ghmj-960	57	18	l	l	PROPN
ghmj-960	57	19	,	,	PUNCT
ghmj-960	57	20	trovato	trovato	PROPN
ghmj-960	57	21	f	f	PROPN
ghmj-960	57	22	,	,	PUNCT
ghmj-960	57	23	vitiello	vitiello	PROPN
ghmj-960	57	24	m	m	PROPN
ghmj-960	57	25	,	,	PUNCT
ghmj-960	57	26	demofonte	demofonte	VERB
ghmj-960	57	27	i	i	PRON
ghmj-960	57	28	,	,	PUNCT
ghmj-960	57	29	fanto	fanto	ADV
ghmj-960	57	30	m	m	PROPN
ghmj-960	57	31	,	,	PUNCT
ghmj-960	57	32	et	et	PROPN
ghmj-960	57	33	al	al	PROPN
ghmj-960	57	34	effects	effect	NOUN
ghmj-960	57	35	of	of	ADP
ghmj-960	57	36	vaccination	vaccination	NOUN
ghmj-960	57	37	against	against	ADP
ghmj-960	57	38	covid19	covid19	NOUN
ghmj-960	57	39	in	in	ADP
ghmj-960	57	40	chronic	chronic	ADJ
ghmj-960	57	41	spontaneous	spontaneous	ADJ
ghmj-960	57	42	and	and	CCONJ
ghmj-960	57	43	inducible	inducible	ADJ
ghmj-960	57	44	urticaria	urticaria	NOUN
ghmj-960	57	45	(	(	PUNCT
ghmj-960	57	46	csu	csu	NOUN
ghmj-960	57	47	/	/	SYM
ghmj-960	57	48	ciu	ciu	ADJ
ghmj-960	57	49	)	)	PUNCT
ghmj-960	57	50	patients	patient	NOUN
ghmj-960	57	51	:	:	PUNCT
ghmj-960	57	52	a	a	DET
ghmj-960	57	53	monocentric	monocentric	ADJ
ghmj-960	57	54	study	study	NOUN
ghmj-960	57	55	.	.	PUNCT
ghmj-960	58	1	2022	2022	NUM
ghmj-960	58	2	from	from	ADP
ghmj-960	58	3	1	1	NUM
ghmj-960	58	4	november	november	PROPN
ghmj-960	58	5	2021	2021	NUM
ghmj-960	58	6	until	until	ADP
ghmj-960	58	7	10	10	NUM
ghmj-960	58	8	december	december	PROPN
ghmj-960	58	9	2021	2021	NUM
ghmj-960	58	10	,	,	PUNCT
ghmj-960	58	11	only	only	ADV
ghmj-960	58	12	160	160	NUM
ghmj-960	58	13	chronic	chronic	ADJ
ghmj-960	58	14	spontaneous	spontaneous	ADJ
ghmj-960	58	15	and	and	CCONJ
ghmj-960	58	16	inducible	inducible	ADJ
ghmj-960	58	17	urticaria	urticaria	NOUN
ghmj-960	58	18	patients	patient	NOUN
ghmj-960	58	19	in	in	ADP
ghmj-960	58	20	antihistamine	antihistamine	PROPN
ghmj-960	58	21	therapy	therapy	NOUN
ghmj-960	58	22	were	be	AUX
ghmj-960	58	23	administered	administer	VERB
ghmj-960	58	24	two	two	NUM
ghmj-960	58	25	doses	dose	NOUN
ghmj-960	58	26	of	of	ADP
ghmj-960	58	27	the	the	DET
ghmj-960	58	28	moderna	moderna	PROPN
ghmj-960	58	29	vaccine	vaccine	NOUN
ghmj-960	58	30	.	.	PUNCT
ghmj-960	59	1	twenty	twenty	NUM
ghmj-960	59	2	of	of	ADP
ghmj-960	59	3	them	they	PRON
ghmj-960	59	4	got	get	VERB
ghmj-960	59	5	booster	booster	NOUN
ghmj-960	59	6	vaccines	vaccine	NOUN
ghmj-960	59	7	.	.	PUNCT
ghmj-960	60	1	a	a	DET
ghmj-960	60	2	web	web	NOUN
ghmj-960	60	3	-	-	PUNCT
ghmj-960	60	4	based	base	VERB
ghmj-960	60	5	questionnaire	questionnaire	NOUN
ghmj-960	60	6	was	be	AUX
ghmj-960	60	7	collected	collect	VERB
ghmj-960	60	8	by	by	ADP
ghmj-960	60	9	phone	phone	NOUN
ghmj-960	60	10	interview	interview	NOUN
ghmj-960	60	11	.	.	PUNCT
ghmj-960	61	1	the	the	DET
ghmj-960	61	2	questionnaire	questionnaire	NOUN
ghmj-960	61	3	consists	consist	VERB
ghmj-960	61	4	of	of	ADP
ghmj-960	61	5	demographics	demographic	NOUN
ghmj-960	61	6	,	,	PUNCT
ghmj-960	61	7	adverse	adverse	ADJ
ghmj-960	61	8	event	event	NOUN
ghmj-960	61	9	following	follow	VERB
ghmj-960	61	10	immunization	immunization	NOUN
ghmj-960	61	11	,	,	PUNCT
ghmj-960	61	12	medical	medical	ADJ
ghmj-960	61	13	history	history	NOUN
ghmj-960	61	14	,	,	PUNCT
ghmj-960	61	15	urticaria	urticaria	NOUN
ghmj-960	61	16	activity	activity	NOUN
ghmj-960	61	17	score-7	score-7	NUM
ghmj-960	61	18	and	and	CCONJ
ghmj-960	61	19	cutaneous	cutaneous	ADJ
ghmj-960	61	20	adverse	adverse	ADJ
ghmj-960	61	21	reactions	reaction	NOUN
ghmj-960	61	22	outcome	outcome	VERB
ghmj-960	61	23	only	only	ADV
ghmj-960	61	24	17.86	17.86	NUM
ghmj-960	61	25	%	%	NOUN
ghmj-960	61	26	patients	patient	NOUN
ghmj-960	61	27	developed	develop	VERB
ghmj-960	61	28	worsening	worsen	VERB
ghmj-960	61	29	pre	pre	ADJ
ghmj-960	61	30	-	-	ADJ
ghmj-960	61	31	existing	existing	ADJ
ghmj-960	61	32	urticaria	urticaria	NOUN
ghmj-960	61	33	with	with	ADP
ghmj-960	61	34	average	average	ADJ
ghmj-960	61	35	urticaria	urticaria	NOUN
ghmj-960	61	36	activity	activity	NOUN
ghmj-960	61	37	score-7	score-7	VERB
ghmj-960	61	38	,	,	PUNCT
ghmj-960	61	39	3.12	3.12	NUM
ghmj-960	61	40	.	.	PUNCT
ghmj-960	62	1	covid-19	covid-19	PROPN
ghmj-960	62	2	vaccination	vaccination	NOUN
ghmj-960	62	3	is	be	AUX
ghmj-960	62	4	secure	secure	ADJ
ghmj-960	62	5	among	among	ADP
ghmj-960	62	6	chronic	chronic	ADJ
ghmj-960	62	7	spontaneous	spontaneous	ADJ
ghmj-960	62	8	and	and	CCONJ
ghmj-960	62	9	inducible	inducible	ADJ
ghmj-960	62	10	urticaria	urticaria	NOUN
ghmj-960	62	11	patients	patient	NOUN
ghmj-960	62	12	.	.	PUNCT
ghmj-960	63	1	the	the	DET
ghmj-960	63	2	cases	case	NOUN
ghmj-960	63	3	of	of	ADP
ghmj-960	63	4	worsening	worsen	VERB
ghmj-960	63	5	disease	disease	NOUN
ghmj-960	63	6	are	be	AUX
ghmj-960	63	7	able	able	ADJ
ghmj-960	63	8	to	to	PART
ghmj-960	63	9	manage	manage	VERB
ghmj-960	63	10	by	by	ADP
ghmj-960	63	11	using	use	VERB
ghmj-960	63	12	antihistamines	antihistamine	NOUN
ghmj-960	63	13	therapies	therapy	NOUN
ghmj-960	63	14	català	català	PROPN
ghmj-960	63	15	a	a	PRON
ghmj-960	63	16	,	,	PUNCT
ghmj-960	63	17	muñoz	muñoz	PROPN
ghmj-960	63	18	-	-	PUNCT
ghmj-960	63	19	santos	santos	PROPN
ghmj-960	63	20	c	c	PROPN
ghmj-960	63	21	,	,	PUNCT
ghmj-960	63	22	galváncasas	galváncasas	PROPN
ghmj-960	63	23	cr	cr	PROPN
ghmj-960	63	24	,	,	PUNCT
ghmj-960	63	25	riesco	riesco	PROPN
ghmj-960	63	26	mr	mr	PROPN
ghmj-960	63	27	,	,	PUNCT
ghmj-960	63	28	nebreda	nebreda	PROPN
ghmj-960	63	29	d	d	PROPN
ghmj-960	63	30	,	,	PUNCT
ghmj-960	63	31	solá	solá	NOUN
ghmj-960	63	32	-	-	PUNCT
ghmj-960	63	33	truyols	truyol	NOUN
ghmj-960	63	34	a	a	PRON
ghmj-960	63	35	,	,	PUNCT
ghmj-960	63	36	et	et	PROPN
ghmj-960	63	37	al	al	PROPN
ghmj-960	63	38	.	.	PUNCT
ghmj-960	64	1	cutaneous	cutaneous	ADJ
ghmj-960	64	2	reactions	reaction	NOUN
ghmj-960	64	3	after	after	ADP
ghmj-960	64	4	sars	sars	PROPN
ghmj-960	64	5	-	-	PUNCT
ghmj-960	64	6	cov-2	cov-2	PART
ghmj-960	64	7	vaccination	vaccination	NOUN
ghmj-960	64	8	:	:	PUNCT
ghmj-960	64	9	a	a	DET
ghmj-960	64	10	cross	cross	ADJ
ghmj-960	64	11	-	-	ADJ
ghmj-960	64	12	sectional	sectional	ADJ
ghmj-960	64	13	spanish	spanish	ADJ
ghmj-960	64	14	nationwide	nationwide	ADJ
ghmj-960	64	15	study	study	NOUN
ghmj-960	64	16	of	of	ADP
ghmj-960	64	17	405	405	NUM
ghmj-960	64	18	cases	case	NOUN
ghmj-960	64	19	2021	2021	NUM
ghmj-960	64	20	this	this	DET
ghmj-960	64	21	study	study	NOUN
ghmj-960	64	22	,	,	PUNCT
ghmj-960	64	23	a	a	DET
ghmj-960	64	24	cross	cross	ADJ
ghmj-960	64	25	-	-	ADJ
ghmj-960	64	26	sectional	sectional	ADJ
ghmj-960	64	27	study	study	NOUN
ghmj-960	64	28	,	,	PUNCT
ghmj-960	64	29	was	be	AUX
ghmj-960	64	30	conducted	conduct	VERB
ghmj-960	64	31	from	from	ADP
ghmj-960	64	32	16	16	NUM
ghmj-960	64	33	february	february	NOUN
ghmj-960	64	34	until	until	ADP
ghmj-960	64	35	15	15	NUM
ghmj-960	64	36	may	may	NOUN
ghmj-960	64	37	2021	2021	NUM
ghmj-960	64	38	.	.	PUNCT
ghmj-960	65	1	the	the	DET
ghmj-960	65	2	sample	sample	NOUN
ghmj-960	65	3	of	of	ADP
ghmj-960	65	4	this	this	DET
ghmj-960	65	5	study	study	NOUN
ghmj-960	65	6	is	be	AUX
ghmj-960	65	7	patients	patient	NOUN
ghmj-960	65	8	who	who	PRON
ghmj-960	65	9	developed	develop	VERB
ghmj-960	65	10	cutaneous	cutaneous	ADJ
ghmj-960	65	11	reactions	reaction	NOUN
ghmj-960	65	12	within	within	ADP
ghmj-960	65	13	21	21	NUM
ghmj-960	65	14	days	day	NOUN
ghmj-960	65	15	following	follow	VERB
ghmj-960	65	16	covid-19	covid-19	PROPN
ghmj-960	65	17	vaccine	vaccine	NOUN
ghmj-960	65	18	administration	administration	NOUN
ghmj-960	65	19	.	.	PUNCT
ghmj-960	66	1	an	an	DET
ghmj-960	66	2	electronic	electronic	ADJ
ghmj-960	66	3	case	case	NOUN
ghmj-960	66	4	report	report	NOUN
ghmj-960	66	5	form	form	NOUN
ghmj-960	66	6	and	and	CCONJ
ghmj-960	66	7	questionnaire	questionnaire	NOUN
ghmj-960	66	8	were	be	AUX
ghmj-960	66	9	collected	collect	VERB
ghmj-960	66	10	.	.	PUNCT
ghmj-960	67	1	an	an	DET
ghmj-960	67	2	online	online	ADJ
ghmj-960	67	3	professional	professional	ADJ
ghmj-960	67	4	survey	survey	NOUN
ghmj-960	67	5	reported	report	VERB
ghmj-960	67	6	reactions	reaction	NOUN
ghmj-960	67	7	of	of	ADP
ghmj-960	67	8	cutaneous	cutaneous	ADJ
ghmj-960	67	9	after	after	ADP
ghmj-960	67	10	having	have	VERB
ghmj-960	67	11	a	a	DET
ghmj-960	67	12	visit	visit	NOUN
ghmj-960	67	13	with	with	ADP
ghmj-960	67	14	a	a	DET
ghmj-960	67	15	dermatologist	dermatologist	NOUN
ghmj-960	67	16	.	.	PUNCT
ghmj-960	68	1	clinical	clinical	ADJ
ghmj-960	68	2	images	image	NOUN
ghmj-960	68	3	were	be	AUX
ghmj-960	68	4	sent	send	VERB
ghmj-960	68	5	by	by	ADP
ghmj-960	68	6	email	email	NOUN
ghmj-960	68	7	.	.	PUNCT
ghmj-960	69	1	the	the	DET
ghmj-960	69	2	examiner	examiner	NOUN
ghmj-960	69	3	identified	identify	VERB
ghmj-960	69	4	for	for	ADP
ghmj-960	69	5	consensus	consensus	NOUN
ghmj-960	69	6	on	on	ADP
ghmj-960	69	7	clinical	clinical	ADJ
ghmj-960	69	8	patterns	pattern	NOUN
ghmj-960	69	9	and	and	CCONJ
ghmj-960	69	10	classification	classification	NOUN
ghmj-960	69	11	only	only	ADV
ghmj-960	69	12	405	405	NUM
ghmj-960	69	13	patients	patient	NOUN
ghmj-960	69	14	were	be	AUX
ghmj-960	69	15	with	with	ADP
ghmj-960	69	16	a	a	DET
ghmj-960	69	17	mean	mean	NOUN
ghmj-960	69	18	of	of	ADP
ghmj-960	69	19	age	age	NOUN
ghmj-960	69	20	of	of	ADP
ghmj-960	69	21	(	(	PUNCT
ghmj-960	69	22	50.7	50.7	NUM
ghmj-960	69	23	)	)	PUNCT
ghmj-960	69	24	(	(	PUNCT
ghmj-960	69	25	17.6	17.6	NUM
ghmj-960	69	26	)	)	PUNCT
ghmj-960	69	27	and	and	CCONJ
ghmj-960	69	28	80.2	80.2	NUM
ghmj-960	69	29	%	%	NOUN
ghmj-960	69	30	of	of	ADP
ghmj-960	69	31	them	they	PRON
ghmj-960	69	32	were	be	AUX
ghmj-960	69	33	female	female	ADJ
ghmj-960	69	34	.	.	PUNCT
ghmj-960	70	1	there	there	PRON
ghmj-960	70	2	were	be	VERB
ghmj-960	70	3	40.2	40.2	NUM
ghmj-960	70	4	%	%	NOUN
ghmj-960	70	5	of	of	ADP
ghmj-960	70	6	the	the	DET
ghmj-960	70	7	pfizer	pfizer	NOUN
ghmj-960	70	8	administration	administration	NOUN
ghmj-960	70	9	,	,	PUNCT
ghmj-960	70	10	36.3	36.3	NUM
ghmj-960	70	11	%	%	NOUN
ghmj-960	70	12	of	of	ADP
ghmj-960	70	13	the	the	DET
ghmj-960	70	14	moderna	moderna	PROPN
ghmj-960	70	15	administration	administration	PROPN
ghmj-960	70	16	,	,	PUNCT
ghmj-960	70	17	and	and	CCONJ
ghmj-960	70	18	23.5	23.5	NUM
ghmj-960	70	19	%	%	NOUN
ghmj-960	70	20	of	of	ADP
ghmj-960	70	21	the	the	DET
ghmj-960	70	22	astrazeneca	astrazeneca	PROPN
ghmj-960	70	23	administration	administration	PROPN
ghmj-960	70	24	.	.	PUNCT
ghmj-960	71	1	cutaneous	cutaneous	ADJ
ghmj-960	71	2	reactions	reaction	NOUN
ghmj-960	71	3	represented	represent	VERB
ghmj-960	71	4	covid	covid	PROPN
ghmj-960	71	5	arm	arm	NOUN
ghmj-960	71	6	(	(	PUNCT
ghmj-960	71	7	32.1	32.1	NUM
ghmj-960	71	8	%	%	NOUN
ghmj-960	71	9	)	)	PUNCT
ghmj-960	71	10	,	,	PUNCT
ghmj-960	71	11	urticaria	urticaria	INTJ
ghmj-960	71	12	(	(	PUNCT
ghmj-960	71	13	14.6	14.6	NUM
ghmj-960	71	14	%	%	NOUN
ghmj-960	71	15	)	)	PUNCT
ghmj-960	71	16	,	,	PUNCT
ghmj-960	71	17	morbiliform	morbiliform	NOUN
ghmj-960	71	18	(	(	PUNCT
ghmj-960	71	19	8.9	8.9	NUM
ghmj-960	71	20	%	%	NOUN
ghmj-960	71	21	)	)	PUNCT
ghmj-960	71	22	,	,	PUNCT
ghmj-960	71	23	papulovesicular	papulovesicular	INTJ
ghmj-960	71	24	(	(	PUNCT
ghmj-960	71	25	6.4	6.4	NUM
ghmj-960	71	26	%	%	NOUN
ghmj-960	71	27	)	)	PUNCT
ghmj-960	71	28	,	,	PUNCT
ghmj-960	71	29	pityriasis	pityriasis	ADJ
ghmj-960	71	30	rosea	rosea	NOUN
ghmj-960	71	31	-	-	PUNCT
ghmj-960	71	32	like	like	ADJ
ghmj-960	71	33	(	(	PUNCT
ghmj-960	71	34	4.9	4.9	NUM
ghmj-960	71	35	%	%	NOUN
ghmj-960	71	36	)	)	PUNCT
ghmj-960	71	37	and	and	CCONJ
ghmj-960	71	38	purpuric	purpuric	ADJ
ghmj-960	71	39	(	(	PUNCT
ghmj-960	71	40	4	4	NUM
ghmj-960	71	41	%	%	NOUN
ghmj-960	71	42	)	)	PUNCT
ghmj-960	71	43	reactions	reaction	NOUN
ghmj-960	71	44	.	.	PUNCT
ghmj-960	72	1	varicella	varicella	NOUN
ghmj-960	72	2	zoster	zoster	NOUN
ghmj-960	72	3	and	and	CCONJ
ghmj-960	72	4	herpes	herpe	NOUN
ghmj-960	72	5	simplex	simplex	NOUN
ghmj-960	72	6	virus	virus	NOUN
ghmj-960	72	7	reactivations	reactivation	NOUN
ghmj-960	72	8	accounted	account	VERB
ghmj-960	72	9	for	for	ADP
ghmj-960	72	10	13.8	13.8	NUM
ghmj-960	72	11	%	%	NOUN
ghmj-960	72	12	of	of	ADP
ghmj-960	72	13	reactions	reaction	NOUN
ghmj-960	72	14	.	.	PUNCT
ghmj-960	73	1	urticaria	urticaria	NOUN
ghmj-960	73	2	and/	and/	PROPN
ghmj-960	73	3	angioedema	angioedema	VERB
ghmj-960	73	4	reactions	reaction	NOUN
ghmj-960	73	5	after	after	SCONJ
ghmj-960	73	6	pfizer	pfizer	PROPN
ghmj-960	73	7	administration	administration	NOUN
ghmj-960	73	8	was	be	AUX
ghmj-960	73	9	higher	high	ADJ
ghmj-960	73	10	than	than	ADP
ghmj-960	73	11	moderna	moderna	PROPN
ghmj-960	73	12	and	and	CCONJ
ghmj-960	73	13	astrazeneca	astrazeneca	PROPN
ghmj-960	73	14	.	.	PUNCT
ghmj-960	74	1	pfizer	pfizer	PROPN
ghmj-960	74	2	was	be	AUX
ghmj-960	74	3	24	24	NUM
ghmj-960	74	4	patients	patient	NOUN
ghmj-960	74	5	(	(	PUNCT
ghmj-960	74	6	40.7	40.7	NUM
ghmj-960	74	7	%	%	NOUN
ghmj-960	74	8	)	)	PUNCT
ghmj-960	74	9	.	.	PUNCT
ghmj-960	75	1	astrazeneca	astrazeneca	PROPN
ghmj-960	75	2	was	be	AUX
ghmj-960	75	3	20	20	NUM
ghmj-960	75	4	patients	patient	NOUN
ghmj-960	75	5	(	(	PUNCT
ghmj-960	75	6	33.9	33.9	NUM
ghmj-960	75	7	%	%	NOUN
ghmj-960	75	8	)	)	PUNCT
ghmj-960	75	9	.	.	PUNCT
ghmj-960	76	1	moderna	moderna	PROPN
ghmj-960	76	2	was	be	AUX
ghmj-960	76	3	15	15	NUM
ghmj-960	76	4	patients	patient	NOUN
ghmj-960	76	5	(	(	PUNCT
ghmj-960	76	6	25.9	25.9	NUM
ghmj-960	76	7	%	%	NOUN
ghmj-960	76	8	)	)	PUNCT
ghmj-960	76	9	.	.	PUNCT
ghmj-960	77	1	only	only	ADV
ghmj-960	77	2	46	46	NUM
ghmj-960	77	3	patients	patient	NOUN
ghmj-960	77	4	(	(	PUNCT
ghmj-960	77	5	78	78	NUM
ghmj-960	77	6	%	%	NOUN
ghmj-960	77	7	)	)	PUNCT
ghmj-960	77	8	of	of	ADP
ghmj-960	77	9	59	59	NUM
ghmj-960	77	10	patients	patient	NOUN
ghmj-960	77	11	with	with	ADP
ghmj-960	77	12	urticaria	urticaria	NOUN
ghmj-960	77	13	and/	and/	PROPN
ghmj-960	77	14	angioedema	angioedema	NOUN
ghmj-960	77	15	reactions	reaction	NOUN
ghmj-960	77	16	were	be	AUX
ghmj-960	77	17	female	female	ADJ
ghmj-960	77	18	.	.	PUNCT
ghmj-960	78	1	mostly	mostly	ADV
ghmj-960	78	2	its	its	PRON
ghmj-960	78	3	reaction	reaction	NOUN
ghmj-960	78	4	developed	develop	VERB
ghmj-960	78	5	after	after	ADP
ghmj-960	78	6	the	the	DET
ghmj-960	78	7	first	first	ADJ
ghmj-960	78	8	dose	dose	NOUN
ghmj-960	78	9	of	of	ADP
ghmj-960	78	10	covid-19	covid-19	PROPN
ghmj-960	78	11	vaccines	vaccine	NOUN
ghmj-960	78	12	.	.	PUNCT
ghmj-960	79	1	cutaneous	cutaneous	ADJ
ghmj-960	79	2	reactions	reaction	NOUN
ghmj-960	79	3	following	follow	VERB
ghmj-960	79	4	the	the	DET
ghmj-960	79	5	covid-19	covid-19	PROPN
ghmj-960	79	6	vaccine	vaccine	NOUN
ghmj-960	79	7	administration	administration	NOUN
ghmj-960	79	8	are	be	AUX
ghmj-960	79	9	diverse	diverse	ADJ
ghmj-960	79	10	.	.	PUNCT
ghmj-960	80	1	nugrahaeni	nugrahaeni	PROPN
ghmj-960	80	2	&	&	CCONJ
ghmj-960	80	3	budiyanti	budiyanti	PROPN
ghmj-960	80	4	ghmj	ghmj	PROPN
ghmj-960	80	5	(	(	PUNCT
ghmj-960	80	6	global	global	ADJ
ghmj-960	80	7	health	health	PROPN
ghmj-960	80	8	management	management	NOUN
ghmj-960	80	9	journal	journal	PROPN
ghmj-960	80	10	)	)	PUNCT
ghmj-960	80	11	2023	2023	NUM
ghmj-960	80	12	,	,	PUNCT
ghmj-960	80	13	vol	vol	NOUN
ghmj-960	80	14	.	.	PROPN
ghmj-960	81	1	6	6	NUM
ghmj-960	81	2	,	,	PUNCT
ghmj-960	81	3	no	no	INTJ
ghmj-960	81	4	.	.	NOUN
ghmj-960	81	5	2	2	NUM
ghmj-960	81	6	60	60	NUM
ghmj-960	81	7	author	author	NOUN
ghmj-960	81	8	title	title	NOUN
ghmj-960	81	9	year	year	NOUN
ghmj-960	81	10	method	method	NOUN
ghmj-960	81	11	resume	resume	NOUN
ghmj-960	81	12	pourani	pourani	VERB
ghmj-960	81	13	mr	mr	PROPN
ghmj-960	81	14	,	,	PUNCT
ghmj-960	81	15	shahidi	shahidi	NOUN
ghmj-960	81	16	dadras	dadras	PROPN
ghmj-960	81	17	m	m	PROPN
ghmj-960	81	18	,	,	PUNCT
ghmj-960	81	19	salari	salari	PROPN
ghmj-960	81	20	m	m	PROPN
ghmj-960	81	21	,	,	PUNCT
ghmj-960	81	22	diab	diab	PROPN
ghmj-960	81	23	r	r	PROPN
ghmj-960	81	24	,	,	PUNCT
ghmj-960	81	25	namazi	namazi	NOUN
ghmj-960	81	26	n	n	CCONJ
ghmj-960	81	27	,	,	PUNCT
ghmj-960	81	28	abdollahimajd	abdollahimajd	PROPN
ghmj-960	81	29	f.	f.	PROPN
ghmj-960	81	30	cutaneous	cutaneous	ADJ
ghmj-960	81	31	adverse	adverse	ADJ
ghmj-960	81	32	events	event	NOUN
ghmj-960	81	33	related	relate	VERB
ghmj-960	81	34	to	to	ADP
ghmj-960	81	35	covid-19	covid-19	PROPN
ghmj-960	81	36	vaccines	vaccine	NOUN
ghmj-960	81	37	:	:	PUNCT
ghmj-960	81	38	a	a	DET
ghmj-960	81	39	cross	cross	ADJ
ghmj-960	81	40	-	-	ADJ
ghmj-960	81	41	sectional	sectional	ADJ
ghmj-960	81	42	questionnairebased	questionnairebased	ADJ
ghmj-960	81	43	study	study	NOUN
ghmj-960	81	44	of	of	ADP
ghmj-960	81	45	867	867	NUM
ghmj-960	81	46	patients	patient	NOUN
ghmj-960	81	47	2022	2022	NUM
ghmj-960	81	48	this	this	DET
ghmj-960	81	49	study	study	NOUN
ghmj-960	81	50	was	be	AUX
ghmj-960	81	51	a	a	DET
ghmj-960	81	52	descriptive	descriptive	ADJ
ghmj-960	81	53	cross	cross	ADJ
ghmj-960	81	54	-	-	ADJ
ghmj-960	81	55	sectional	sectional	ADJ
ghmj-960	81	56	questionnaire	questionnaire	NOUN
ghmj-960	81	57	study	study	NOUN
ghmj-960	81	58	.	.	PUNCT
ghmj-960	82	1	the	the	DET
ghmj-960	82	2	online	online	ADJ
ghmj-960	82	3	questionnaire	questionnaire	NOUN
ghmj-960	82	4	was	be	AUX
ghmj-960	82	5	shared	share	VERB
ghmj-960	82	6	from	from	ADP
ghmj-960	82	7	the	the	DET
ghmj-960	82	8	first	first	ADJ
ghmj-960	82	9	of	of	ADP
ghmj-960	82	10	june	june	PROPN
ghmj-960	82	11	2021	2021	NUM
ghmj-960	82	12	to	to	ADP
ghmj-960	82	13	1	1	NUM
ghmj-960	82	14	july	july	PROPN
ghmj-960	82	15	2021	2021	NUM
ghmj-960	82	16	.	.	PUNCT
ghmj-960	83	1	the	the	DET
ghmj-960	83	2	questionnaire	questionnaire	NOUN
ghmj-960	83	3	was	be	AUX
ghmj-960	83	4	related	relate	VERB
ghmj-960	83	5	to	to	ADP
ghmj-960	83	6	covid-19	covid-19	PROPN
ghmj-960	83	7	vaccine	vaccine	NOUN
ghmj-960	83	8	reactions	reaction	NOUN
ghmj-960	83	9	.	.	PUNCT
ghmj-960	84	1	the	the	DET
ghmj-960	84	2	questionnaire	questionnaire	NOUN
ghmj-960	84	3	consists	consist	VERB
ghmj-960	84	4	of	of	ADP
ghmj-960	84	5	cutaneous	cutaneous	ADJ
ghmj-960	84	6	reactions	reaction	NOUN
ghmj-960	84	7	,	,	PUNCT
ghmj-960	84	8	the	the	DET
ghmj-960	84	9	onset	onset	NOUN
ghmj-960	84	10	time	time	NOUN
ghmj-960	84	11	,	,	PUNCT
ghmj-960	84	12	and	and	CCONJ
ghmj-960	84	13	the	the	DET
ghmj-960	84	14	persistence	persistence	NOUN
ghmj-960	84	15	duration	duration	NOUN
ghmj-960	84	16	.	.	PUNCT
ghmj-960	85	1	there	there	PRON
ghmj-960	85	2	are	be	VERB
ghmj-960	85	3	30	30	NUM
ghmj-960	85	4	%	%	NOUN
ghmj-960	85	5	of	of	ADP
ghmj-960	85	6	iran	iran	PROPN
ghmj-960	85	7	people	people	NOUN
ghmj-960	85	8	who	who	PRON
ghmj-960	85	9	developed	develop	VERB
ghmj-960	85	10	cutaneous	cutaneous	ADJ
ghmj-960	85	11	reactions	reaction	NOUN
ghmj-960	85	12	after	after	ADP
ghmj-960	85	13	covid-19	covid-19	PROPN
ghmj-960	85	14	vaccine	vaccine	NOUN
ghmj-960	85	15	administration	administration	NOUN
ghmj-960	85	16	.	.	PUNCT
ghmj-960	86	1	the	the	DET
ghmj-960	86	2	most	most	ADV
ghmj-960	86	3	frequent	frequent	ADJ
ghmj-960	86	4	effects	effect	NOUN
ghmj-960	86	5	against	against	ADP
ghmj-960	86	6	covid-19	covid-19	PROPN
ghmj-960	86	7	vaccine	vaccine	NOUN
ghmj-960	86	8	were	be	AUX
ghmj-960	86	9	urticaria	urticaria	ADJ
ghmj-960	86	10	,	,	PUNCT
ghmj-960	86	11	focal	focal	ADJ
ghmj-960	86	12	injection	injection	NOUN
ghmj-960	86	13	site	site	NOUN
ghmj-960	86	14	reaction	reaction	NOUN
ghmj-960	86	15	,	,	PUNCT
ghmj-960	86	16	and	and	CCONJ
ghmj-960	86	17	exanthematous	exanthematous	ADJ
ghmj-960	86	18	rash	rash	NOUN
ghmj-960	86	19	.	.	PUNCT
ghmj-960	87	1	there	there	PRON
ghmj-960	87	2	were	be	VERB
ghmj-960	87	3	25	25	NUM
ghmj-960	87	4	urticaria	urticaria	NOUN
ghmj-960	87	5	cases	case	NOUN
ghmj-960	87	6	.	.	PUNCT
ghmj-960	88	1	bruusgaardmouritsen	bruusgaardmouritsen	PROPN
ghmj-960	88	2	m	m	PROPN
ghmj-960	88	3	,	,	PUNCT
ghmj-960	88	4	jensen	jensen	PROPN
ghmj-960	88	5	bm	bm	PROPN
ghmj-960	88	6	,	,	PUNCT
ghmj-960	88	7	poulsen	poulsen	VERB
ghmj-960	88	8	lk	lk	PROPN
ghmj-960	88	9	,	,	PUNCT
ghmj-960	88	10	johansen	johansen	PROPN
ghmj-960	88	11	jd	jd	PROPN
ghmj-960	88	12	,	,	PUNCT
ghmj-960	88	13	garvey	garvey	PROPN
ghmj-960	88	14	lh	lh	PROPN
ghmj-960	88	15	.	.	PUNCT
ghmj-960	89	1	optimizing	optimize	VERB
ghmj-960	89	2	investigation	investigation	NOUN
ghmj-960	89	3	of	of	ADP
ghmj-960	89	4	suspected	suspect	VERB
ghmj-960	89	5	allergy	allergy	NOUN
ghmj-960	89	6	to	to	ADP
ghmj-960	89	7	polyethylene	polyethylene	NOUN
ghmj-960	89	8	glycols	glycol	NOUN
ghmj-960	89	9	2022	2022	NUM
ghmj-960	89	10	the	the	DET
ghmj-960	89	11	results	result	NOUN
ghmj-960	89	12	of	of	ADP
ghmj-960	89	13	the	the	DET
ghmj-960	89	14	histamine	histamine	NOUN
ghmj-960	89	15	test	test	NOUN
ghmj-960	89	16	and	and	CCONJ
ghmj-960	89	17	the	the	DET
ghmj-960	89	18	result	result	NOUN
ghmj-960	89	19	of	of	ADP
ghmj-960	89	20	the	the	DET
ghmj-960	89	21	skin	skin	NOUN
ghmj-960	89	22	prick	prick	NOUN
ghmj-960	89	23	test	test	NOUN
ghmj-960	89	24	were	be	AUX
ghmj-960	89	25	collected	collect	VERB
ghmj-960	89	26	from	from	ADP
ghmj-960	89	27	diagnosis	diagnosis	NOUN
ghmj-960	89	28	time	time	NOUN
ghmj-960	89	29	and	and	CCONJ
ghmj-960	89	30	early	early	ADJ
ghmj-960	89	31	allergy	allergy	NOUN
ghmj-960	89	32	assessment	assessment	NOUN
ghmj-960	89	33	the	the	DET
ghmj-960	89	34	positive	positive	ADJ
ghmj-960	89	35	skin	skin	NOUN
ghmj-960	89	36	prick	prick	NOUN
ghmj-960	89	37	test	test	NOUN
ghmj-960	89	38	patients	patient	NOUN
ghmj-960	89	39	and	and	CCONJ
ghmj-960	89	40	the	the	DET
ghmj-960	89	41	positive	positive	ADJ
ghmj-960	89	42	polyethylene	polyethylene	NOUN
ghmj-960	89	43	glycols	glycol	NOUN
ghmj-960	89	44	3000/6000	3000/6000	NUM
ghmj-960	89	45	patients	patient	NOUN
ghmj-960	89	46	reported	report	VERB
ghmj-960	89	47	positive	positive	ADJ
ghmj-960	89	48	on	on	ADP
ghmj-960	89	49	polyethylene	polyethylene	NOUN
ghmj-960	89	50	glycols	glycol	NOUN
ghmj-960	89	51	20000	20000	NUM
ghmj-960	89	52	.	.	PUNCT
ghmj-960	90	1	three	three	NUM
ghmj-960	90	2	patients	patient	NOUN
ghmj-960	90	3	had	have	VERB
ghmj-960	90	4	systematic	systematic	ADJ
ghmj-960	90	5	urticaria	urticaria	NOUN
ghmj-960	90	6	during	during	ADP
ghmj-960	90	7	the	the	DET
ghmj-960	90	8	skin	skin	NOUN
ghmj-960	90	9	prick	prick	NOUN
ghmj-960	90	10	test	test	NOUN
ghmj-960	90	11	.	.	PUNCT
ghmj-960	91	1	only	only	ADV
ghmj-960	91	2	8	8	NUM
ghmj-960	91	3	patients	patient	NOUN
ghmj-960	91	4	developed	develop	VERB
ghmj-960	91	5	cross	cross	NOUN
ghmj-960	91	6	-	-	NOUN
ghmj-960	91	7	sensitization	sensitization	NOUN
ghmj-960	91	8	to	to	ADP
ghmj-960	91	9	poloxamer	poloxamer	PROPN
ghmj-960	91	10	407	407	NUM
ghmj-960	91	11	and	and	CCONJ
ghmj-960	91	12	3	3	NUM
ghmj-960	91	13	to	to	PART
ghmj-960	91	14	polysorbate	polysorbate	NOUN
ghmj-960	91	15	80	80	NUM
ghmj-960	91	16	.	.	PUNCT
ghmj-960	92	1	all	all	DET
ghmj-960	92	2	controls	control	NOUN
ghmj-960	92	3	tested	test	VERB
ghmj-960	92	4	negative	negative	ADJ
ghmj-960	92	5	.	.	PUNCT
ghmj-960	93	1	the	the	DET
ghmj-960	93	2	skin	skin	NOUN
ghmj-960	93	3	prick	prick	PROPN
ghmj-960	93	4	test	test	NOUN
ghmj-960	93	5	with	with	ADP
ghmj-960	93	6	rising	rise	VERB
ghmj-960	93	7	polyethylene	polyethylene	NOUN
ghmj-960	93	8	glycols	glycol	NOUN
ghmj-960	93	9	20000	20000	NUM
ghmj-960	93	10	concentration	concentration	NOUN
ghmj-960	93	11	is	be	AUX
ghmj-960	93	12	able	able	ADJ
ghmj-960	93	13	to	to	PART
ghmj-960	93	14	be	be	AUX
ghmj-960	93	15	diagnostic	diagnostic	ADJ
ghmj-960	93	16	when	when	SCONJ
ghmj-960	93	17	the	the	DET
ghmj-960	93	18	molecular	molecular	ADJ
ghmj-960	93	19	weight	weight	NOUN
ghmj-960	93	20	of	of	ADP
ghmj-960	93	21	polyethylene	polyethylene	NOUN
ghmj-960	93	22	glycols	glycol	NOUN
ghmj-960	93	23	is	be	AUX
ghmj-960	93	24	negative	negative	ADJ
ghmj-960	93	25	.	.	PUNCT
ghmj-960	94	1	the	the	DET
ghmj-960	94	2	skin	skin	NOUN
ghmj-960	94	3	prick	prick	PROPN
ghmj-960	94	4	test	test	NOUN
ghmj-960	94	5	is	be	AUX
ghmj-960	94	6	mandatory	mandatory	ADJ
ghmj-960	94	7	magro	magro	NOUN
ghmj-960	94	8	c	c	PROPN
ghmj-960	94	9	,	,	PUNCT
ghmj-960	94	10	nuovo	nuovo	PROPN
ghmj-960	94	11	g	g	PROPN
ghmj-960	94	12	,	,	PUNCT
ghmj-960	94	13	mulvey	mulvey	PROPN
ghmj-960	94	14	j	j	PROPN
ghmj-960	94	15	,	,	PUNCT
ghmj-960	94	16	laurence	laurence	PROPN
ghmj-960	94	17	j	j	PROPN
ghmj-960	94	18	,	,	PUNCT
ghmj-960	94	19	harp	harp	PROPN
ghmj-960	94	20	j	j	PROPN
ghmj-960	94	21	,	,	PUNCT
ghmj-960	94	22	crowson	crowson	NOUN
ghmj-960	94	23	an	an	NOUN
ghmj-960	94	24	.	.	PUNCT
ghmj-960	95	1	the	the	DET
ghmj-960	95	2	skin	skin	NOUN
ghmj-960	95	3	as	as	ADP
ghmj-960	95	4	a	a	DET
ghmj-960	95	5	critical	critical	ADJ
ghmj-960	95	6	window	window	NOUN
ghmj-960	95	7	in	in	ADP
ghmj-960	95	8	unveiling	unveil	VERB
ghmj-960	95	9	the	the	DET
ghmj-960	95	10	pathophysiologic	pathophysiologic	ADJ
ghmj-960	95	11	principles	principle	NOUN
ghmj-960	95	12	of	of	ADP
ghmj-960	95	13	covid-19	covid-19	PROPN
ghmj-960	95	14	2021	2021	NUM
ghmj-960	95	15	the	the	DET
ghmj-960	95	16	dataset	dataset	NOUN
ghmj-960	95	17	of	of	ADP
ghmj-960	95	18	cutaneous	cutaneous	ADJ
ghmj-960	95	19	caused	cause	VERB
ghmj-960	95	20	by	by	ADP
ghmj-960	95	21	covid-19	covid-19	PROPN
ghmj-960	95	22	vaccine	vaccine	NOUN
ghmj-960	95	23	and	and	CCONJ
ghmj-960	95	24	covid-19	covid-19	PROPN
ghmj-960	95	25	.	.	PUNCT
ghmj-960	96	1	the	the	DET
ghmj-960	96	2	data	datum	NOUN
ghmj-960	96	3	provided	provide	VERB
ghmj-960	96	4	by	by	ADP
ghmj-960	96	5	regional	regional	ADJ
ghmj-960	96	6	medical	medical	ADJ
ghmj-960	96	7	laboratory	laboratory	NOUN
ghmj-960	96	8	and	and	CCONJ
ghmj-960	96	9	weill	weill	PROPN
ghmj-960	96	10	cornell	cornell	PROPN
ghmj-960	96	11	medicine	medicine	PROPN
ghmj-960	96	12	and	and	CCONJ
ghmj-960	96	13	in	in	ADP
ghmj-960	96	14	tulsa	tulsa	PROPN
ghmj-960	96	15	,	,	PUNCT
ghmj-960	96	16	oklahoma	oklahoma	PROPN
ghmj-960	96	17	from	from	ADP
ghmj-960	96	18	march	march	PROPN
ghmj-960	96	19	2020	2020	NUM
ghmj-960	96	20	to	to	ADP
ghmj-960	96	21	june	june	PROPN
ghmj-960	96	22	2021	2021	NUM
ghmj-960	96	23	was	be	AUX
ghmj-960	96	24	reviewed	review	VERB
ghmj-960	96	25	.	.	PUNCT
ghmj-960	97	1	these	these	PRON
ghmj-960	97	2	included	include	VERB
ghmj-960	97	3	the	the	DET
ghmj-960	97	4	clinical	clinical	ADJ
ghmj-960	97	5	histories	history	NOUN
ghmj-960	97	6	,	,	PUNCT
ghmj-960	97	7	light	light	ADJ
ghmj-960	97	8	microscopic	microscopic	ADJ
ghmj-960	97	9	findings	finding	NOUN
ghmj-960	97	10	,	,	PUNCT
ghmj-960	97	11	additional	additional	ADJ
ghmj-960	97	12	immunohistochemical	immunohistochemical	ADJ
ghmj-960	97	13	studies	study	NOUN
ghmj-960	97	14	,	,	PUNCT
ghmj-960	97	15	and	and	CCONJ
ghmj-960	97	16	molecular	molecular	ADJ
ghmj-960	97	17	studies	study	NOUN
ghmj-960	97	18	after	after	ADP
ghmj-960	97	19	vaccine	vaccine	NOUN
ghmj-960	97	20	of	of	ADP
ghmj-960	97	21	covid-19	covid-19	PROPN
ghmj-960	97	22	administration	administration	NOUN
ghmj-960	97	23	,	,	PUNCT
ghmj-960	97	24	the	the	DET
ghmj-960	97	25	localization	localization	NOUN
ghmj-960	97	26	of	of	ADP
ghmj-960	97	27	spike	spike	ADJ
ghmj-960	97	28	glycoprotein	glycoprotein	NOUN
ghmj-960	97	29	was	be	AUX
ghmj-960	97	30	found	find	VERB
ghmj-960	97	31	among	among	ADP
ghmj-960	97	32	cutaneous	cutaneous	ADJ
ghmj-960	97	33	cases	case	NOUN
ghmj-960	97	34	.	.	PUNCT
ghmj-960	98	1	it	it	PRON
ghmj-960	98	2	binds	bind	VERB
ghmj-960	98	3	endothelium	endothelium	NOUN
ghmj-960	98	4	in	in	ADP
ghmj-960	98	5	the	the	DET
ghmj-960	98	6	absence	absence	NOUN
ghmj-960	98	7	of	of	ADP
ghmj-960	98	8	an	an	DET
ghmj-960	98	9	intact	intact	ADJ
ghmj-960	98	10	virus	virus	NOUN
ghmj-960	98	11	.	.	PUNCT
ghmj-960	99	1	almuhizi	almuhizi	NOUN
ghmj-960	99	2	f	f	PROPN
ghmj-960	99	3	,	,	PUNCT
ghmj-960	99	4	ton	ton	PROPN
ghmj-960	99	5	-	-	PUNCT
ghmj-960	99	6	leclerc	leclerc	PROPN
ghmj-960	99	7	s	s	PROPN
ghmj-960	99	8	,	,	PUNCT
ghmj-960	99	9	fein	fein	PROPN
ghmj-960	99	10	m	m	PROPN
ghmj-960	99	11	,	,	PUNCT
ghmj-960	99	12	tsoukas	tsoukas	PROPN
ghmj-960	99	13	c	c	X
ghmj-960	99	14	,	,	PUNCT
ghmj-960	99	15	garvey	garvey	PROPN
ghmj-960	99	16	lh	lh	PROPN
ghmj-960	99	17	,	,	PUNCT
ghmj-960	99	18	lee	lee	PROPN
ghmj-960	99	19	d	d	PROPN
ghmj-960	99	20	,	,	PUNCT
ghmj-960	99	21	et	et	PROPN
ghmj-960	99	22	al	al	PROPN
ghmj-960	99	23	.	.	PROPN
ghmj-960	100	1	successful	successful	ADJ
ghmj-960	100	2	desensitization	desensitization	NOUN
ghmj-960	100	3	to	to	ADP
ghmj-960	100	4	mrna	mrna	PROPN
ghmj-960	100	5	covid-19	covid-19	PROPN
ghmj-960	100	6	vaccine	vaccine	NOUN
ghmj-960	100	7	in	in	ADP
ghmj-960	100	8	a	a	DET
ghmj-960	100	9	case	case	NOUN
ghmj-960	100	10	series	series	NOUN
ghmj-960	100	11	of	of	ADP
ghmj-960	100	12	patients	patient	NOUN
ghmj-960	100	13	with	with	ADP
ghmj-960	100	14	a	a	DET
ghmj-960	100	15	history	history	NOUN
ghmj-960	100	16	of	of	ADP
ghmj-960	100	17	anaphylaxis	anaphylaxis	NOUN
ghmj-960	100	18	to	to	ADP
ghmj-960	100	19	the	the	DET
ghmj-960	100	20	first	first	ADJ
ghmj-960	100	21	vaccine	vaccine	NOUN
ghmj-960	100	22	dose	dose	VERB
ghmj-960	100	23	2022	2022	NUM
ghmj-960	100	24	participants	participant	NOUN
ghmj-960	100	25	chosen	choose	VERB
ghmj-960	100	26	from	from	ADP
ghmj-960	100	27	cohort	cohort	NOUN
ghmj-960	100	28	of	of	ADP
ghmj-960	100	29	study	study	NOUN
ghmj-960	100	30	related	relate	VERB
ghmj-960	100	31	to	to	ADP
ghmj-960	100	32	ongoing	ongoing	ADJ
ghmj-960	100	33	reaction	reaction	NOUN
ghmj-960	100	34	of	of	ADP
ghmj-960	100	35	allergic	allergic	NOUN
ghmj-960	100	36	to	to	ADP
ghmj-960	100	37	covid-19	covid-19	PROPN
ghmj-960	100	38	vaccine	vaccine	NOUN
ghmj-960	100	39	.	.	PUNCT
ghmj-960	101	1	the	the	DET
ghmj-960	101	2	clinical	clinical	ADJ
ghmj-960	101	3	evaluation	evaluation	NOUN
ghmj-960	101	4	after	after	ADP
ghmj-960	101	5	the	the	DET
ghmj-960	101	6	first	first	ADJ
ghmj-960	101	7	dose	dose	NOUN
ghmj-960	101	8	of	of	ADP
ghmj-960	101	9	either	either	CCONJ
ghmj-960	101	10	the	the	DET
ghmj-960	101	11	pfizer	pfizer	NOUN
ghmj-960	101	12	or	or	CCONJ
ghmj-960	101	13	the	the	DET
ghmj-960	101	14	moderna	moderna	NOUN
ghmj-960	101	15	was	be	AUX
ghmj-960	101	16	hold	hold	VERB
ghmj-960	101	17	at	at	ADP
ghmj-960	101	18	the	the	DET
ghmj-960	101	19	mcgill	mcgill	PROPN
ghmj-960	101	20	university	university	PROPN
ghmj-960	101	21	health	health	NOUN
ghmj-960	101	22	center	center	NOUN
ghmj-960	101	23	(	(	PUNCT
ghmj-960	101	24	muhc	muhc	PROPN
ghmj-960	101	25	)	)	PUNCT
ghmj-960	101	26	.	.	PUNCT
ghmj-960	102	1	the	the	DET
ghmj-960	102	2	participants	participant	NOUN
ghmj-960	102	3	undertook	undertake	VERB
ghmj-960	102	4	skin	skin	NOUN
ghmj-960	102	5	prick	prick	NOUN
ghmj-960	102	6	testing	testing	NOUN
ghmj-960	102	7	.	.	PUNCT
ghmj-960	103	1	a	a	DET
ghmj-960	103	2	desensitization	desensitization	NOUN
ghmj-960	103	3	protocol	protocol	NOUN
ghmj-960	103	4	applied	apply	VERB
ghmj-960	103	5	for	for	ADP
ghmj-960	103	6	the	the	DET
ghmj-960	103	7	second	second	ADJ
ghmj-960	103	8	dose	dose	NOUN
ghmj-960	103	9	six	six	NUM
ghmj-960	103	10	of	of	ADP
ghmj-960	103	11	142	142	NUM
ghmj-960	103	12	patients	patient	NOUN
ghmj-960	103	13	were	be	AUX
ghmj-960	103	14	chosen	choose	VERB
ghmj-960	103	15	with	with	ADP
ghmj-960	103	16	allergic	allergic	ADJ
ghmj-960	103	17	history	history	NOUN
ghmj-960	103	18	.	.	PUNCT
ghmj-960	104	1	all	all	DET
ghmj-960	104	2	participants	participant	NOUN
ghmj-960	104	3	were	be	AUX
ghmj-960	104	4	female	female	ADJ
ghmj-960	104	5	.	.	PUNCT
ghmj-960	105	1	most	most	ADJ
ghmj-960	105	2	of	of	ADP
ghmj-960	105	3	them	they	PRON
ghmj-960	105	4	developed	develop	VERB
ghmj-960	105	5	urticaria	urticaria	NOUN
ghmj-960	105	6	within	within	ADP
ghmj-960	105	7	30	30	NUM
ghmj-960	105	8	minutes	minute	NOUN
ghmj-960	105	9	after	after	ADP
ghmj-960	105	10	the	the	DET
ghmj-960	105	11	first	first	ADJ
ghmj-960	105	12	dose	dose	NOUN
ghmj-960	105	13	of	of	ADP
ghmj-960	105	14	covid-19	covid-19	PROPN
ghmj-960	105	15	vaccine	vaccine	NOUN
ghmj-960	105	16	.	.	PUNCT
ghmj-960	106	1	a	a	DET
ghmj-960	106	2	desensitization	desensitization	NOUN
ghmj-960	106	3	protocol	protocol	NOUN
ghmj-960	106	4	applies	apply	VERB
ghmj-960	106	5	for	for	ADP
ghmj-960	106	6	the	the	DET
ghmj-960	106	7	immediate	immediate	ADJ
ghmj-960	106	8	reaction	reaction	NOUN
ghmj-960	106	9	following	follow	VERB
ghmj-960	106	10	the	the	DET
ghmj-960	106	11	first	first	ADJ
ghmj-960	106	12	dose	dose	NOUN
ghmj-960	106	13	of	of	ADP
ghmj-960	106	14	mrna	mrna	PROPN
ghmj-960	106	15	covid-19	covid-19	PROPN
ghmj-960	106	16	vaccine	vaccine	NOUN
ghmj-960	106	17	.	.	PUNCT
ghmj-960	107	1	61	61	NUM
ghmj-960	107	2	ghmj	ghmj	NOUN
ghmj-960	107	3	(	(	PUNCT
ghmj-960	107	4	global	global	ADJ
ghmj-960	107	5	health	health	PROPN
ghmj-960	107	6	management	management	NOUN
ghmj-960	107	7	journal	journal	PROPN
ghmj-960	107	8	)	)	PUNCT
ghmj-960	107	9	2023	2023	NUM
ghmj-960	107	10	,	,	PUNCT
ghmj-960	107	11	vol	vol	NOUN
ghmj-960	107	12	.	.	PROPN
ghmj-960	107	13	6	6	NUM
ghmj-960	107	14	,	,	PUNCT
ghmj-960	107	15	no	no	NOUN
ghmj-960	107	16	.	.	NOUN
ghmj-960	107	17	2	2	NUM
ghmj-960	107	18	nugrahaeni	nugrahaeni	NOUN
ghmj-960	107	19	&	&	CCONJ
ghmj-960	107	20	budiyanti	budiyanti	PROPN
ghmj-960	107	21	author	author	NOUN
ghmj-960	107	22	title	title	NOUN
ghmj-960	107	23	year	year	NOUN
ghmj-960	107	24	method	method	NOUN
ghmj-960	107	25	resume	resume	NOUN
ghmj-960	107	26	pitlick	pitlick	PROPN
ghmj-960	107	27	mm	mm	PROPN
ghmj-960	107	28	,	,	PUNCT
ghmj-960	107	29	joshi	joshi	PROPN
ghmj-960	107	30	ay	ay	PROPN
ghmj-960	107	31	,	,	PUNCT
ghmj-960	107	32	gonzalezestrada	gonzalezestrada	PROPN
ghmj-960	107	33	a	a	NOUN
ghmj-960	107	34	,	,	PUNCT
ghmj-960	107	35	chiarella	chiarella	PROPN
ghmj-960	107	36	se	se	X
ghmj-960	107	37	delayed	delay	VERB
ghmj-960	107	38	systematic	systematic	ADJ
ghmj-960	107	39	urticarial	urticarial	ADJ
ghmj-960	107	40	reactions	reaction	NOUN
ghmj-960	107	41	following	follow	VERB
ghmj-960	107	42	mrna	mrna	PROPN
ghmj-960	107	43	covid19	covid19	NOUN
ghmj-960	107	44	vaccination	vaccination	NOUN
ghmj-960	107	45	2022	2022	NUM
ghmj-960	107	46	the	the	DET
ghmj-960	107	47	study	study	NOUN
ghmj-960	107	48	was	be	AUX
ghmj-960	107	49	a	a	DET
ghmj-960	107	50	retrospective	retrospective	ADJ
ghmj-960	107	51	case	case	NOUN
ghmj-960	107	52	series	series	NOUN
ghmj-960	107	53	from	from	ADP
ghmj-960	107	54	19	19	NUM
ghmj-960	107	55	january	january	NOUN
ghmj-960	107	56	2021	2021	NUM
ghmj-960	107	57	until	until	ADP
ghmj-960	107	58	30	30	NUM
ghmj-960	107	59	april	april	PROPN
ghmj-960	107	60	2021	2021	NUM
ghmj-960	107	61	.	.	PUNCT
ghmj-960	108	1	there	there	PRON
ghmj-960	108	2	were	be	VERB
ghmj-960	108	3	twelve	twelve	NUM
ghmj-960	108	4	patients	patient	NOUN
ghmj-960	108	5	referring	refer	VERB
ghmj-960	108	6	to	to	ADP
ghmj-960	108	7	mayo	mayo	NOUN
ghmj-960	108	8	clinics	clinic	NOUN
ghmj-960	108	9	in	in	ADP
ghmj-960	108	10	jacksonville	jacksonville	PROPN
ghmj-960	108	11	,	,	PUNCT
ghmj-960	108	12	florida	florida	PROPN
ghmj-960	108	13	,	,	PUNCT
ghmj-960	108	14	and	and	CCONJ
ghmj-960	108	15	rochester	rochester	PROPN
ghmj-960	108	16	,	,	PUNCT
ghmj-960	108	17	minnesota	minnesota	PROPN
ghmj-960	108	18	following	follow	VERB
ghmj-960	108	19	mrna	mrna	PROPN
ghmj-960	108	20	covid-19	covid-19	PROPN
ghmj-960	108	21	administration	administration	NOUN
ghmj-960	108	22	in	in	ADP
ghmj-960	108	23	order	order	NOUN
ghmj-960	108	24	to	to	PART
ghmj-960	108	25	evaluate	evaluate	VERB
ghmj-960	108	26	delayed	delay	VERB
ghmj-960	108	27	systemic	systemic	ADJ
ghmj-960	108	28	urticarial	urticarial	ADJ
ghmj-960	108	29	reactions	reaction	NOUN
ghmj-960	108	30	.	.	PUNCT
ghmj-960	109	1	each	each	DET
ghmj-960	109	2	patient	patient	NOUN
ghmj-960	109	3	reported	report	VERB
ghmj-960	109	4	a	a	DET
ghmj-960	109	5	history	history	NOUN
ghmj-960	109	6	of	of	ADP
ghmj-960	109	7	medical	medical	ADJ
ghmj-960	109	8	and	and	CCONJ
ghmj-960	109	9	allergic	allergic	ADJ
ghmj-960	109	10	,	,	PUNCT
ghmj-960	109	11	demographics	demographic	NOUN
ghmj-960	109	12	,	,	PUNCT
ghmj-960	109	13	a	a	DET
ghmj-960	109	14	side	side	ADJ
ghmj-960	109	15	effect	effect	NOUN
ghmj-960	109	16	of	of	ADP
ghmj-960	109	17	the	the	DET
ghmj-960	109	18	covid-19	covid-19	PROPN
ghmj-960	109	19	vaccine	vaccine	NOUN
ghmj-960	109	20	,	,	PUNCT
ghmj-960	109	21	and	and	CCONJ
ghmj-960	109	22	the	the	DET
ghmj-960	109	23	results	result	NOUN
ghmj-960	109	24	of	of	ADP
ghmj-960	109	25	vaccine	vaccine	NOUN
ghmj-960	109	26	excipient	excipient	ADJ
ghmj-960	109	27	skin	skin	NOUN
ghmj-960	109	28	testing	testing	NOUN
ghmj-960	109	29	.	.	PUNCT
ghmj-960	110	1	eleven	eleven	NUM
ghmj-960	110	2	patients	patient	NOUN
ghmj-960	110	3	who	who	PRON
ghmj-960	110	4	developed	develop	VERB
ghmj-960	110	5	delayed	delay	VERB
ghmj-960	110	6	urticaria	urticaria	NOUN
ghmj-960	110	7	after	after	ADP
ghmj-960	110	8	getting	get	VERB
ghmj-960	110	9	the	the	DET
ghmj-960	110	10	first	first	ADJ
ghmj-960	110	11	dose	dose	NOUN
ghmj-960	110	12	of	of	ADP
ghmj-960	110	13	covid-19	covid-19	PROPN
ghmj-960	110	14	vaccines	vaccine	NOUN
ghmj-960	110	15	.	.	PUNCT
ghmj-960	111	1	antihistamines	antihistamine	NOUN
ghmj-960	111	2	are	be	AUX
ghmj-960	111	3	able	able	ADJ
ghmj-960	111	4	to	to	PART
ghmj-960	111	5	treat	treat	VERB
ghmj-960	111	6	delayed	delay	VERB
ghmj-960	111	7	systemic	systemic	ADJ
ghmj-960	111	8	urticarial	urticarial	ADJ
ghmj-960	111	9	reactions	reaction	NOUN
ghmj-960	111	10	after	after	ADP
ghmj-960	111	11	mrna	mrna	PROPN
ghmj-960	111	12	covid-19	covid-19	PROPN
ghmj-960	111	13	vaccine	vaccine	NOUN
ghmj-960	111	14	administration	administration	NOUN
ghmj-960	111	15	.	.	PUNCT
ghmj-960	112	1	macy	macy	PROPN
ghmj-960	112	2	e	e	PROPN
ghmj-960	112	3	,	,	PUNCT
ghmj-960	112	4	pandya	pandya	PROPN
ghmj-960	112	5	s	s	PROPN
ghmj-960	112	6	,	,	PUNCT
ghmj-960	112	7	sheikh	sheikh	PROPN
ghmj-960	112	8	j	j	PROPN
ghmj-960	112	9	,	,	PUNCT
ghmj-960	112	10	brunette	brunette	PROPN
ghmj-960	112	11	a	a	X
ghmj-960	112	12	,	,	PUNCT
ghmj-960	112	13	m.shi	m.shi	PROPN
ghmj-960	112	14	j	j	PROPN
ghmj-960	112	15	,	,	PUNCT
ghmj-960	112	16	chung	chung	PROPN
ghmj-960	112	17	j	j	PROPN
ghmj-960	112	18	,	,	PUNCT
ghmj-960	112	19	et	et	PROPN
ghmj-960	112	20	al	al	PROPN
ghmj-960	112	21	population	population	PROPN
ghmj-960	112	22	based	base	VERB
ghmj-960	112	23	incidence	incidence	NOUN
ghmj-960	112	24	,	,	PUNCT
ghmj-960	112	25	severity	severity	NOUN
ghmj-960	112	26	,	,	PUNCT
ghmj-960	112	27	and	and	CCONJ
ghmj-960	112	28	risk	risk	NOUN
ghmj-960	112	29	factors	factor	NOUN
ghmj-960	112	30	associated	associate	VERB
ghmj-960	112	31	with	with	ADP
ghmj-960	112	32	treated	treat	VERB
ghmj-960	112	33	acuteonset	acuteonset	NOUN
ghmj-960	112	34	covid19	covid19	PROPN
ghmj-960	112	35	mrna	mrna	PROPN
ghmj-960	112	36	vaccinationassociated	vaccinationassociate	VERB
ghmj-960	112	37	hypersensitivity	hypersensitivity	NOUN
ghmj-960	112	38	reactions	reaction	NOUN
ghmj-960	112	39	2022	2022	NUM
ghmj-960	112	40	this	this	DET
ghmj-960	112	41	study	study	NOUN
ghmj-960	112	42	collected	collect	VERB
ghmj-960	112	43	unique	unique	ADJ
ghmj-960	112	44	individuals	individual	NOUN
ghmj-960	112	45	with	with	ADP
ghmj-960	112	46	active	active	ADJ
ghmj-960	112	47	kaiser	kaiser	PROPN
ghmj-960	112	48	permanente	permanente	PROPN
ghmj-960	112	49	southern	southern	PROPN
ghmj-960	112	50	california	california	PROPN
ghmj-960	112	51	(	(	PUNCT
ghmj-960	112	52	kpsc	kpsc	PROPN
ghmj-960	112	53	)	)	PUNCT
ghmj-960	112	54	health	health	NOUN
ghmj-960	112	55	plan	plan	NOUN
ghmj-960	112	56	coverage	coverage	NOUN
ghmj-960	112	57	.	.	PUNCT
ghmj-960	113	1	they	they	PRON
ghmj-960	113	2	were	be	AUX
ghmj-960	113	3	administered	administer	VERB
ghmj-960	113	4	the	the	DET
ghmj-960	113	5	covid-19	covid-19	PROPN
ghmj-960	113	6	mrna	mrna	NOUN
ghmj-960	113	7	vaccine	vaccine	NOUN
ghmj-960	113	8	at	at	ADP
ghmj-960	113	9	the	the	DET
ghmj-960	113	10	kpsc	kpsc	PROPN
ghmj-960	113	11	facility	facility	NOUN
ghmj-960	113	12	from	from	ADP
ghmj-960	113	13	16	16	NUM
ghmj-960	113	14	december	december	PROPN
ghmj-960	113	15	2020	2020	NUM
ghmj-960	113	16	until	until	ADP
ghmj-960	113	17	11	11	NUM
ghmj-960	113	18	march	march	NOUN
ghmj-960	113	19	2021	2021	NUM
ghmj-960	113	20	.	.	PUNCT
ghmj-960	114	1	they	they	PRON
ghmj-960	114	2	were	be	AUX
ghmj-960	114	3	also	also	ADV
ghmj-960	114	4	identified	identify	VERB
ghmj-960	114	5	,	,	PUNCT
ghmj-960	114	6	characterized	characterize	VERB
ghmj-960	114	7	,	,	PUNCT
ghmj-960	114	8	and	and	CCONJ
ghmj-960	114	9	along	along	ADP
ghmj-960	114	10	with	with	ADP
ghmj-960	114	11	all	all	DET
ghmj-960	114	12	treated	treat	VERB
ghmj-960	114	13	acute	acute	NOUN
ghmj-960	114	14	-	-	PUNCT
ghmj-960	114	15	onset	onset	NOUN
ghmj-960	114	16	vaccinationassociated	vaccinationassociate	VERB
ghmj-960	114	17	hypersensitivity	hypersensitivity	NOUN
ghmj-960	114	18	events	event	NOUN
ghmj-960	114	19	.	.	PUNCT
ghmj-960	115	1	the	the	DET
ghmj-960	115	2	younger	young	ADJ
ghmj-960	115	3	females	female	NOUN
ghmj-960	115	4	with	with	ADP
ghmj-960	115	5	typical	typical	ADJ
ghmj-960	115	6	risk	risk	NOUN
ghmj-960	115	7	factors	factor	NOUN
ghmj-960	115	8	have	have	AUX
ghmj-960	115	9	more	more	ADV
ghmj-960	115	10	likely	likely	ADV
ghmj-960	115	11	treated	treat	VERB
ghmj-960	115	12	with	with	ADP
ghmj-960	115	13	acute	acute	NOUN
ghmj-960	115	14	-	-	PUNCT
ghmj-960	115	15	onset	onset	NOUN
ghmj-960	115	16	hypersensitivity	hypersensitivity	NOUN
ghmj-960	115	17	events	event	NOUN
ghmj-960	115	18	following	follow	VERB
ghmj-960	115	19	covid-19	covid-19	PROPN
ghmj-960	115	20	vaccine	vaccine	NOUN
ghmj-960	115	21	.	.	PUNCT
ghmj-960	116	1	only	only	ADV
ghmj-960	116	2	15200	15200	NUM
ghmj-960	116	3	people	people	NOUN
ghmj-960	116	4	developed	develop	VERB
ghmj-960	116	5	chronic	chronic	ADJ
ghmj-960	116	6	urticaria	urticaria	NOUN
ghmj-960	116	7	.	.	PUNCT
ghmj-960	117	1	16.3	16.3	NUM
ghmj-960	117	2	%	%	NOUN
ghmj-960	117	3	of	of	ADP
ghmj-960	117	4	patients	patient	NOUN
ghmj-960	117	5	with	with	ADP
ghmj-960	117	6	treated	treat	VERB
ghmj-960	117	7	hypersensitivity	hypersensitivity	NOUN
ghmj-960	117	8	reactions	reaction	NOUN
ghmj-960	117	9	had	have	VERB
ghmj-960	117	10	chronic	chronic	ADJ
ghmj-960	117	11	urticarial	urticarial	NOUN
ghmj-960	117	12	after	after	SCONJ
ghmj-960	117	13	first	first	ADJ
ghmj-960	117	14	dose	dose	NOUN
ghmj-960	117	15	reactions	reaction	NOUN
ghmj-960	117	16	and	and	CCONJ
ghmj-960	117	17	12.5	12.5	NUM
ghmj-960	117	18	%	%	NOUN
ghmj-960	117	19	of	of	ADP
ghmj-960	117	20	them	they	PRON
ghmj-960	117	21	had	have	VERB
ghmj-960	117	22	it	it	PRON
ghmj-960	117	23	after	after	ADP
ghmj-960	117	24	the	the	DET
ghmj-960	117	25	second	second	ADJ
ghmj-960	117	26	dose	dose	NOUN
ghmj-960	117	27	reactions	reaction	NOUN
ghmj-960	117	28	.	.	PUNCT
ghmj-960	118	1	3	3	X
ghmj-960	118	2	.	.	X
ghmj-960	118	3	results	result	VERB
ghmj-960	118	4	a.	a.	NOUN
ghmj-960	118	5	prevalence	prevalence	NOUN
ghmj-960	118	6	of	of	ADP
ghmj-960	118	7	urticaria	urticaria	PROPN
ghmj-960	118	8	post	post	ADJ
ghmj-960	118	9	-	-	ADJ
ghmj-960	118	10	covid-19	covid-19	ADJ
ghmj-960	118	11	vaccination	vaccination	NOUN
ghmj-960	118	12	numerous	numerous	ADJ
ghmj-960	118	13	adverse	adverse	ADJ
ghmj-960	118	14	reactions	reaction	NOUN
ghmj-960	118	15	to	to	ADP
ghmj-960	118	16	the	the	DET
ghmj-960	118	17	covid-19	covid-19	PROPN
ghmj-960	118	18	vaccination	vaccination	NOUN
ghmj-960	118	19	have	have	AUX
ghmj-960	118	20	been	be	AUX
ghmj-960	118	21	reported	report	VERB
ghmj-960	118	22	(	(	PUNCT
ghmj-960	118	23	burlando	burlando	NOUN
ghmj-960	118	24	et	et	PROPN
ghmj-960	118	25	al	al	PROPN
ghmj-960	118	26	.	.	PROPN
ghmj-960	118	27	,	,	PUNCT
ghmj-960	118	28	2021	2021	NUM
ghmj-960	118	29	)	)	PUNCT
ghmj-960	118	30	.	.	PUNCT
ghmj-960	119	1	based	base	VERB
ghmj-960	119	2	on	on	ADP
ghmj-960	119	3	burlando	burlando	PROPN
ghmj-960	119	4	et	et	PROPN
ghmj-960	119	5	al	al	PROPN
ghmj-960	119	6	(	(	PUNCT
ghmj-960	119	7	2022	2022	NUM
ghmj-960	119	8	)	)	PUNCT
ghmj-960	119	9	,	,	PUNCT
ghmj-960	119	10	only	only	ADV
ghmj-960	119	11	21	21	NUM
ghmj-960	119	12	of	of	ADP
ghmj-960	119	13	200	200	NUM
ghmj-960	119	14	patients	patient	NOUN
ghmj-960	119	15	developed	develop	VERB
ghmj-960	119	16	cutaneous	cutaneous	ADJ
ghmj-960	119	17	reactions	reaction	NOUN
ghmj-960	119	18	following	follow	VERB
ghmj-960	119	19	covid-19	covid-19	PROPN
ghmj-960	119	20	vaccine	vaccine	NOUN
ghmj-960	119	21	administration	administration	NOUN
ghmj-960	119	22	.	.	PUNCT
ghmj-960	120	1	fifteen	fifteen	NUM
ghmj-960	120	2	(	(	PUNCT
ghmj-960	120	3	71	71	NUM
ghmj-960	120	4	%	%	NOUN
ghmj-960	120	5	)	)	PUNCT
ghmj-960	120	6	patients	patient	NOUN
ghmj-960	120	7	were	be	AUX
ghmj-960	120	8	females	female	NOUN
ghmj-960	120	9	with	with	ADP
ghmj-960	120	10	a	a	DET
ghmj-960	120	11	mean	mean	ADJ
ghmj-960	120	12	age	age	NOUN
ghmj-960	120	13	of	of	ADP
ghmj-960	120	14	48	48	NUM
ghmj-960	120	15	years	year	NOUN
ghmj-960	120	16	.	.	PUNCT
ghmj-960	121	1	ten	ten	NUM
ghmj-960	121	2	of	of	ADP
ghmj-960	121	3	twenty	twenty	NUM
ghmj-960	121	4	-	-	PUNCT
ghmj-960	121	5	one	one	NUM
ghmj-960	121	6	patients	patient	NOUN
ghmj-960	121	7	developed	develop	VERB
ghmj-960	121	8	urticarial	urticarial	ADJ
ghmj-960	121	9	reactions	reaction	NOUN
ghmj-960	121	10	following	follow	VERB
ghmj-960	121	11	covid-19	covid-19	PROPN
ghmj-960	121	12	administration	administration	NOUN
ghmj-960	121	13	.	.	PUNCT
ghmj-960	122	1	four	four	NUM
ghmj-960	122	2	of	of	ADP
ghmj-960	122	3	them	they	PRON
ghmj-960	122	4	appeared	appear	VERB
ghmj-960	122	5	it	it	PRON
ghmj-960	122	6	within	within	ADP
ghmj-960	122	7	24	24	NUM
ghmj-960	122	8	hours	hour	NOUN
ghmj-960	122	9	and	and	CCONJ
ghmj-960	122	10	the	the	DET
ghmj-960	122	11	rest	rest	NOUN
ghmj-960	122	12	after	after	ADP
ghmj-960	122	13	24	24	NUM
ghmj-960	122	14	hours	hour	NOUN
ghmj-960	122	15	.	.	PUNCT
ghmj-960	123	1	astrazeneca	astrazeneca	PROPN
ghmj-960	123	2	,	,	PUNCT
ghmj-960	123	3	moderna	moderna	PROPN
ghmj-960	123	4	,	,	PUNCT
ghmj-960	123	5	and	and	CCONJ
ghmj-960	123	6	pfizer	pfizer	NOUN
ghmj-960	123	7	cause	cause	VERB
ghmj-960	123	8	acute	acute	ADJ
ghmj-960	123	9	urticaria	urticaria	NOUN
ghmj-960	123	10	,	,	PUNCT
ghmj-960	123	11	an	an	DET
ghmj-960	123	12	adverse	adverse	ADJ
ghmj-960	123	13	reaction	reaction	NOUN
ghmj-960	123	14	after	after	ADP
ghmj-960	123	15	getting	get	VERB
ghmj-960	123	16	vaccinated	vaccinate	VERB
ghmj-960	123	17	(	(	PUNCT
ghmj-960	123	18	brooks	brooks	PROPN
ghmj-960	123	19	et	et	PROPN
ghmj-960	123	20	al	al	PROPN
ghmj-960	123	21	.	.	PROPN
ghmj-960	123	22	,	,	PUNCT
ghmj-960	123	23	2022	2022	NUM
ghmj-960	123	24	)	)	PUNCT
ghmj-960	123	25	.	.	PUNCT
ghmj-960	124	1	messenger	messenger	PROPN
ghmj-960	124	2	rna	rna	PROPN
ghmj-960	124	3	(	(	PUNCT
ghmj-960	124	4	mrna	mrna	PROPN
ghmj-960	124	5	)	)	PUNCT
ghmj-960	124	6	which	which	PRON
ghmj-960	124	7	encapsulates	encapsulate	VERB
ghmj-960	124	8	lipid	lipid	ADJ
ghmj-960	124	9	nanoparticles	nanoparticle	NOUN
ghmj-960	124	10	in	in	ADP
ghmj-960	124	11	the	the	DET
ghmj-960	124	12	pfizer	pfizer	NOUN
ghmj-960	124	13	vaccine	vaccine	NOUN
ghmj-960	124	14	and	and	CCONJ
ghmj-960	124	15	the	the	DET
ghmj-960	124	16	moderna	moderna	PROPN
ghmj-960	124	17	vaccine	vaccine	NOUN
ghmj-960	124	18	,	,	PUNCT
ghmj-960	124	19	encrypt	encrypt	VERB
ghmj-960	124	20	the	the	DET
ghmj-960	124	21	sars	sar	NOUN
ghmj-960	124	22	cov	cov	PROPN
ghmj-960	124	23	2	2	NUM
ghmj-960	124	24	viral	viral	ADJ
ghmj-960	124	25	spike	spike	ADJ
ghmj-960	124	26	protein	protein	NOUN
ghmj-960	124	27	inducing	induce	VERB
ghmj-960	124	28	both	both	DET
ghmj-960	124	29	cell	cell	NOUN
ghmj-960	124	30	-	-	PUNCT
ghmj-960	124	31	mediated	mediate	VERB
ghmj-960	124	32	responses	response	NOUN
ghmj-960	124	33	and	and	CCONJ
ghmj-960	124	34	antibodies	antibody	NOUN
ghmj-960	124	35	.	.	PUNCT
ghmj-960	125	1	a	a	DET
ghmj-960	125	2	viral	viral	ADJ
ghmj-960	125	3	vector	vector	NOUN
ghmj-960	125	4	needs	need	VERB
ghmj-960	125	5	to	to	PART
ghmj-960	125	6	synthesize	synthesize	VERB
ghmj-960	125	7	sars	sar	NOUN
ghmj-960	125	8	-	-	PUNCT
ghmj-960	125	9	cov-2	cov-2	NOUN
ghmj-960	125	10	protein	protein	NOUN
ghmj-960	125	11	s	s	VERB
ghmj-960	125	12	is	be	AUX
ghmj-960	125	13	the	the	DET
ghmj-960	125	14	astrazeneca	astrazeneca	NOUN
ghmj-960	125	15	vaccine	vaccine	NOUN
ghmj-960	125	16	(	(	PUNCT
ghmj-960	125	17	bianchi	bianchi	PROPN
ghmj-960	125	18	et	et	PROPN
ghmj-960	125	19	al	al	PROPN
ghmj-960	125	20	.	.	PROPN
ghmj-960	125	21	,	,	PUNCT
ghmj-960	125	22	2021	2021	NUM
ghmj-960	125	23	)	)	PUNCT
ghmj-960	125	24	.	.	PUNCT
ghmj-960	126	1	after	after	ADP
ghmj-960	126	2	getting	get	VERB
ghmj-960	126	3	messenger	messenger	NOUN
ghmj-960	126	4	rna	rna	NOUN
ghmj-960	126	5	or	or	CCONJ
ghmj-960	126	6	mrna	mrna	PROPN
ghmj-960	126	7	vaccination	vaccination	NOUN
ghmj-960	126	8	from	from	ADP
ghmj-960	126	9	moderna	moderna	PROPN
ghmj-960	126	10	and	and	CCONJ
ghmj-960	126	11	pfizer	pfizer	NOUN
ghmj-960	126	12	,	,	PUNCT
ghmj-960	126	13	the	the	DET
ghmj-960	126	14	local	local	ADJ
ghmj-960	126	15	reactions	reaction	NOUN
ghmj-960	126	16	were	be	AUX
ghmj-960	126	17	the	the	DET
ghmj-960	126	18	most	most	ADV
ghmj-960	126	19	frequent	frequent	ADJ
ghmj-960	126	20	cutaneous	cutaneous	ADJ
ghmj-960	126	21	findings	finding	NOUN
ghmj-960	126	22	.	.	PUNCT
ghmj-960	127	1	the	the	DET
ghmj-960	127	2	immune	immune	ADJ
ghmj-960	127	3	response	response	NOUN
ghmj-960	127	4	shows	show	VERB
ghmj-960	127	5	as	as	ADP
ghmj-960	127	6	rash	rash	NOUN
ghmj-960	127	7	against	against	ADP
ghmj-960	127	8	spike	spike	ADJ
ghmj-960	127	9	protein	protein	NOUN
ghmj-960	127	10	which	which	PRON
ghmj-960	127	11	is	be	AUX
ghmj-960	127	12	similar	similar	ADJ
ghmj-960	127	13	to	to	ADP
ghmj-960	127	14	morbilliform	morbilliform	ADJ
ghmj-960	127	15	eruptions	eruption	NOUN
ghmj-960	127	16	that	that	PRON
ghmj-960	127	17	are	be	AUX
ghmj-960	127	18	negative	negative	ADJ
ghmj-960	127	19	.	.	PUNCT
ghmj-960	128	1	like	like	ADP
ghmj-960	128	2	patients	patient	NOUN
ghmj-960	128	3	with	with	ADP
ghmj-960	128	4	primary	primary	ADJ
ghmj-960	128	5	covid-19	covid-19	PROPN
ghmj-960	128	6	infection	infection	NOUN
ghmj-960	128	7	,	,	PUNCT
ghmj-960	128	8	their	their	PRON
ghmj-960	128	9	negatives	negative	NOUN
ghmj-960	128	10	are	be	AUX
ghmj-960	128	11	in	in	ADP
ghmj-960	128	12	viral	viral	ADJ
ghmj-960	128	13	particles	particle	NOUN
ghmj-960	128	14	(	(	PUNCT
ghmj-960	128	15	burlando	burlando	NOUN
ghmj-960	128	16	et	et	PROPN
ghmj-960	128	17	al	al	PROPN
ghmj-960	128	18	.	.	PROPN
ghmj-960	128	19	,	,	PUNCT
ghmj-960	128	20	2021	2021	NUM
ghmj-960	128	21	)	)	PUNCT
ghmj-960	128	22	.	.	PUNCT
ghmj-960	129	1	only	only	ADV
ghmj-960	129	2	28	28	NUM
ghmj-960	129	3	%	%	NOUN
ghmj-960	129	4	of	of	ADP
ghmj-960	129	5	urticarial	urticarial	ADJ
ghmj-960	129	6	rashes	rash	NOUN
ghmj-960	129	7	incident	incident	NOUN
ghmj-960	129	8	found	find	VERB
ghmj-960	129	9	among	among	ADP
ghmj-960	129	10	all	all	DET
ghmj-960	129	11	cutaneous	cutaneous	ADJ
ghmj-960	129	12	adverse	adverse	ADJ
ghmj-960	129	13	reactions	reaction	NOUN
ghmj-960	129	14	.	.	PUNCT
ghmj-960	130	1	the	the	DET
ghmj-960	130	2	most	most	ADV
ghmj-960	130	3	common	common	ADJ
ghmj-960	130	4	of	of	ADP
ghmj-960	130	5	it	it	PRON
ghmj-960	130	6	in	in	ADP
ghmj-960	130	7	patients	patient	NOUN
ghmj-960	130	8	are	be	AUX
ghmj-960	130	9	rash	rash	ADJ
ghmj-960	130	10	and	and	CCONJ
ghmj-960	130	11	itching	itch	VERB
ghmj-960	130	12	after	after	ADP
ghmj-960	130	13	receiving	receive	VERB
ghmj-960	130	14	mrna	mrna	PROPN
ghmj-960	130	15	covid-19	covid-19	PROPN
ghmj-960	130	16	vaccines	vaccine	NOUN
ghmj-960	130	17	(	(	PUNCT
ghmj-960	130	18	grieco	grieco	PROPN
ghmj-960	130	19	et	et	PROPN
ghmj-960	130	20	al	al	PROPN
ghmj-960	130	21	.	.	PROPN
ghmj-960	130	22	,	,	PUNCT
ghmj-960	130	23	2022	2022	NUM
ghmj-960	130	24	)	)	PUNCT
ghmj-960	130	25	.	.	PUNCT
ghmj-960	131	1	the	the	DET
ghmj-960	131	2	risk	risk	NOUN
ghmj-960	131	3	of	of	ADP
ghmj-960	131	4	urticaria	urticaria	NOUN
ghmj-960	131	5	after	after	ADP
ghmj-960	131	6	administration	administration	NOUN
ghmj-960	131	7	of	of	ADP
ghmj-960	131	8	the	the	DET
ghmj-960	131	9	pfizer	pfizer	NOUN
ghmj-960	131	10	mrna	mrna	PROPN
ghmj-960	131	11	covid-19	covid-19	PROPN
ghmj-960	131	12	vaccine	vaccine	NOUN
ghmj-960	131	13	among	among	ADP
ghmj-960	131	14	healthcare	healthcare	NOUN
ghmj-960	131	15	workers	worker	NOUN
ghmj-960	131	16	was	be	AUX
ghmj-960	131	17	higher	high	ADJ
ghmj-960	131	18	among	among	ADP
ghmj-960	131	19	females	female	NOUN
ghmj-960	131	20	and	and	CCONJ
ghmj-960	131	21	people	people	NOUN
ghmj-960	131	22	aged	age	VERB
ghmj-960	131	23	45	45	NUM
ghmj-960	131	24	-	-	SYM
ghmj-960	131	25	49	49	NUM
ghmj-960	131	26	years	year	NOUN
ghmj-960	131	27	old	old	ADJ
ghmj-960	131	28	.	.	PUNCT
ghmj-960	132	1	it	it	PRON
ghmj-960	132	2	rose	rise	VERB
ghmj-960	132	3	in	in	ADP
ghmj-960	132	4	people	people	NOUN
ghmj-960	132	5	with	with	ADP
ghmj-960	132	6	had	have	AUX
ghmj-960	132	7	previous	previous	ADJ
ghmj-960	132	8	covid-19	covid-19	PROPN
ghmj-960	132	9	infections	infection	NOUN
ghmj-960	132	10	and	and	CCONJ
ghmj-960	132	11	people	people	NOUN
ghmj-960	132	12	with	with	ADP
ghmj-960	132	13	an	an	DET
ghmj-960	132	14	allergy	allergy	NOUN
ghmj-960	132	15	history	history	NOUN
ghmj-960	132	16	(	(	PUNCT
ghmj-960	132	17	cugno	cugno	NOUN
ghmj-960	132	18	et	et	PROPN
ghmj-960	132	19	al	al	PROPN
ghmj-960	132	20	.	.	PROPN
ghmj-960	132	21	,	,	PUNCT
ghmj-960	132	22	2021	2021	NUM
ghmj-960	132	23	)	)	PUNCT
ghmj-960	132	24	.	.	PUNCT
ghmj-960	133	1	nugrahaeni	nugrahaeni	PROPN
ghmj-960	133	2	&	&	CCONJ
ghmj-960	133	3	budiyanti	budiyanti	PROPN
ghmj-960	133	4	ghmj	ghmj	PROPN
ghmj-960	133	5	(	(	PUNCT
ghmj-960	133	6	global	global	ADJ
ghmj-960	133	7	health	health	PROPN
ghmj-960	133	8	management	management	NOUN
ghmj-960	133	9	journal	journal	PROPN
ghmj-960	133	10	)	)	PUNCT
ghmj-960	133	11	2023	2023	NUM
ghmj-960	133	12	,	,	PUNCT
ghmj-960	133	13	vol	vol	NOUN
ghmj-960	133	14	.	.	PROPN
ghmj-960	133	15	6	6	NUM
ghmj-960	133	16	,	,	PUNCT
ghmj-960	133	17	no	no	INTJ
ghmj-960	133	18	.	.	NOUN
ghmj-960	133	19	2	2	NUM
ghmj-960	133	20	62	62	NUM
ghmj-960	133	21	in	in	ADP
ghmj-960	133	22	spanish	spanish	ADJ
ghmj-960	133	23	,	,	PUNCT
ghmj-960	133	24	only	only	ADV
ghmj-960	133	25	21.1	21.1	NUM
ghmj-960	133	26	%	%	NOUN
ghmj-960	133	27	of	of	ADP
ghmj-960	133	28	patients	patient	NOUN
ghmj-960	133	29	had	have	VERB
ghmj-960	133	30	urticaria	urticaria	NOUN
ghmj-960	133	31	after	after	ADP
ghmj-960	133	32	getting	get	VERB
ghmj-960	133	33	astrazeneca	astrazeneca	NOUN
ghmj-960	133	34	,	,	PUNCT
ghmj-960	133	35	the	the	DET
ghmj-960	133	36	covid-19	covid-19	PROPN
ghmj-960	133	37	vaccine	vaccine	NOUN
ghmj-960	133	38	.	.	PUNCT
ghmj-960	134	1	it	it	PRON
ghmj-960	134	2	was	be	AUX
ghmj-960	134	3	the	the	DET
ghmj-960	134	4	most	most	ADV
ghmj-960	134	5	frequent	frequent	ADJ
ghmj-960	134	6	reaction	reaction	NOUN
ghmj-960	134	7	after	after	ADP
ghmj-960	134	8	administration	administration	NOUN
ghmj-960	134	9	(	(	PUNCT
ghmj-960	134	10	català	català	PROPN
ghmj-960	134	11	et	et	PROPN
ghmj-960	134	12	al	al	PROPN
ghmj-960	134	13	.	.	PROPN
ghmj-960	134	14	,	,	PUNCT
ghmj-960	134	15	2021	2021	NUM
ghmj-960	134	16	)	)	PUNCT
ghmj-960	134	17	.	.	PUNCT
ghmj-960	135	1	the	the	DET
ghmj-960	135	2	higher	high	ADJ
ghmj-960	135	3	urticarial	urticarial	NOUN
ghmj-960	135	4	and	and	CCONJ
ghmj-960	135	5	.	.	PUNCT
ghmj-960	136	1	angioedema	angioedema	NOUN
ghmj-960	136	2	reactions	reaction	NOUN
ghmj-960	136	3	were	be	AUX
ghmj-960	136	4	40.7	40.7	NUM
ghmj-960	136	5	%	%	NOUN
ghmj-960	136	6	(	(	PUNCT
ghmj-960	136	7	n=	n=	ADJ
ghmj-960	136	8	24	24	NUM
ghmj-960	136	9	)	)	PUNCT
ghmj-960	136	10	of	of	ADP
ghmj-960	136	11	patients	patient	NOUN
ghmj-960	136	12	after	after	ADP
ghmj-960	136	13	pfizer	pfizer	NOUN
ghmj-960	136	14	administration	administration	NOUN
ghmj-960	136	15	.	.	PUNCT
ghmj-960	137	1	astrazeneca	astrazeneca	PROPN
ghmj-960	137	2	was	be	AUX
ghmj-960	137	3	20	20	NUM
ghmj-960	137	4	patients	patient	NOUN
ghmj-960	137	5	(	(	PUNCT
ghmj-960	137	6	33.9	33.9	NUM
ghmj-960	137	7	%	%	NOUN
ghmj-960	137	8	)	)	PUNCT
ghmj-960	137	9	.	.	PUNCT
ghmj-960	138	1	moderna	moderna	PROPN
ghmj-960	138	2	was	be	AUX
ghmj-960	138	3	15	15	NUM
ghmj-960	138	4	patients	patient	NOUN
ghmj-960	138	5	(	(	PUNCT
ghmj-960	138	6	25.9	25.9	NUM
ghmj-960	138	7	%	%	NOUN
ghmj-960	138	8	)	)	PUNCT
ghmj-960	138	9	.	.	PUNCT
ghmj-960	139	1	only	only	ADV
ghmj-960	139	2	46	46	NUM
ghmj-960	139	3	patients	patient	NOUN
ghmj-960	139	4	(	(	PUNCT
ghmj-960	139	5	78	78	NUM
ghmj-960	139	6	%	%	NOUN
ghmj-960	139	7	)	)	PUNCT
ghmj-960	139	8	of	of	ADP
ghmj-960	139	9	59	59	NUM
ghmj-960	139	10	patients	patient	NOUN
ghmj-960	139	11	with	with	ADP
ghmj-960	139	12	urticaria	urticaria	NOUN
ghmj-960	139	13	and/	and/	PROPN
ghmj-960	139	14	angioedema	angioedema	NOUN
ghmj-960	139	15	reactions	reaction	NOUN
ghmj-960	139	16	were	be	AUX
ghmj-960	139	17	female	female	ADJ
ghmj-960	139	18	.	.	PUNCT
ghmj-960	140	1	mostly	mostly	ADV
ghmj-960	140	2	its	its	PRON
ghmj-960	140	3	reaction	reaction	NOUN
ghmj-960	140	4	developed	develop	VERB
ghmj-960	140	5	after	after	ADP
ghmj-960	140	6	the	the	DET
ghmj-960	140	7	first	first	ADJ
ghmj-960	140	8	dose	dose	NOUN
ghmj-960	140	9	of	of	ADP
ghmj-960	140	10	covid-19	covid-19	PROPN
ghmj-960	140	11	vaccines	vaccine	NOUN
ghmj-960	140	12	.	.	PUNCT
ghmj-960	141	1	based	base	VERB
ghmj-960	141	2	on	on	ADP
ghmj-960	141	3	brooks	brooks	PROPN
ghmj-960	141	4	et	et	PROPN
ghmj-960	141	5	al	al	PROPN
ghmj-960	141	6	(	(	PUNCT
ghmj-960	141	7	2022	2022	NUM
ghmj-960	141	8	)	)	PUNCT
ghmj-960	141	9	,	,	PUNCT
ghmj-960	141	10	chronic	chronic	ADJ
ghmj-960	141	11	spontaneous	spontaneous	ADJ
ghmj-960	141	12	urticaria	urticaria	NOUN
ghmj-960	141	13	triggered	trigger	VERB
ghmj-960	141	14	by	by	ADP
ghmj-960	141	15	astrazeneca	astrazeneca	PROPN
ghmj-960	141	16	was	be	AUX
ghmj-960	141	17	reported	report	VERB
ghmj-960	141	18	.	.	PUNCT
ghmj-960	142	1	the	the	DET
ghmj-960	142	2	patient	patient	NOUN
ghmj-960	142	3	with	with	ADP
ghmj-960	142	4	an	an	DET
ghmj-960	142	5	asthma	asthma	NOUN
ghmj-960	142	6	history	history	NOUN
ghmj-960	142	7	and	and	CCONJ
ghmj-960	142	8	environmental	environmental	ADJ
ghmj-960	142	9	allergies	allergy	NOUN
ghmj-960	142	10	had	have	VERB
ghmj-960	142	11	the	the	DET
ghmj-960	142	12	first	first	ADJ
ghmj-960	142	13	dose	dose	NOUN
ghmj-960	142	14	of	of	ADP
ghmj-960	142	15	astrazeneca	astrazeneca	PROPN
ghmj-960	142	16	,	,	PUNCT
ghmj-960	142	17	the	the	DET
ghmj-960	142	18	covid-19	covid-19	PROPN
ghmj-960	142	19	vaccination	vaccination	NOUN
ghmj-960	142	20	.	.	PUNCT
ghmj-960	143	1	in	in	ADP
ghmj-960	143	2	five	five	NUM
ghmj-960	143	3	days	day	NOUN
ghmj-960	143	4	,	,	PUNCT
ghmj-960	143	5	the	the	DET
ghmj-960	143	6	60	60	NUM
ghmj-960	143	7	years	year	NOUN
ghmj-960	143	8	old	old	ADJ
ghmj-960	143	9	man	man	NOUN
ghmj-960	143	10	developed	develop	VERB
ghmj-960	143	11	erythema	erythema	ADV
ghmj-960	143	12	on	on	ADP
ghmj-960	143	13	his	his	PRON
ghmj-960	143	14	palms	palm	NOUN
ghmj-960	143	15	and	and	CCONJ
ghmj-960	143	16	cheeks	cheek	NOUN
ghmj-960	143	17	followed	follow	VERB
ghmj-960	143	18	by	by	ADP
ghmj-960	143	19	a	a	DET
ghmj-960	143	20	pruritic	pruritic	ADJ
ghmj-960	143	21	rash	rash	NOUN
ghmj-960	143	22	on	on	ADP
ghmj-960	143	23	his	his	PRON
ghmj-960	143	24	scalp	scalp	NOUN
ghmj-960	143	25	,	,	PUNCT
ghmj-960	143	26	face	face	NOUN
ghmj-960	143	27	,	,	PUNCT
ghmj-960	143	28	neck	neck	NOUN
ghmj-960	143	29	,	,	PUNCT
ghmj-960	143	30	shoulder	shoulder	NOUN
ghmj-960	143	31	,	,	PUNCT
ghmj-960	143	32	and	and	CCONJ
ghmj-960	143	33	armpit	armpit	NOUN
ghmj-960	143	34	.	.	PUNCT
ghmj-960	144	1	a	a	DET
ghmj-960	144	2	caucasian	caucasian	ADJ
ghmj-960	144	3	female	female	NOUN
ghmj-960	144	4	who	who	PRON
ghmj-960	144	5	was	be	AUX
ghmj-960	144	6	48	48	NUM
ghmj-960	144	7	years	year	NOUN
ghmj-960	144	8	old	old	ADJ
ghmj-960	144	9	had	have	VERB
ghmj-960	144	10	acute	acute	ADJ
ghmj-960	144	11	urticaria	urticaria	NOUN
ghmj-960	144	12	within	within	ADP
ghmj-960	144	13	3	3	NUM
ghmj-960	144	14	hours	hour	NOUN
ghmj-960	144	15	after	after	ADP
ghmj-960	144	16	the	the	DET
ghmj-960	144	17	second	second	ADJ
ghmj-960	144	18	dose	dose	NOUN
ghmj-960	144	19	of	of	ADP
ghmj-960	144	20	astrazeneca	astrazeneca	PROPN
ghmj-960	144	21	(	(	PUNCT
ghmj-960	144	22	burlando	burlando	NOUN
ghmj-960	144	23	et	et	PROPN
ghmj-960	144	24	al	al	PROPN
ghmj-960	144	25	.	.	PROPN
ghmj-960	144	26	,	,	PUNCT
ghmj-960	144	27	2021	2021	NUM
ghmj-960	144	28	)	)	PUNCT
ghmj-960	144	29	.	.	PUNCT
ghmj-960	145	1	a	a	DET
ghmj-960	145	2	39	39	NUM
ghmj-960	145	3	years	year	NOUN
ghmj-960	145	4	old	old	ADJ
ghmj-960	145	5	man	man	NOUN
ghmj-960	145	6	without	without	ADP
ghmj-960	145	7	a	a	DET
ghmj-960	145	8	history	history	NOUN
ghmj-960	145	9	of	of	ADP
ghmj-960	145	10	atopic	atopic	NOUN
ghmj-960	145	11	disorders	disorder	NOUN
ghmj-960	145	12	developed	develop	VERB
ghmj-960	145	13	widespread	widespread	ADJ
ghmj-960	145	14	urticaria	urticaria	NOUN
ghmj-960	145	15	and	and	CCONJ
ghmj-960	145	16	swelling	swelling	NOUN
ghmj-960	145	17	of	of	ADP
ghmj-960	145	18	his	his	PRON
ghmj-960	145	19	hands	hand	NOUN
ghmj-960	145	20	.	.	PUNCT
ghmj-960	146	1	he	he	PRON
ghmj-960	146	2	got	get	VERB
ghmj-960	146	3	a	a	DET
ghmj-960	146	4	jab	jab	NOUN
ghmj-960	146	5	of	of	ADP
ghmj-960	146	6	the	the	DET
ghmj-960	146	7	second	second	NOUN
ghmj-960	146	8	of	of	ADP
ghmj-960	146	9	astra	astra	PROPN
ghmj-960	146	10	zeneca	zeneca	PROPN
ghmj-960	146	11	and	and	CCONJ
ghmj-960	146	12	urticaria	urticaria	NOUN
ghmj-960	146	13	showed	show	VERB
ghmj-960	146	14	up	up	ADP
ghmj-960	146	15	in	in	ADP
ghmj-960	146	16	2	2	NUM
ghmj-960	146	17	weeks	week	NOUN
ghmj-960	146	18	(	(	PUNCT
ghmj-960	146	19	suan	suan	NOUN
ghmj-960	146	20	and	and	CCONJ
ghmj-960	146	21	lee	lee	PROPN
ghmj-960	146	22	,	,	PUNCT
ghmj-960	146	23	2022	2022	NUM
ghmj-960	146	24	)	)	PUNCT
ghmj-960	146	25	.	.	PUNCT
ghmj-960	147	1	in	in	ADP
ghmj-960	147	2	iran	iran	PROPN
ghmj-960	147	3	,	,	PUNCT
ghmj-960	147	4	it	it	PRON
ghmj-960	147	5	is	be	AUX
ghmj-960	147	6	reported	report	VERB
ghmj-960	147	7	that	that	SCONJ
ghmj-960	147	8	25	25	NUM
ghmj-960	147	9	cases	case	NOUN
ghmj-960	147	10	of	of	ADP
ghmj-960	147	11	urticaria	urticaria	NOUN
ghmj-960	147	12	after	after	ADP
ghmj-960	147	13	getting	get	VERB
ghmj-960	147	14	astra	astra	PROPN
ghmj-960	147	15	zeneca	zeneca	PROPN
ghmj-960	147	16	,	,	PUNCT
ghmj-960	147	17	sinopharm	sinopharm	PROPN
ghmj-960	147	18	,	,	PUNCT
ghmj-960	147	19	sputnik	sputnik	X
ghmj-960	147	20	v	v	NOUN
ghmj-960	147	21	,	,	PUNCT
ghmj-960	147	22	and	and	CCONJ
ghmj-960	147	23	bharat	bharat	NOUN
ghmj-960	147	24	vaccines	vaccine	NOUN
ghmj-960	147	25	.	.	PUNCT
ghmj-960	148	1	however	however	ADV
ghmj-960	148	2	,	,	PUNCT
ghmj-960	148	3	most	most	ADJ
ghmj-960	148	4	of	of	ADP
ghmj-960	148	5	them	they	PRON
ghmj-960	148	6	were	be	AUX
ghmj-960	148	7	vaccinated	vaccinate	VERB
ghmj-960	148	8	using	use	VERB
ghmj-960	148	9	astra	astra	PROPN
ghmj-960	148	10	zeneca	zeneca	PROPN
ghmj-960	148	11	(	(	PUNCT
ghmj-960	148	12	pourani	pourani	PROPN
ghmj-960	148	13	et	et	PROPN
ghmj-960	148	14	al	al	PROPN
ghmj-960	148	15	.	.	PROPN
ghmj-960	148	16	,	,	PUNCT
ghmj-960	148	17	2022	2022	NUM
ghmj-960	148	18	)	)	PUNCT
ghmj-960	148	19	.	.	PUNCT
ghmj-960	149	1	in	in	ADP
ghmj-960	149	2	thailand	thailand	PROPN
ghmj-960	149	3	,	,	PUNCT
ghmj-960	149	4	the	the	DET
ghmj-960	149	5	most	most	ADV
ghmj-960	149	6	common	common	ADJ
ghmj-960	149	7	skin	skin	NOUN
ghmj-960	149	8	allergy	allergy	NOUN
ghmj-960	149	9	reactions	reaction	NOUN
ghmj-960	149	10	from	from	ADP
ghmj-960	149	11	35,229	35,229	NUM
ghmj-960	149	12	injections	injection	NOUN
ghmj-960	149	13	of	of	ADP
ghmj-960	149	14	vaccination	vaccination	NOUN
ghmj-960	149	15	were	be	AUX
ghmj-960	149	16	urticaria	urticaria	ADJ
ghmj-960	149	17	after	after	ADP
ghmj-960	149	18	getting	get	VERB
ghmj-960	149	19	astrazeneca	astrazeneca	NOUN
ghmj-960	149	20	and	and	CCONJ
ghmj-960	149	21	sinovac	sinovac	PROPN
ghmj-960	149	22	(	(	PUNCT
ghmj-960	149	23	rerknimitr	rerknimitr	NOUN
ghmj-960	149	24	et	et	PROPN
ghmj-960	149	25	al	al	PROPN
ghmj-960	149	26	.	.	PROPN
ghmj-960	149	27	,	,	PUNCT
ghmj-960	149	28	2022	2022	NUM
ghmj-960	149	29	)	)	PUNCT
ghmj-960	149	30	.	.	PUNCT
ghmj-960	150	1	the	the	DET
ghmj-960	150	2	previous	previous	ADJ
ghmj-960	150	3	study	study	NOUN
ghmj-960	150	4	reported	report	VERB
ghmj-960	150	5	that	that	SCONJ
ghmj-960	150	6	urticaria	urticaria	PROPN
ghmj-960	150	7	prevalence	prevalence	NOUN
ghmj-960	150	8	after	after	SCONJ
ghmj-960	150	9	the	the	DET
ghmj-960	150	10	coronavac	coronavac	PROPN
ghmj-960	150	11	vaccine	vaccine	NOUN
ghmj-960	150	12	administration	administration	NOUN
ghmj-960	150	13	among	among	ADP
ghmj-960	150	14	healthcare	healthcare	NOUN
ghmj-960	150	15	workers	worker	NOUN
ghmj-960	150	16	in	in	ADP
ghmj-960	150	17	turkey	turkey	NOUN
ghmj-960	150	18	was	be	AUX
ghmj-960	150	19	about	about	ADV
ghmj-960	150	20	0.8	0.8	NUM
ghmj-960	150	21	%	%	NOUN
ghmj-960	150	22	(	(	PUNCT
ghmj-960	150	23	triwatcharikorn	triwatcharikorn	VERB
ghmj-960	150	24	et	et	PROPN
ghmj-960	150	25	al	al	PROPN
ghmj-960	150	26	.	.	PROPN
ghmj-960	150	27	,	,	PUNCT
ghmj-960	150	28	2022	2022	NUM
ghmj-960	150	29	)	)	PUNCT
ghmj-960	150	30	.	.	PUNCT
ghmj-960	151	1	urticaria	urticaria	PROPN
ghmj-960	151	2	was	be	AUX
ghmj-960	151	3	the	the	DET
ghmj-960	151	4	most	most	ADV
ghmj-960	151	5	frequent	frequent	ADJ
ghmj-960	151	6	reaction	reaction	NOUN
ghmj-960	151	7	among	among	ADP
ghmj-960	151	8	healthcare	healthcare	NOUN
ghmj-960	151	9	workers	worker	NOUN
ghmj-960	151	10	in	in	ADP
ghmj-960	151	11	turkey	turkey	NOUN
ghmj-960	151	12	after	after	ADP
ghmj-960	151	13	administering	administer	VERB
ghmj-960	151	14	with	with	ADP
ghmj-960	151	15	sinovac/	sinovac/	NUM
ghmj-960	151	16	coronavac	coronavac	NOUN
ghmj-960	151	17	(	(	PUNCT
ghmj-960	151	18	durmaz	durmaz	NOUN
ghmj-960	151	19	et	et	PROPN
ghmj-960	151	20	al	al	PROPN
ghmj-960	151	21	.	.	PROPN
ghmj-960	151	22	,	,	PUNCT
ghmj-960	151	23	2022	2022	NUM
ghmj-960	151	24	)	)	PUNCT
ghmj-960	151	25	.	.	PUNCT
ghmj-960	152	1	the	the	DET
ghmj-960	152	2	study	study	NOUN
ghmj-960	152	3	reported	report	VERB
ghmj-960	152	4	a-28	a-28	CCONJ
ghmj-960	152	5	years	year	NOUN
ghmj-960	152	6	old	old	ADJ
ghmj-960	152	7	patient	patient	NOUN
ghmj-960	152	8	who	who	PRON
ghmj-960	152	9	was	be	AUX
ghmj-960	152	10	under	under	ADP
ghmj-960	152	11	regular	regular	ADJ
ghmj-960	152	12	histamine	histamine	NOUN
ghmj-960	152	13	treatment	treatment	NOUN
ghmj-960	152	14	had	have	VERB
ghmj-960	152	15	chronic	chronic	ADJ
ghmj-960	152	16	urticaria	urticaria	NOUN
ghmj-960	152	17	after	after	ADP
ghmj-960	152	18	getting	get	VERB
ghmj-960	152	19	the	the	DET
ghmj-960	152	20	first	first	ADJ
ghmj-960	152	21	dose	dose	NOUN
ghmj-960	152	22	of	of	ADP
ghmj-960	152	23	coronavac	coronavac	PROPN
ghmj-960	152	24	.	.	PUNCT
ghmj-960	153	1	another	another	DET
ghmj-960	153	2	study	study	NOUN
ghmj-960	153	3	recorded	record	VERB
ghmj-960	153	4	a	a	DET
ghmj-960	153	5	female	female	ADJ
ghmj-960	153	6	patient	patient	NOUN
ghmj-960	153	7	who	who	PRON
ghmj-960	153	8	an	an	DET
ghmj-960	153	9	allergy	allergy	NOUN
ghmj-960	153	10	history	history	NOUN
ghmj-960	153	11	had	have	AUX
ghmj-960	153	12	developed	develop	VERB
ghmj-960	153	13	urticaria	urticaria	NOUN
ghmj-960	153	14	within	within	ADP
ghmj-960	153	15	10	10	NUM
ghmj-960	153	16	minutes	minute	NOUN
ghmj-960	153	17	of	of	ADP
ghmj-960	153	18	getting	get	VERB
ghmj-960	153	19	coronavac	coronavac	NOUN
ghmj-960	153	20	(	(	PUNCT
ghmj-960	153	21	kaya	kaya	PROPN
ghmj-960	153	22	and	and	CCONJ
ghmj-960	153	23	kaya	kaya	PROPN
ghmj-960	153	24	,	,	PUNCT
ghmj-960	153	25	2022	2022	NUM
ghmj-960	153	26	)	)	PUNCT
ghmj-960	153	27	.	.	PUNCT
ghmj-960	154	1	other	other	ADJ
ghmj-960	154	2	studies	study	NOUN
ghmj-960	154	3	reported	report	VERB
ghmj-960	154	4	that	that	SCONJ
ghmj-960	154	5	four	four	NUM
ghmj-960	154	6	patients	patient	NOUN
ghmj-960	154	7	developed	develop	VERB
ghmj-960	154	8	symptoms	symptom	NOUN
ghmj-960	154	9	of	of	ADP
ghmj-960	154	10	urticaria	urticaria	NOUN
ghmj-960	154	11	after	after	ADP
ghmj-960	154	12	coronavac	coronavac	PROPN
ghmj-960	154	13	administration	administration	NOUN
ghmj-960	154	14	.	.	PUNCT
ghmj-960	155	1	three	three	NUM
ghmj-960	155	2	of	of	ADP
ghmj-960	155	3	them	they	PRON
ghmj-960	155	4	had	have	VERB
ghmj-960	155	5	it	it	PRON
ghmj-960	155	6	after	after	ADP
ghmj-960	155	7	the	the	DET
ghmj-960	155	8	first	first	ADJ
ghmj-960	155	9	dose	dose	NOUN
ghmj-960	155	10	of	of	ADP
ghmj-960	155	11	coronavac	coronavac	PROPN
ghmj-960	155	12	.	.	PUNCT
ghmj-960	156	1	another	another	DET
ghmj-960	156	2	one	one	NOUN
ghmj-960	156	3	presented	present	VERB
ghmj-960	156	4	symptoms	symptom	NOUN
ghmj-960	156	5	of	of	ADP
ghmj-960	156	6	urticaria	urticaria	NOUN
ghmj-960	156	7	after	after	ADP
ghmj-960	156	8	the	the	DET
ghmj-960	156	9	second	second	ADJ
ghmj-960	156	10	dose	dose	NOUN
ghmj-960	156	11	of	of	ADP
ghmj-960	156	12	coronavac	coronavac	PROPN
ghmj-960	156	13	(	(	PUNCT
ghmj-960	156	14	akdaş	akdaş	NOUN
ghmj-960	156	15	et	et	PROPN
ghmj-960	156	16	al	al	PROPN
ghmj-960	156	17	.	.	PROPN
ghmj-960	156	18	,	,	PUNCT
ghmj-960	156	19	2022	2022	NUM
ghmj-960	156	20	)	)	PUNCT
ghmj-960	156	21	.	.	PUNCT
ghmj-960	157	1	b.	b.	PROPN
ghmj-960	157	2	pathophysiology	pathophysiology	PROPN
ghmj-960	157	3	of	of	ADP
ghmj-960	157	4	urticaria	urticaria	PROPN
ghmj-960	157	5	post	post	ADJ
ghmj-960	157	6	-	-	ADJ
ghmj-960	157	7	covid-19	covid-19	ADJ
ghmj-960	157	8	vaccination	vaccination	NOUN
ghmj-960	157	9	the	the	DET
ghmj-960	157	10	mrna	mrna	PROPN
ghmj-960	157	11	vaccines	vaccine	NOUN
ghmj-960	157	12	use	use	VERB
ghmj-960	157	13	polyethylene	polyethylene	NOUN
ghmj-960	157	14	glycols	glycol	NOUN
ghmj-960	157	15	(	(	PUNCT
ghmj-960	157	16	pegs	peg	NOUN
ghmj-960	157	17	)	)	PUNCT
ghmj-960	157	18	as	as	ADP
ghmj-960	157	19	excipients	excipient	NOUN
ghmj-960	157	20	.	.	PUNCT
ghmj-960	158	1	it	it	PRON
ghmj-960	158	2	contains	contain	VERB
ghmj-960	158	3	varied	varied	ADJ
ghmj-960	158	4	polymers	polymer	NOUN
ghmj-960	158	5	'	'	PART
ghmj-960	158	6	molecular	molecular	ADJ
ghmj-960	158	7	weight	weight	NOUN
ghmj-960	158	8	(	(	PUNCT
ghmj-960	158	9	bruusgaard	bruusgaard	NOUN
ghmj-960	158	10	-	-	PUNCT
ghmj-960	158	11	mouritsen	mouritsen	VERB
ghmj-960	158	12	et	et	PROPN
ghmj-960	158	13	al	al	PROPN
ghmj-960	158	14	.	.	PROPN
ghmj-960	158	15	,	,	PUNCT
ghmj-960	158	16	2022	2022	NUM
ghmj-960	158	17	)	)	PUNCT
ghmj-960	158	18	.	.	PUNCT
ghmj-960	159	1	the	the	DET
ghmj-960	159	2	peg2000	peg2000	NOUN
ghmj-960	159	3	or	or	CCONJ
ghmj-960	159	4	polyethylene	polyethylene	NOUN
ghmj-960	159	5	glycols	glycol	NOUN
ghmj-960	159	6	have	have	VERB
ghmj-960	159	7	2000	2000	NUM
ghmj-960	159	8	molecular	molecular	ADJ
ghmj-960	159	9	weight	weight	NOUN
ghmj-960	159	10	present	present	NOUN
ghmj-960	159	11	as	as	ADP
ghmj-960	159	12	a	a	DET
ghmj-960	159	13	stabilizer	stabilizer	NOUN
ghmj-960	159	14	,	,	PUNCT
ghmj-960	159	15	a	a	DET
ghmj-960	159	16	solubilizer	solubilizer	NOUN
ghmj-960	159	17	,	,	PUNCT
ghmj-960	159	18	and	and	CCONJ
ghmj-960	159	19	an	an	DET
ghmj-960	159	20	adjuvant	adjuvant	NOUN
ghmj-960	159	21	.	.	PUNCT
ghmj-960	160	1	being	be	AUX
ghmj-960	160	2	a	a	DET
ghmj-960	160	3	stabilizer	stabilizer	NOUN
ghmj-960	160	4	avoids	avoid	VERB
ghmj-960	160	5	premature	premature	ADJ
ghmj-960	160	6	degradation	degradation	NOUN
ghmj-960	160	7	of	of	ADP
ghmj-960	160	8	the	the	DET
ghmj-960	160	9	nanoparticles	nanoparticle	NOUN
ghmj-960	160	10	by	by	ADP
ghmj-960	160	11	the	the	DET
ghmj-960	160	12	mononuclear	mononuclear	ADJ
ghmj-960	160	13	phagocytosis	phagocytosis	NOUN
ghmj-960	160	14	system	system	NOUN
ghmj-960	160	15	.	.	PUNCT
ghmj-960	161	1	during	during	ADP
ghmj-960	161	2	the	the	DET
ghmj-960	161	3	transition	transition	NOUN
ghmj-960	161	4	of	of	ADP
ghmj-960	161	5	the	the	DET
ghmj-960	161	6	particles	particle	NOUN
ghmj-960	161	7	into	into	ADP
ghmj-960	161	8	the	the	DET
ghmj-960	161	9	intracellular	intracellular	ADJ
ghmj-960	161	10	cytosol	cytosol	NOUN
ghmj-960	161	11	,	,	PUNCT
ghmj-960	161	12	the	the	DET
ghmj-960	161	13	peg2000	peg2000	NOUN
ghmj-960	161	14	is	be	AUX
ghmj-960	161	15	a	a	DET
ghmj-960	161	16	solubilizer	solubilizer	NOUN
ghmj-960	161	17	.	.	PUNCT
ghmj-960	162	1	being	be	AUX
ghmj-960	162	2	an	an	DET
ghmj-960	162	3	adjuvant	adjuvant	NOUN
ghmj-960	162	4	is	be	AUX
ghmj-960	162	5	for	for	ADP
ghmj-960	162	6	immunogenic	immunogenic	ADJ
ghmj-960	162	7	potential	potential	NOUN
ghmj-960	162	8	.	.	PUNCT
ghmj-960	163	1	ethylene	ethylene	NOUN
ghmj-960	163	2	oxide	oxide	NOUN
ghmj-960	163	3	makes	make	VERB
ghmj-960	163	4	pegs	peg	NOUN
ghmj-960	163	5	by	by	ADP
ghmj-960	163	6	polymerization	polymerization	NOUN
ghmj-960	163	7	(	(	PUNCT
ghmj-960	163	8	worm	worm	NOUN
ghmj-960	163	9	et	et	PROPN
ghmj-960	163	10	al	al	PROPN
ghmj-960	163	11	.	.	PROPN
ghmj-960	163	12	,	,	PUNCT
ghmj-960	163	13	2021	2021	NUM
ghmj-960	163	14	)	)	PUNCT
ghmj-960	163	15	.	.	PUNCT
ghmj-960	164	1	formaldehyde	formaldehyde	NOUN
ghmj-960	164	2	,	,	PUNCT
ghmj-960	164	3	neomycin	neomycin	NOUN
ghmj-960	164	4	,	,	PUNCT
ghmj-960	164	5	propylene	propylene	NOUN
ghmj-960	164	6	glycol	glycol	NOUN
ghmj-960	164	7	,	,	PUNCT
ghmj-960	164	8	and	and	CCONJ
ghmj-960	164	9	thimerosal	thimerosal	NOUN
ghmj-960	164	10	are	be	AUX
ghmj-960	164	11	exogenous	exogenous	ADJ
ghmj-960	164	12	antigens	antigen	NOUN
ghmj-960	164	13	in	in	ADP
ghmj-960	164	14	vaccine	vaccine	NOUN
ghmj-960	164	15	constituents	constituent	NOUN
ghmj-960	164	16	that	that	PRON
ghmj-960	164	17	cause	cause	VERB
ghmj-960	164	18	allergic	allergic	ADJ
ghmj-960	164	19	contact	contact	NOUN
ghmj-960	164	20	dermatitis	dermatitis	NOUN
ghmj-960	164	21	.	.	PUNCT
ghmj-960	165	1	polyethylene	polyethylene	NOUN
ghmj-960	165	2	glycol	glycol	NOUN
ghmj-960	165	3	moieties	moiety	NOUN
ghmj-960	165	4	and	and	CCONJ
ghmj-960	165	5	polysorbate-80	polysorbate-80	PROPN
ghmj-960	165	6	have	have	VERB
ghmj-960	165	7	the	the	DET
ghmj-960	165	8	potential	potential	NOUN
ghmj-960	165	9	to	to	PART
ghmj-960	165	10	cause	cause	VERB
ghmj-960	165	11	immediate	immediate	ADJ
ghmj-960	165	12	hypersensitivity	hypersensitivity	NOUN
ghmj-960	165	13	reactions	reaction	NOUN
ghmj-960	165	14	,	,	PUNCT
ghmj-960	165	15	as	as	ADV
ghmj-960	165	16	well	well	ADV
ghmj-960	165	17	as	as	ADP
ghmj-960	165	18	delayed	delay	VERB
ghmj-960	165	19	hypersensitivity	hypersensitivity	NOUN
ghmj-960	165	20	reactions	reaction	NOUN
ghmj-960	165	21	(	(	PUNCT
ghmj-960	165	22	magro	magro	PROPN
ghmj-960	165	23	et	et	PROPN
ghmj-960	165	24	al	al	PROPN
ghmj-960	165	25	.	.	PROPN
ghmj-960	165	26	,	,	PUNCT
ghmj-960	165	27	2021	2021	NUM
ghmj-960	165	28	)	)	PUNCT
ghmj-960	165	29	.	.	PUNCT
ghmj-960	166	1	polyethylene	polyethylene	NOUN
ghmj-960	166	2	glycol	glycol	NOUN
ghmj-960	166	3	(	(	PUNCT
ghmj-960	166	4	peg	peg	NOUN
ghmj-960	166	5	)	)	PUNCT
ghmj-960	166	6	and	and	CCONJ
ghmj-960	166	7	structurally	structurally	ADV
ghmj-960	166	8	-	-	PUNCT
ghmj-960	166	9	related	relate	VERB
ghmj-960	166	10	polysorbate-80	polysorbate-80	PROPN
ghmj-960	166	11	stimulate	stimulate	VERB
ghmj-960	166	12	both	both	DET
ghmj-960	166	13	non	non	ADJ
ghmj-960	166	14	-	-	ADJ
ghmj-960	166	15	ige	ige	ADJ
ghmj-960	166	16	-	-	PUNCT
ghmj-960	166	17	mediated	mediate	VERB
ghmj-960	166	18	reactions	reaction	NOUN
ghmj-960	166	19	and	and	CCONJ
ghmj-960	166	20	ige	ige	PROPN
ghmj-960	166	21	reactions	reaction	NOUN
ghmj-960	166	22	among	among	ADP
ghmj-960	166	23	people	people	NOUN
ghmj-960	166	24	with	with	ADP
ghmj-960	166	25	type	type	NOUN
ghmj-960	166	26	i	i	PRON
ghmj-960	166	27	allergic	allergic	ADJ
ghmj-960	166	28	reactions	reaction	NOUN
ghmj-960	166	29	after	after	ADP
ghmj-960	166	30	covid-19	covid-19	PROPN
ghmj-960	166	31	vaccine	vaccine	NOUN
ghmj-960	166	32	administration	administration	NOUN
ghmj-960	166	33	(	(	PUNCT
ghmj-960	166	34	grieco	grieco	PROPN
ghmj-960	166	35	et	et	PROPN
ghmj-960	166	36	al	al	PROPN
ghmj-960	166	37	.	.	PROPN
ghmj-960	166	38	,	,	PUNCT
ghmj-960	166	39	2022	2022	NUM
ghmj-960	166	40	)	)	PUNCT
ghmj-960	166	41	.	.	PUNCT
ghmj-960	167	1	polyethylene	polyethylene	NOUN
ghmj-960	167	2	glycol	glycol	NOUN
ghmj-960	167	3	enhances	enhance	VERB
ghmj-960	167	4	water	water	NOUN
ghmj-960	167	5	solubility	solubility	NOUN
ghmj-960	167	6	as	as	ADP
ghmj-960	167	7	an	an	DET
ghmj-960	167	8	excipient	excipient	NOUN
ghmj-960	167	9	.	.	PUNCT
ghmj-960	168	1	alike	alike	ADP
ghmj-960	168	2	peg	peg	NOUN
ghmj-960	168	3	,	,	PUNCT
ghmj-960	168	4	polysorbate	polysorbate	NOUN
ghmj-960	168	5	80	80	NUM
ghmj-960	168	6	is	be	AUX
ghmj-960	168	7	an	an	DET
ghmj-960	168	8	excipient	excipient	NOUN
ghmj-960	168	9	in	in	ADP
ghmj-960	168	10	johnson	johnson	PROPN
ghmj-960	168	11	&	&	CCONJ
ghmj-960	168	12	johnson	johnson	PROPN
ghmj-960	168	13	and	and	CCONJ
ghmj-960	168	14	the	the	DET
ghmj-960	168	15	astrazeneca	astrazeneca	NOUN
ghmj-960	168	16	vaccines	vaccine	NOUN
ghmj-960	168	17	against	against	ADP
ghmj-960	168	18	covid-19	covid-19	PROPN
ghmj-960	168	19	.	.	PUNCT
ghmj-960	169	1	the	the	DET
ghmj-960	169	2	two	two	NUM
ghmj-960	169	3	mrna	mrna	PROPN
ghmj-960	169	4	vaccines	vaccine	NOUN
ghmj-960	169	5	contain	contain	VERB
ghmj-960	169	6	peg	peg	NOUN
ghmj-960	169	7	-	-	PUNCT
ghmj-960	169	8	triggering	trigger	VERB
ghmj-960	169	9	hypersensitivity	hypersensitivity	NOUN
ghmj-960	169	10	reactions	reaction	NOUN
ghmj-960	169	11	.	.	PUNCT
ghmj-960	170	1	it	it	PRON
ghmj-960	170	2	is	be	AUX
ghmj-960	170	3	caused	cause	VERB
ghmj-960	170	4	by	by	ADP
ghmj-960	170	5	previous	previous	ADJ
ghmj-960	170	6	sensitization	sensitization	NOUN
ghmj-960	170	7	to	to	ADP
ghmj-960	170	8	polysorbate	polysorbate	NOUN
ghmj-960	170	9	80	80	NUM
ghmj-960	170	10	and	and	CCONJ
ghmj-960	170	11	cross	cross	NOUN
ghmj-960	170	12	-	-	NOUN
ghmj-960	170	13	reactivity	reactivity	NOUN
ghmj-960	170	14	between	between	ADP
ghmj-960	170	15	polysorbate	polysorbate	NOUN
ghmj-960	170	16	80	80	NUM
ghmj-960	170	17	and	and	CCONJ
ghmj-960	170	18	peg	peg	NOUN
ghmj-960	170	19	(	(	PUNCT
ghmj-960	170	20	almuhizi	almuhizi	NOUN
ghmj-960	170	21	et	et	PROPN
ghmj-960	170	22	al	al	PROPN
ghmj-960	170	23	.	.	PROPN
ghmj-960	170	24	,	,	PUNCT
ghmj-960	170	25	2022	2022	NUM
ghmj-960	170	26	)	)	PUNCT
ghmj-960	170	27	.	.	PUNCT
ghmj-960	171	1	the	the	DET
ghmj-960	171	2	whole	whole	ADJ
ghmj-960	171	3	inactivated	inactivated	ADJ
ghmj-960	171	4	viruses	virus	NOUN
ghmj-960	171	5	are	be	AUX
ghmj-960	171	6	the	the	DET
ghmj-960	171	7	primary	primary	ADJ
ghmj-960	171	8	element	element	NOUN
ghmj-960	171	9	in	in	ADP
ghmj-960	171	10	coronavac	coronavac	NOUN
ghmj-960	171	11	which	which	PRON
ghmj-960	171	12	is	be	AUX
ghmj-960	171	13	cultured	cultured	ADJ
ghmj-960	171	14	with	with	ADP
ghmj-960	171	15	aluminum	aluminum	NOUN
ghmj-960	171	16	hydroxide	hydroxide	NOUN
ghmj-960	171	17	adjuvant	adjuvant	NOUN
ghmj-960	171	18	and	and	CCONJ
ghmj-960	171	19	some	some	DET
ghmj-960	171	20	mineral	mineral	NOUN
ghmj-960	171	21	salts	salt	NOUN
ghmj-960	171	22	in	in	ADP
ghmj-960	171	23	vero	vero	PROPN
ghmj-960	171	24	cell	cell	NOUN
ghmj-960	171	25	.	.	PUNCT
ghmj-960	172	1	urticaria	urticaria	PROPN
ghmj-960	172	2	related	relate	VERB
ghmj-960	172	3	to	to	PART
ghmj-960	172	4	coronavac	coronavac	VERB
ghmj-960	172	5	is	be	AUX
ghmj-960	172	6	less	less	ADV
ghmj-960	172	7	likely	likely	ADJ
ghmj-960	172	8	to	to	PART
ghmj-960	172	9	be	be	AUX
ghmj-960	172	10	ige	ige	NOUN
ghmj-960	172	11	-	-	PUNCT
ghmj-960	172	12	mediated	mediate	VERB
ghmj-960	172	13	hypersensitivity	hypersensitivity	NOUN
ghmj-960	172	14	.	.	PUNCT
ghmj-960	173	1	the	the	DET
ghmj-960	173	2	immune	immune	ADJ
ghmj-960	173	3	response	response	NOUN
ghmj-960	173	4	plays	play	VERB
ghmj-960	173	5	a	a	DET
ghmj-960	173	6	role	role	NOUN
ghmj-960	173	7	in	in	ADP
ghmj-960	173	8	the	the	DET
ghmj-960	173	9	pathogenesis	pathogenesis	NOUN
ghmj-960	173	10	of	of	ADP
ghmj-960	173	11	coronavac	coronavac	PROPN
ghmj-960	173	12	.	.	PUNCT
ghmj-960	174	1	the	the	DET
ghmj-960	174	2	result	result	NOUN
ghmj-960	174	3	of	of	ADP
ghmj-960	174	4	a	a	DET
ghmj-960	174	5	cross	cross	ADJ
ghmj-960	174	6	-	-	ADJ
ghmj-960	174	7	reactive	reactive	ADJ
ghmj-960	174	8	immune	immune	ADJ
ghmj-960	174	9	response	response	NOUN
ghmj-960	174	10	to	to	ADP
ghmj-960	174	11	the	the	DET
ghmj-960	174	12	sars	sar	NOUN
ghmj-960	174	13	-	-	PUNCT
ghmj-960	174	14	cov-2	cov-2	NOUN
ghmj-960	174	15	-	-	ADJ
ghmj-960	174	16	spike	spike	ADJ
ghmj-960	174	17	protein	protein	NOUN
ghmj-960	174	18	present	present	ADJ
ghmj-960	174	19	63	63	NUM
ghmj-960	174	20	ghmj	ghmj	NOUN
ghmj-960	174	21	(	(	PUNCT
ghmj-960	174	22	global	global	ADJ
ghmj-960	174	23	health	health	PROPN
ghmj-960	174	24	management	management	NOUN
ghmj-960	174	25	journal	journal	PROPN
ghmj-960	174	26	)	)	PUNCT
ghmj-960	174	27	2023	2023	NUM
ghmj-960	174	28	,	,	PUNCT
ghmj-960	174	29	vol	vol	NOUN
ghmj-960	174	30	.	.	PROPN
ghmj-960	174	31	6	6	NUM
ghmj-960	174	32	,	,	PUNCT
ghmj-960	174	33	no	no	NOUN
ghmj-960	174	34	.	.	NOUN
ghmj-960	174	35	2	2	NUM
ghmj-960	174	36	nugrahaeni	nugrahaeni	NOUN
ghmj-960	174	37	&	&	CCONJ
ghmj-960	174	38	budiyanti	budiyanti	PROPN
ghmj-960	174	39	in	in	ADP
ghmj-960	174	40	previous	previous	ADJ
ghmj-960	174	41	coronavirus	coronavirus	NOUN
ghmj-960	174	42	infections	infection	NOUN
ghmj-960	174	43	causes	cause	VERB
ghmj-960	174	44	urticaria	urticaria	NOUN
ghmj-960	174	45	for	for	ADP
ghmj-960	174	46	sensitive	sensitive	ADJ
ghmj-960	174	47	people	people	NOUN
ghmj-960	174	48	(	(	PUNCT
ghmj-960	174	49	triwatcharikorn	triwatcharikorn	VERB
ghmj-960	174	50	et	et	PROPN
ghmj-960	174	51	al	al	PROPN
ghmj-960	174	52	.	.	PROPN
ghmj-960	174	53	,	,	PUNCT
ghmj-960	174	54	2022	2022	NUM
ghmj-960	174	55	)	)	PUNCT
ghmj-960	174	56	.	.	PUNCT
ghmj-960	175	1	morbilliform	morbilliform	NOUN
ghmj-960	175	2	eruptions	eruption	NOUN
ghmj-960	175	3	and	and	CCONJ
ghmj-960	175	4	urticaria	urticaria	NOUN
ghmj-960	175	5	are	be	AUX
ghmj-960	175	6	the	the	DET
ghmj-960	175	7	main	main	ADJ
ghmj-960	175	8	reason	reason	NOUN
ghmj-960	175	9	for	for	ADP
ghmj-960	175	10	hypersensitivity	hypersensitivity	NOUN
ghmj-960	175	11	reactions	reaction	NOUN
ghmj-960	175	12	primarily	primarily	ADV
ghmj-960	175	13	(	(	PUNCT
ghmj-960	175	14	namazi	namazi	PROPN
ghmj-960	175	15	et	et	PROPN
ghmj-960	175	16	al	al	PROPN
ghmj-960	175	17	.	.	PROPN
ghmj-960	175	18	,	,	PUNCT
ghmj-960	175	19	2022	2022	NUM
ghmj-960	175	20	)	)	PUNCT
ghmj-960	175	21	.	.	PUNCT
ghmj-960	176	1	three	three	NUM
ghmj-960	176	2	of	of	ADP
ghmj-960	176	3	four	four	NUM
ghmj-960	176	4	patients	patient	NOUN
ghmj-960	176	5	developed	develop	VERB
ghmj-960	176	6	recurrent	recurrent	ADJ
ghmj-960	176	7	delayed	delay	VERB
ghmj-960	176	8	urticaria	urticaria	NOUN
ghmj-960	176	9	after	after	ADP
ghmj-960	176	10	the	the	DET
ghmj-960	176	11	second	second	ADJ
ghmj-960	176	12	dose	dose	NOUN
ghmj-960	176	13	of	of	ADP
ghmj-960	176	14	the	the	DET
ghmj-960	176	15	covid-19	covid-19	PROPN
ghmj-960	176	16	vaccine	vaccine	NOUN
ghmj-960	176	17	.	.	PUNCT
ghmj-960	177	1	these	these	DET
ghmj-960	177	2	patients	patient	NOUN
ghmj-960	177	3	thrive	thrive	VERB
ghmj-960	177	4	a	a	DET
ghmj-960	177	5	memory	memory	NOUN
ghmj-960	177	6	t	t	NOUN
ghmj-960	177	7	-	-	PUNCT
ghmj-960	177	8	cell	cell	NOUN
ghmj-960	177	9	response	response	NOUN
ghmj-960	177	10	to	to	ADP
ghmj-960	177	11	the	the	DET
ghmj-960	177	12	mrna	mrna	PROPN
ghmj-960	177	13	covid-19	covid-19	PROPN
ghmj-960	177	14	vaccine	vaccine	NOUN
ghmj-960	177	15	.	.	PUNCT
ghmj-960	178	1	another	another	DET
ghmj-960	178	2	reason	reason	NOUN
ghmj-960	178	3	is	be	AUX
ghmj-960	178	4	the	the	DET
ghmj-960	178	5	delayed	delay	VERB
ghmj-960	178	6	t	t	NOUN
ghmj-960	178	7	-	-	PUNCT
ghmj-960	178	8	cell	cell	NOUN
ghmj-960	178	9	responses	response	NOUN
ghmj-960	178	10	(	(	PUNCT
ghmj-960	178	11	pitlick	pitlick	NOUN
ghmj-960	178	12	et	et	PROPN
ghmj-960	178	13	al	al	PROPN
ghmj-960	178	14	.	.	PROPN
ghmj-960	178	15	,	,	PUNCT
ghmj-960	178	16	2022	2022	NUM
ghmj-960	178	17	)	)	PUNCT
ghmj-960	178	18	.	.	PUNCT
ghmj-960	179	1	either	either	CCONJ
ghmj-960	179	2	ige	ige	PROPN
ghmj-960	179	3	mediated	mediate	VERB
ghmj-960	179	4	or	or	CCONJ
ghmj-960	179	5	igg	igg	PROPN
ghmj-960	179	6	is	be	AUX
ghmj-960	179	7	the	the	DET
ghmj-960	179	8	reaction	reaction	NOUN
ghmj-960	179	9	from	from	ADP
ghmj-960	179	10	hypersensitivity	hypersensitivity	NOUN
ghmj-960	179	11	after	after	ADP
ghmj-960	179	12	vaccine	vaccine	NOUN
ghmj-960	179	13	administration	administration	NOUN
ghmj-960	179	14	.	.	PUNCT
ghmj-960	180	1	it	it	PRON
ghmj-960	180	2	is	be	AUX
ghmj-960	180	3	caused	cause	VERB
ghmj-960	180	4	by	by	ADP
ghmj-960	180	5	complementmediated	complementmediate	VERB
ghmj-960	180	6	anaphylactic	anaphylactic	ADJ
ghmj-960	180	7	and	and	CCONJ
ghmj-960	180	8	delayed	delay	VERB
ghmj-960	180	9	t	t	NOUN
ghmj-960	180	10	-	-	PUNCT
ghmj-960	180	11	cell	cell	NOUN
ghmj-960	180	12	-	-	PUNCT
ghmj-960	180	13	mediated	mediate	VERB
ghmj-960	180	14	reactions	reaction	NOUN
ghmj-960	180	15	ige	ige	PROPN
ghmj-960	180	16	(	(	PUNCT
ghmj-960	180	17	namazi	namazi	PROPN
ghmj-960	180	18	et	et	PROPN
ghmj-960	180	19	al	al	PROPN
ghmj-960	180	20	.	.	PROPN
ghmj-960	180	21	,	,	PUNCT
ghmj-960	180	22	2022	2022	NUM
ghmj-960	180	23	)	)	PUNCT
ghmj-960	180	24	c.	c.	NOUN
ghmj-960	180	25	urticaria	urticaria	PROPN
ghmj-960	180	26	treatment	treatment	NOUN
ghmj-960	180	27	post	post	ADJ
ghmj-960	180	28	-	-	ADJ
ghmj-960	180	29	covid-19	covid-19	ADJ
ghmj-960	180	30	vaccination	vaccination	NOUN
ghmj-960	180	31	second	second	ADJ
ghmj-960	180	32	-	-	PUNCT
ghmj-960	180	33	generation	generation	NOUN
ghmj-960	180	34	h1	h1	PROPN
ghmj-960	180	35	antihistamine	antihistamine	PROPN
ghmj-960	180	36	is	be	AUX
ghmj-960	180	37	the	the	DET
ghmj-960	180	38	first	first	ADJ
ghmj-960	180	39	-	-	PUNCT
ghmj-960	180	40	line	line	NOUN
ghmj-960	180	41	treatment	treatment	NOUN
ghmj-960	180	42	that	that	PRON
ghmj-960	180	43	resulted	result	VERB
ghmj-960	180	44	in	in	ADP
ghmj-960	180	45	half	half	NOUN
ghmj-960	180	46	of	of	ADP
ghmj-960	180	47	reduction	reduction	NOUN
ghmj-960	180	48	in	in	ADP
ghmj-960	180	49	the	the	DET
ghmj-960	180	50	urticaria	urticaria	NOUN
ghmj-960	180	51	treatment	treatment	NOUN
ghmj-960	180	52	.	.	PUNCT
ghmj-960	181	1	treatment	treatment	NOUN
ghmj-960	181	2	of	of	ADP
ghmj-960	181	3	omalizumab	omalizumab	NOUN
ghmj-960	181	4	is	be	AUX
ghmj-960	181	5	required	require	VERB
ghmj-960	181	6	to	to	PART
ghmj-960	181	7	prevent	prevent	VERB
ghmj-960	181	8	urticaria	urticaria	NOUN
ghmj-960	181	9	flares	flare	NOUN
ghmj-960	181	10	during	during	ADP
ghmj-960	181	11	the	the	DET
ghmj-960	181	12	vaccination	vaccination	NOUN
ghmj-960	181	13	period	period	NOUN
ghmj-960	181	14	(	(	PUNCT
ghmj-960	181	15	grieco	grieco	PROPN
ghmj-960	181	16	et	et	PROPN
ghmj-960	181	17	al	al	PROPN
ghmj-960	181	18	.	.	PROPN
ghmj-960	181	19	,	,	PUNCT
ghmj-960	181	20	2022	2022	NUM
ghmj-960	181	21	)	)	PUNCT
ghmj-960	181	22	.	.	PUNCT
ghmj-960	182	1	a	a	DET
ghmj-960	182	2	recombinant	recombinant	ADJ
ghmj-960	182	3	humanized	humanize	VERB
ghmj-960	182	4	monoclonal	monoclonal	NOUN
ghmj-960	182	5	anti	anti	ADJ
ghmj-960	182	6	-	-	ADJ
ghmj-960	182	7	ige	ige	ADJ
ghmj-960	182	8	antibody	antibody	NOUN
ghmj-960	182	9	,	,	PUNCT
ghmj-960	182	10	omalizumab	omalizumab	NOUN
ghmj-960	182	11	,	,	PUNCT
ghmj-960	182	12	is	be	AUX
ghmj-960	182	13	effective	effective	ADJ
ghmj-960	182	14	to	to	PART
ghmj-960	182	15	inhibit	inhibit	VERB
ghmj-960	182	16	hypersensitivity	hypersensitivity	NOUN
ghmj-960	182	17	reactions	reaction	NOUN
ghmj-960	182	18	(	(	PUNCT
ghmj-960	182	19	smola	smola	PROPN
ghmj-960	182	20	et	et	PROPN
ghmj-960	182	21	al	al	PROPN
ghmj-960	182	22	.	.	PROPN
ghmj-960	182	23	,	,	PUNCT
ghmj-960	182	24	2021	2021	NUM
ghmj-960	182	25	)	)	PUNCT
ghmj-960	182	26	.	.	PUNCT
ghmj-960	183	1	omalizumab	omalizumab	NOUN
ghmj-960	183	2	is	be	AUX
ghmj-960	183	3	an	an	DET
ghmj-960	183	4	anti	anti	ADJ
ghmj-960	183	5	-	-	ADJ
ghmj-960	183	6	ige	ige	ADJ
ghmj-960	183	7	antibody	antibody	NOUN
ghmj-960	183	8	for	for	ADP
ghmj-960	183	9	the	the	DET
ghmj-960	183	10	treatment	treatment	NOUN
ghmj-960	183	11	of	of	ADP
ghmj-960	183	12	chronic	chronic	ADJ
ghmj-960	183	13	spontaneous	spontaneous	ADJ
ghmj-960	183	14	urticaria	urticaria	NOUN
ghmj-960	183	15	as	as	ADV
ghmj-960	183	16	well	well	ADV
ghmj-960	183	17	(	(	PUNCT
ghmj-960	183	18	bernstein	bernstein	PROPN
ghmj-960	183	19	et	et	PROPN
ghmj-960	183	20	al	al	PROPN
ghmj-960	183	21	.	.	PROPN
ghmj-960	183	22	,	,	PUNCT
ghmj-960	183	23	2020	2020	NUM
ghmj-960	183	24	)	)	PUNCT
ghmj-960	183	25	.	.	PUNCT
ghmj-960	184	1	dosing	dose	VERB
ghmj-960	184	2	does	do	AUX
ghmj-960	184	3	not	not	PART
ghmj-960	184	4	depend	depend	VERB
ghmj-960	184	5	on	on	ADP
ghmj-960	184	6	total	total	ADJ
ghmj-960	184	7	serum	serum	NOUN
ghmj-960	184	8	ige	ige	PROPN
ghmj-960	184	9	(	(	PUNCT
ghmj-960	184	10	zuberbier	zuberbier	PROPN
ghmj-960	184	11	et	et	PROPN
ghmj-960	184	12	al	al	PROPN
ghmj-960	184	13	.	.	PROPN
ghmj-960	184	14	,	,	PUNCT
ghmj-960	184	15	2022	2022	NUM
ghmj-960	184	16	)	)	PUNCT
ghmj-960	184	17	.	.	PUNCT
ghmj-960	185	1	high	high	ADJ
ghmj-960	185	2	-	-	PUNCT
ghmj-960	185	3	dose	dose	NOUN
ghmj-960	185	4	nonsedating	nonsedate	VERB
ghmj-960	185	5	antihistamines	antihistamine	NOUN
ghmj-960	185	6	like	like	ADP
ghmj-960	185	7	up	up	ADP
ghmj-960	185	8	to	to	PART
ghmj-960	185	9	40	40	NUM
ghmj-960	185	10	mg	mg	PROPN
ghmj-960	185	11	cetirizine	cetirizine	PROPN
ghmj-960	185	12	daily	daily	ADV
ghmj-960	185	13	are	be	AUX
ghmj-960	185	14	needed	need	VERB
ghmj-960	185	15	to	to	PART
ghmj-960	185	16	treat	treat	VERB
ghmj-960	185	17	urticaria	urticaria	NOUN
ghmj-960	185	18	associated	associate	VERB
ghmj-960	185	19	with	with	ADP
ghmj-960	185	20	covid	covid	PROPN
ghmj-960	185	21	mrna	mrna	PROPN
ghmj-960	185	22	vaccination	vaccination	NOUN
ghmj-960	185	23	.	.	PUNCT
ghmj-960	186	1	systemic	systemic	ADJ
ghmj-960	186	2	corticosteroids	corticosteroid	NOUN
ghmj-960	186	3	did	do	AUX
ghmj-960	186	4	not	not	PART
ghmj-960	186	5	work	work	VERB
ghmj-960	186	6	for	for	ADP
ghmj-960	186	7	acute	acute	ADJ
ghmj-960	186	8	urticaria	urticaria	NOUN
ghmj-960	186	9	or	or	CCONJ
ghmj-960	186	10	any	any	DET
ghmj-960	186	11	cause	cause	NOUN
ghmj-960	186	12	.	.	PUNCT
ghmj-960	187	1	it	it	PRON
ghmj-960	187	2	causes	cause	VERB
ghmj-960	187	3	unsharpened	unsharpened	ADJ
ghmj-960	187	4	development	development	NOUN
ghmj-960	187	5	of	of	ADP
ghmj-960	187	6	effective	effective	ADJ
ghmj-960	187	7	t	t	NOUN
ghmj-960	187	8	-	-	PUNCT
ghmj-960	187	9	cell	cell	NOUN
ghmj-960	187	10	–	–	PUNCT
ghmj-960	187	11	mediated	mediate	VERB
ghmj-960	187	12	immunity	immunity	NOUN
ghmj-960	187	13	(	(	PUNCT
ghmj-960	187	14	macy	macy	PROPN
ghmj-960	187	15	et	et	PROPN
ghmj-960	187	16	al	al	PROPN
ghmj-960	187	17	.	.	PROPN
ghmj-960	187	18	,	,	PUNCT
ghmj-960	187	19	2022	2022	NUM
ghmj-960	187	20	)	)	PUNCT
ghmj-960	187	21	.	.	PUNCT
ghmj-960	188	1	patients	patient	NOUN
ghmj-960	188	2	with	with	ADP
ghmj-960	188	3	chronic	chronic	ADJ
ghmj-960	188	4	spontaneous	spontaneous	ADJ
ghmj-960	188	5	urticaria	urticaria	NOUN
ghmj-960	188	6	require	require	VERB
ghmj-960	188	7	regular	regular	ADJ
ghmj-960	188	8	antihistamines	antihistamine	NOUN
ghmj-960	188	9	for	for	ADP
ghmj-960	188	10	2	2	NUM
ghmj-960	188	11	days	day	NOUN
ghmj-960	188	12	prior	prior	ADV
ghmj-960	188	13	to	to	ADP
ghmj-960	188	14	and	and	CCONJ
ghmj-960	188	15	after	after	ADP
ghmj-960	188	16	receiving	receive	VERB
ghmj-960	188	17	the	the	DET
ghmj-960	188	18	vaccine	vaccine	NOUN
ghmj-960	188	19	.	.	PUNCT
ghmj-960	189	1	patients	patient	NOUN
ghmj-960	189	2	on	on	ADP
ghmj-960	189	3	long	long	ADJ
ghmj-960	189	4	-	-	PUNCT
ghmj-960	189	5	term	term	NOUN
ghmj-960	189	6	antihistamines	antihistamine	NOUN
ghmj-960	189	7	may	may	AUX
ghmj-960	189	8	be	be	AUX
ghmj-960	189	9	advised	advise	VERB
ghmj-960	189	10	to	to	PART
ghmj-960	189	11	increase	increase	VERB
ghmj-960	189	12	their	their	PRON
ghmj-960	189	13	usual	usual	ADJ
ghmj-960	189	14	dose	dose	NOUN
ghmj-960	189	15	for	for	ADP
ghmj-960	189	16	this	this	DET
ghmj-960	189	17	period	period	NOUN
ghmj-960	189	18	(	(	PUNCT
ghmj-960	189	19	under	under	ADP
ghmj-960	189	20	clinical	clinical	ADJ
ghmj-960	189	21	supervision	supervision	NOUN
ghmj-960	189	22	)	)	PUNCT
ghmj-960	190	1	(	(	PUNCT
ghmj-960	190	2	bermingham	bermingham	NOUN
ghmj-960	190	3	et	et	PROPN
ghmj-960	190	4	al	al	PROPN
ghmj-960	190	5	.	.	PROPN
ghmj-960	190	6	,	,	PUNCT
ghmj-960	190	7	2021	2021	NUM
ghmj-960	190	8	)	)	PUNCT
ghmj-960	190	9	.	.	PUNCT
ghmj-960	191	1	4	4	X
ghmj-960	191	2	.	.	X
ghmj-960	191	3	discussion	discussion	NOUN
ghmj-960	191	4	astrazeneca	astrazeneca	PROPN
ghmj-960	191	5	contains	contain	VERB
ghmj-960	191	6	sensitizing	sensitize	VERB
ghmj-960	191	7	excipients	excipient	NOUN
ghmj-960	191	8	namely	namely	ADV
ghmj-960	191	9	polysorbate	polysorbate	ADJ
ghmj-960	191	10	80	80	NUM
ghmj-960	191	11	.	.	PUNCT
ghmj-960	192	1	an	an	DET
ghmj-960	192	2	immediate	immediate	ADJ
ghmj-960	192	3	hypersensitivity	hypersensitivity	NOUN
ghmj-960	192	4	type	type	NOUN
ghmj-960	192	5	i	i	PRON
ghmj-960	192	6	reaction	reaction	NOUN
ghmj-960	192	7	,	,	PUNCT
ghmj-960	192	8	urticarial	urticarial	ADJ
ghmj-960	192	9	rash	rash	NOUN
ghmj-960	192	10	,	,	PUNCT
ghmj-960	192	11	is	be	AUX
ghmj-960	192	12	developed	develop	VERB
ghmj-960	192	13	after	after	ADP
ghmj-960	192	14	getting	getting	AUX
ghmj-960	192	15	vaccinated	vaccinate	VERB
ghmj-960	192	16	of	of	ADP
ghmj-960	192	17	astrazeneca	astrazeneca	PROPN
ghmj-960	192	18	(	(	PUNCT
ghmj-960	192	19	burlando	burlando	NOUN
ghmj-960	192	20	et	et	PROPN
ghmj-960	192	21	al	al	PROPN
ghmj-960	192	22	.	.	PROPN
ghmj-960	192	23	,	,	PUNCT
ghmj-960	192	24	2021	2021	NUM
ghmj-960	192	25	)	)	PUNCT
ghmj-960	192	26	.	.	PUNCT
ghmj-960	193	1	pfizer	pfizer	NOUN
ghmj-960	193	2	involves	involve	VERB
ghmj-960	193	3	polyethylene	polyethylene	NOUN
ghmj-960	193	4	glycol	glycol	NOUN
ghmj-960	193	5	2000	2000	NUM
ghmj-960	193	6	which	which	PRON
ghmj-960	193	7	is	be	AUX
ghmj-960	193	8	excipient	excipient	ADJ
ghmj-960	193	9	with	with	ADP
ghmj-960	193	10	sensitizing	sensitize	VERB
ghmj-960	193	11	.	.	PUNCT
ghmj-960	194	1	moderna	moderna	PROPN
ghmj-960	194	2	consists	consist	VERB
ghmj-960	194	3	of	of	ADP
ghmj-960	194	4	polyethylene	polyethylene	NOUN
ghmj-960	194	5	glycol	glycol	NOUN
ghmj-960	194	6	2000	2000	NUM
ghmj-960	194	7	and	and	CCONJ
ghmj-960	194	8	tromethamine	tromethamine	PROPN
ghmj-960	194	9	(	(	PUNCT
ghmj-960	194	10	bianchi	bianchi	NOUN
ghmj-960	194	11	et	et	PROPN
ghmj-960	194	12	al	al	PROPN
ghmj-960	194	13	.	.	PROPN
ghmj-960	194	14	,	,	PUNCT
ghmj-960	194	15	2021	2021	NUM
ghmj-960	194	16	)	)	PUNCT
ghmj-960	194	17	.	.	PUNCT
ghmj-960	195	1	polyethylene	polyethylene	NOUN
ghmj-960	195	2	glycol‐2000	glycol‐2000	PROPN
ghmj-960	195	3	(	(	PUNCT
ghmj-960	195	4	peg‐	peg‐	NOUN
ghmj-960	195	5	2000	2000	NUM
ghmj-960	195	6	)	)	PUNCT
ghmj-960	196	1	in	in	ADP
ghmj-960	196	2	some	some	DET
ghmj-960	196	3	drugs	drug	NOUN
ghmj-960	196	4	produces	produce	VERB
ghmj-960	196	5	hypersensitivity	hypersensitivity	NOUN
ghmj-960	196	6	reactions	reaction	NOUN
ghmj-960	196	7	1	1	NUM
ghmj-960	196	8	right	right	ADV
ghmj-960	196	9	away	away	ADV
ghmj-960	196	10	and	and	CCONJ
ghmj-960	196	11	plays	play	VERB
ghmj-960	196	12	a	a	DET
ghmj-960	196	13	role	role	NOUN
ghmj-960	196	14	the	the	DET
ghmj-960	196	15	urticarial	urticarial	ADJ
ghmj-960	196	16	manifestations	manifestation	NOUN
ghmj-960	196	17	(	(	PUNCT
ghmj-960	196	18	farinazzo	farinazzo	VERB
ghmj-960	196	19	et	et	PROPN
ghmj-960	196	20	al	al	PROPN
ghmj-960	196	21	.	.	PROPN
ghmj-960	196	22	,	,	PUNCT
ghmj-960	196	23	2021	2021	NUM
ghmj-960	196	24	)	)	PUNCT
ghmj-960	196	25	.	.	PUNCT
ghmj-960	197	1	the	the	DET
ghmj-960	197	2	main	main	ADJ
ghmj-960	197	3	elements	element	NOUN
ghmj-960	197	4	in	in	ADP
ghmj-960	197	5	coronavac	coronavac	NOUN
ghmj-960	197	6	are	be	AUX
ghmj-960	197	7	whole	whole	ADJ
ghmj-960	197	8	inactivated	inactivated	ADJ
ghmj-960	197	9	viruses	virus	NOUN
ghmj-960	197	10	.	.	PUNCT
ghmj-960	198	1	these	these	PRON
ghmj-960	198	2	are	be	AUX
ghmj-960	198	3	cultured	cultured	ADJ
ghmj-960	198	4	with	with	ADP
ghmj-960	198	5	aluminum	aluminum	NOUN
ghmj-960	198	6	hydroxide	hydroxide	NOUN
ghmj-960	198	7	adjuvant	adjuvant	NOUN
ghmj-960	198	8	and	and	CCONJ
ghmj-960	198	9	some	some	DET
ghmj-960	198	10	mineral	mineral	NOUN
ghmj-960	198	11	salts	salt	NOUN
ghmj-960	198	12	in	in	ADP
ghmj-960	198	13	vero	vero	PROPN
ghmj-960	198	14	cells	cell	NOUN
ghmj-960	198	15	.	.	PUNCT
ghmj-960	199	1	coronavac	coronavac	NOUN
ghmj-960	199	2	-	-	PUNCT
ghmj-960	199	3	associated	associate	VERB
ghmj-960	199	4	urticaria	urticaria	NOUN
ghmj-960	199	5	is	be	AUX
ghmj-960	199	6	less	less	ADV
ghmj-960	199	7	likely	likely	ADJ
ghmj-960	199	8	to	to	PART
ghmj-960	199	9	be	be	AUX
ghmj-960	199	10	ige	ige	NOUN
ghmj-960	199	11	-	-	PUNCT
ghmj-960	199	12	mediated	mediate	VERB
ghmj-960	199	13	hypersensitivity	hypersensitivity	NOUN
ghmj-960	199	14	to	to	ADP
ghmj-960	199	15	the	the	DET
ghmj-960	199	16	vaccine	vaccine	NOUN
ghmj-960	199	17	.	.	PUNCT
ghmj-960	200	1	an	an	DET
ghmj-960	200	2	immune	immune	ADJ
ghmj-960	200	3	response	response	NOUN
ghmj-960	200	4	to	to	ADP
ghmj-960	200	5	the	the	DET
ghmj-960	200	6	sars	sar	NOUN
ghmj-960	200	7	-	-	PUNCT
ghmj-960	200	8	cov-2	cov-2	NOUN
ghmj-960	200	9	-	-	ADJ
ghmj-960	200	10	spike	spike	ADJ
ghmj-960	200	11	protein	protein	NOUN
ghmj-960	200	12	,	,	PUNCT
ghmj-960	200	13	rather	rather	ADV
ghmj-960	200	14	than	than	ADP
ghmj-960	200	15	the	the	DET
ghmj-960	200	16	vaccine	vaccine	NOUN
ghmj-960	200	17	excipients	excipient	NOUN
ghmj-960	200	18	,	,	PUNCT
ghmj-960	200	19	may	may	AUX
ghmj-960	200	20	play	play	VERB
ghmj-960	200	21	a	a	DET
ghmj-960	200	22	role	role	NOUN
ghmj-960	200	23	in	in	ADP
ghmj-960	200	24	the	the	DET
ghmj-960	200	25	pathogenesis	pathogenesis	NOUN
ghmj-960	200	26	of	of	ADP
ghmj-960	200	27	coronavac	coronavac	NOUN
ghmj-960	200	28	-	-	PUNCT
ghmj-960	200	29	associated	associate	VERB
ghmj-960	200	30	urticaria	urticaria	NOUN
ghmj-960	200	31	.	.	PUNCT
ghmj-960	201	1	the	the	DET
ghmj-960	201	2	result	result	NOUN
ghmj-960	201	3	of	of	ADP
ghmj-960	201	4	a	a	DET
ghmj-960	201	5	cross	cross	ADJ
ghmj-960	201	6	-	-	ADJ
ghmj-960	201	7	reactive	reactive	ADJ
ghmj-960	201	8	immune	immune	ADJ
ghmj-960	201	9	response	response	NOUN
ghmj-960	201	10	to	to	ADP
ghmj-960	201	11	sars	sars	PROPN
ghmj-960	201	12	-	-	PUNCT
ghmj-960	201	13	cov-2	cov-2	NOUN
ghmj-960	201	14	-	-	ADJ
ghmj-960	201	15	spike	spike	ADJ
ghmj-960	201	16	protein	protein	NOUN
ghmj-960	201	17	present	present	ADJ
ghmj-960	201	18	in	in	ADP
ghmj-960	201	19	previous	previous	ADJ
ghmj-960	201	20	coronavirus	coronavirus	NOUN
ghmj-960	201	21	infections	infection	NOUN
ghmj-960	201	22	causes	cause	VERB
ghmj-960	201	23	urticaria	urticaria	NOUN
ghmj-960	201	24	for	for	ADP
ghmj-960	201	25	sensitive	sensitive	ADJ
ghmj-960	201	26	people	people	NOUN
ghmj-960	201	27	(	(	PUNCT
ghmj-960	201	28	triwatcharikorn	triwatcharikorn	VERB
ghmj-960	201	29	et	et	PROPN
ghmj-960	201	30	al	al	PROPN
ghmj-960	201	31	.	.	PROPN
ghmj-960	201	32	,	,	PUNCT
ghmj-960	201	33	2022	2022	NUM
ghmj-960	201	34	)	)	PUNCT
ghmj-960	201	35	.	.	PUNCT
ghmj-960	202	1	urticaria	urticaria	NOUN
ghmj-960	202	2	which	which	PRON
ghmj-960	202	3	is	be	AUX
ghmj-960	202	4	immediate	immediate	ADJ
ghmj-960	202	5	hypersensitivity	hypersensitivity	NOUN
ghmj-960	202	6	based	base	VERB
ghmj-960	202	7	on	on	ADP
ghmj-960	202	8	centers	center	NOUN
ghmj-960	202	9	for	for	ADP
ghmj-960	202	10	disease	disease	NOUN
ghmj-960	202	11	control	control	NOUN
ghmj-960	202	12	and	and	CCONJ
ghmj-960	202	13	prevention	prevention	NOUN
ghmj-960	202	14	(	(	PUNCT
ghmj-960	202	15	cdc	cdc	PROPN
ghmj-960	202	16	)	)	PUNCT
ghmj-960	202	17	happen	happen	VERB
ghmj-960	202	18	within	within	ADP
ghmj-960	202	19	4	4	NUM
ghmj-960	202	20	hours	hour	NOUN
ghmj-960	202	21	after	after	ADP
ghmj-960	202	22	administrating	administrate	VERB
ghmj-960	202	23	vaccines	vaccine	NOUN
ghmj-960	202	24	(	(	PUNCT
ghmj-960	202	25	gronbeck	gronbeck	NOUN
ghmj-960	202	26	and	and	CCONJ
ghmj-960	202	27	grant	grant	NOUN
ghmj-960	202	28	-	-	PUNCT
ghmj-960	202	29	kels	kel	NOUN
ghmj-960	202	30	,	,	PUNCT
ghmj-960	202	31	2021	2021	NUM
ghmj-960	202	32	)	)	PUNCT
ghmj-960	202	33	.	.	PUNCT
ghmj-960	203	1	either	either	CCONJ
ghmj-960	203	2	ige	ige	PROPN
ghmj-960	203	3	mediated	mediate	VERB
ghmj-960	203	4	or	or	CCONJ
ghmj-960	203	5	igg	igg	PROPN
ghmj-960	203	6	is	be	AUX
ghmj-960	203	7	the	the	DET
ghmj-960	203	8	reaction	reaction	NOUN
ghmj-960	203	9	from	from	ADP
ghmj-960	203	10	hypersensitivity	hypersensitivity	NOUN
ghmj-960	203	11	after	after	ADP
ghmj-960	203	12	vaccine	vaccine	NOUN
ghmj-960	203	13	administration	administration	NOUN
ghmj-960	203	14	.	.	PUNCT
ghmj-960	204	1	it	it	PRON
ghmj-960	204	2	is	be	AUX
ghmj-960	204	3	caused	cause	VERB
ghmj-960	204	4	by	by	ADP
ghmj-960	204	5	complement	complement	NOUN
ghmj-960	204	6	-	-	PUNCT
ghmj-960	204	7	mediated	mediate	VERB
ghmj-960	204	8	anaphylactic	anaphylactic	ADJ
ghmj-960	204	9	and	and	CCONJ
ghmj-960	204	10	delayed	delay	VERB
ghmj-960	204	11	t	t	NOUN
ghmj-960	204	12	-	-	PUNCT
ghmj-960	204	13	cell	cell	NOUN
ghmj-960	204	14	-	-	PUNCT
ghmj-960	204	15	mediated	mediate	VERB
ghmj-960	204	16	reactions	reaction	NOUN
ghmj-960	204	17	ige	ige	PROPN
ghmj-960	204	18	(	(	PUNCT
ghmj-960	204	19	namazi	namazi	PROPN
ghmj-960	204	20	et	et	PROPN
ghmj-960	204	21	al	al	PROPN
ghmj-960	204	22	.	.	PROPN
ghmj-960	204	23	,	,	PUNCT
ghmj-960	204	24	2022	2022	NUM
ghmj-960	204	25	)	)	PUNCT
ghmj-960	204	26	.	.	PUNCT
ghmj-960	205	1	people	people	NOUN
ghmj-960	205	2	who	who	PRON
ghmj-960	205	3	developed	develop	VERB
ghmj-960	205	4	urticaria	urticaria	NOUN
ghmj-960	205	5	less	less	ADJ
ghmj-960	205	6	than	than	ADP
ghmj-960	205	7	30	30	NUM
ghmj-960	205	8	minutes	minute	NOUN
ghmj-960	205	9	after	after	ADP
ghmj-960	205	10	the	the	DET
ghmj-960	205	11	first	first	ADJ
ghmj-960	205	12	dose	dose	NOUN
ghmj-960	205	13	of	of	ADP
ghmj-960	205	14	vaccination	vaccination	NOUN
ghmj-960	205	15	had	have	VERB
ghmj-960	205	16	an	an	DET
ghmj-960	205	17	increased	increase	VERB
ghmj-960	205	18	risk	risk	NOUN
ghmj-960	205	19	of	of	ADP
ghmj-960	205	20	urticaria	urticaria	NOUN
ghmj-960	205	21	after	after	ADP
ghmj-960	205	22	the	the	DET
ghmj-960	205	23	second	second	ADJ
ghmj-960	205	24	vaccination	vaccination	NOUN
ghmj-960	205	25	(	(	PUNCT
ghmj-960	205	26	rerknimitr	rerknimitr	NOUN
ghmj-960	205	27	et	et	PROPN
ghmj-960	205	28	al	al	PROPN
ghmj-960	205	29	.	.	PROPN
ghmj-960	205	30	,	,	PUNCT
ghmj-960	205	31	2022	2022	NUM
ghmj-960	205	32	)	)	PUNCT
ghmj-960	205	33	.	.	PUNCT
ghmj-960	206	1	a	a	DET
ghmj-960	206	2	minor	minor	ADJ
ghmj-960	206	3	subset	subset	NOUN
ghmj-960	206	4	of	of	ADP
ghmj-960	206	5	cases	case	NOUN
ghmj-960	206	6	demonstrated	demonstrate	VERB
ghmj-960	206	7	urticarial	urticarial	ADJ
ghmj-960	206	8	vasculitis	vasculitis	PROPN
ghmj-960	206	9	,	,	PUNCT
ghmj-960	206	10	a	a	DET
ghmj-960	206	11	morphologic	morphologic	ADJ
ghmj-960	206	12	subset	subset	NOUN
ghmj-960	206	13	of	of	ADP
ghmj-960	206	14	leukocytoclastic	leukocytoclastic	ADJ
ghmj-960	206	15	vasculitis	vasculitis	PROPN
ghmj-960	206	16	characteristically	characteristically	ADV
ghmj-960	206	17	triggered	trigger	VERB
ghmj-960	206	18	by	by	ADP
ghmj-960	206	19	immune	immune	ADJ
ghmj-960	206	20	complex	complex	ADJ
ghmj-960	206	21	deposition	deposition	NOUN
ghmj-960	206	22	but	but	CCONJ
ghmj-960	206	23	other	other	ADJ
ghmj-960	206	24	proinflammatory	proinflammatory	ADJ
ghmj-960	206	25	pathways	pathway	NOUN
ghmj-960	206	26	can	can	AUX
ghmj-960	206	27	be	be	AUX
ghmj-960	206	28	implicated	implicate	VERB
ghmj-960	206	29	.	.	PUNCT
ghmj-960	207	1	antibodies	antibody	NOUN
ghmj-960	207	2	bound	bind	VERB
ghmj-960	207	3	to	to	ADP
ghmj-960	207	4	an	an	DET
ghmj-960	207	5	undefined	undefined	ADJ
ghmj-960	207	6	foreign	foreign	ADJ
ghmj-960	207	7	protein	protein	NOUN
ghmj-960	207	8	introduced	introduce	VERB
ghmj-960	207	9	by	by	ADP
ghmj-960	207	10	the	the	DET
ghmj-960	207	11	vaccine	vaccine	NOUN
ghmj-960	207	12	could	could	AUX
ghmj-960	207	13	be	be	AUX
ghmj-960	207	14	deposited	deposit	VERB
ghmj-960	207	15	in	in	ADP
ghmj-960	207	16	microvessels	microvessel	NOUN
ghmj-960	207	17	as	as	ADP
ghmj-960	207	18	an	an	DET
ghmj-960	207	19	immune	immune	ADJ
ghmj-960	207	20	complex	complex	NOUN
ghmj-960	207	21	and	and	CCONJ
ghmj-960	207	22	trigger	trigger	VERB
ghmj-960	207	23	the	the	DET
ghmj-960	207	24	classic	classic	ADJ
ghmj-960	207	25	complement	complement	NOUN
ghmj-960	207	26	pathway	pathway	NOUN
ghmj-960	207	27	to	to	PART
ghmj-960	207	28	result	result	VERB
ghmj-960	207	29	in	in	ADP
ghmj-960	207	30	a	a	DET
ghmj-960	207	31	neutrophil	neutrophil	ADJ
ghmj-960	207	32	-	-	PUNCT
ghmj-960	207	33	rich	rich	ADJ
ghmj-960	207	34	inflammatory	inflammatory	ADJ
ghmj-960	207	35	reaction	reaction	NOUN
ghmj-960	207	36	(	(	PUNCT
ghmj-960	207	37	magro	magro	PROPN
ghmj-960	207	38	et	et	PROPN
ghmj-960	207	39	al	al	PROPN
ghmj-960	207	40	.	.	PROPN
ghmj-960	207	41	,	,	PUNCT
ghmj-960	207	42	2021	2021	NUM
ghmj-960	207	43	)	)	PUNCT
ghmj-960	207	44	.	.	PUNCT
ghmj-960	208	1	nugrahaeni	nugrahaeni	PROPN
ghmj-960	208	2	&	&	CCONJ
ghmj-960	208	3	budiyanti	budiyanti	PROPN
ghmj-960	208	4	ghmj	ghmj	PROPN
ghmj-960	208	5	(	(	PUNCT
ghmj-960	208	6	global	global	ADJ
ghmj-960	208	7	health	health	PROPN
ghmj-960	208	8	management	management	NOUN
ghmj-960	208	9	journal	journal	PROPN
ghmj-960	208	10	)	)	PUNCT
ghmj-960	208	11	2023	2023	NUM
ghmj-960	208	12	,	,	PUNCT
ghmj-960	208	13	vol	vol	NOUN
ghmj-960	208	14	.	.	PROPN
ghmj-960	208	15	6	6	NUM
ghmj-960	208	16	,	,	PUNCT
ghmj-960	208	17	no	no	INTJ
ghmj-960	208	18	.	.	NOUN
ghmj-960	208	19	2	2	NUM
ghmj-960	208	20	64	64	NUM
ghmj-960	208	21	5	5	NUM
ghmj-960	208	22	.	.	PUNCT
ghmj-960	209	1	conclusion	conclusion	NOUN
ghmj-960	209	2	urticaria	urticaria	NOUN
ghmj-960	209	3	is	be	AUX
ghmj-960	209	4	the	the	DET
ghmj-960	209	5	most	most	ADV
ghmj-960	209	6	frequent	frequent	ADJ
ghmj-960	209	7	reaction	reaction	NOUN
ghmj-960	209	8	after	after	ADP
ghmj-960	209	9	the	the	DET
ghmj-960	209	10	covid-19	covid-19	PROPN
ghmj-960	209	11	vaccine	vaccine	NOUN
ghmj-960	209	12	administration	administration	NOUN
ghmj-960	209	13	.	.	PUNCT
ghmj-960	210	1	this	this	DET
ghmj-960	210	2	concerns	concern	NOUN
ghmj-960	210	3	hypersensitivity	hypersensitivity	NOUN
ghmj-960	210	4	reaction	reaction	NOUN
ghmj-960	210	5	which	which	PRON
ghmj-960	210	6	is	be	AUX
ghmj-960	210	7	related	relate	VERB
ghmj-960	210	8	to	to	ADP
ghmj-960	210	9	ige	ige	NOUN
ghmj-960	210	10	-	-	PUNCT
ghmj-960	210	11	mediated	mediate	VERB
ghmj-960	210	12	,	,	PUNCT
ghmj-960	210	13	igg	igg	PROPN
ghmj-960	210	14	,	,	PUNCT
ghmj-960	210	15	and	and	CCONJ
ghmj-960	210	16	sensitizing	sensitize	VERB
ghmj-960	210	17	excipients	excipient	NOUN
ghmj-960	210	18	in	in	ADP
ghmj-960	210	19	covid-19	covid-19	PROPN
ghmj-960	210	20	vaccines	vaccine	NOUN
ghmj-960	210	21	.	.	PUNCT
ghmj-960	211	1	the	the	DET
ghmj-960	211	2	awareness	awareness	NOUN
ghmj-960	211	3	of	of	ADP
ghmj-960	211	4	healthcare	healthcare	NOUN
ghmj-960	211	5	professionals	professional	NOUN
ghmj-960	211	6	is	be	AUX
ghmj-960	211	7	essential	essential	ADJ
ghmj-960	211	8	in	in	ADP
ghmj-960	211	9	order	order	NOUN
ghmj-960	211	10	to	to	PART
ghmj-960	211	11	recognize	recognize	VERB
ghmj-960	211	12	and	and	CCONJ
ghmj-960	211	13	treat	treat	VERB
ghmj-960	211	14	eventual	eventual	ADJ
ghmj-960	211	15	severe	severe	ADJ
ghmj-960	211	16	reactions	reaction	NOUN
ghmj-960	211	17	from	from	ADP
ghmj-960	211	18	covid-19	covid-19	PROPN
ghmj-960	211	19	vaccinations	vaccination	NOUN
ghmj-960	211	20	.	.	PUNCT
ghmj-960	212	1	besides	besides	SCONJ
ghmj-960	212	2	,	,	PUNCT
ghmj-960	212	3	medical	medical	ADJ
ghmj-960	212	4	history	history	NOUN
ghmj-960	212	5	is	be	AUX
ghmj-960	212	6	required	require	VERB
ghmj-960	212	7	to	to	PART
ghmj-960	212	8	discover	discover	VERB
ghmj-960	212	9	possible	possible	ADJ
ghmj-960	212	10	risk	risk	NOUN
ghmj-960	212	11	factors	factor	NOUN
ghmj-960	212	12	and	and	CCONJ
ghmj-960	212	13	keep	keep	VERB
ghmj-960	212	14	down	down	ADP
ghmj-960	212	15	adverse	adverse	ADJ
ghmj-960	212	16	reaction	reaction	NOUN
ghmj-960	212	17	incidence	incidence	NOUN
ghmj-960	212	18	.	.	PUNCT
ghmj-960	213	1	furthermore	furthermore	ADV
ghmj-960	213	2	,	,	PUNCT
ghmj-960	213	3	immunology	immunology	NOUN
ghmj-960	213	4	/	/	SYM
ghmj-960	213	5	allergy	allergy	NOUN
ghmj-960	213	6	consultation	consultation	NOUN
ghmj-960	213	7	might	might	AUX
ghmj-960	213	8	be	be	AUX
ghmj-960	213	9	advantageous	advantageous	ADJ
ghmj-960	213	10	to	to	PART
ghmj-960	213	11	assess	assess	VERB
ghmj-960	213	12	the	the	DET
ghmj-960	213	13	risk	risk	NOUN
ghmj-960	213	14	of	of	ADP
ghmj-960	213	15	allergy	allergy	NOUN
ghmj-960	213	16	and	and	CCONJ
ghmj-960	213	17	the	the	DET
ghmj-960	213	18	guidance	guidance	NOUN
ghmj-960	213	19	of	of	ADP
ghmj-960	213	20	the	the	DET
ghmj-960	213	21	vaccine	vaccine	NOUN
ghmj-960	213	22	.	.	PUNCT
ghmj-960	214	1	conflict	conflict	NOUN
ghmj-960	214	2	of	of	ADP
ghmj-960	214	3	interest	interest	NOUN
ghmj-960	214	4	the	the	DET
ghmj-960	214	5	authors	author	NOUN
ghmj-960	214	6	declare	declare	VERB
ghmj-960	214	7	no	no	DET
ghmj-960	214	8	conflicts	conflict	NOUN
ghmj-960	214	9	of	of	ADP
ghmj-960	214	10	interest	interest	NOUN
ghmj-960	214	11	,	,	PUNCT
ghmj-960	214	12	and	and	CCONJ
ghmj-960	214	13	no	no	DET
ghmj-960	214	14	financial	financial	ADJ
ghmj-960	214	15	support	support	NOUN
ghmj-960	214	16	.	.	PUNCT
ghmj-960	215	1	references	reference	NOUN
ghmj-960	215	2	akdaş	akdaş	PROPN
ghmj-960	215	3	,	,	PUNCT
ghmj-960	215	4	e.	e.	PROPN
ghmj-960	215	5	,	,	PUNCT
ghmj-960	215	6	öğüt	öğüt	PROPN
ghmj-960	215	7	,	,	PUNCT
ghmj-960	215	8	b.	b.	PROPN
ghmj-960	215	9	,	,	PUNCT
ghmj-960	215	10	erdem	erdem	PROPN
ghmj-960	215	11	,	,	PUNCT
ghmj-960	215	12	ö.	ö.	NOUN
ghmj-960	215	13	,	,	PUNCT
ghmj-960	215	14	öztaş	öztaş	ADJ
ghmj-960	215	15	,	,	PUNCT
ghmj-960	215	16	m.	m.	NOUN
ghmj-960	215	17	o.	o.	PROPN
ghmj-960	215	18	,	,	PUNCT
ghmj-960	215	19	&	&	CCONJ
ghmj-960	215	20	i̇lter	i̇lter	NOUN
ghmj-960	215	21	,	,	PUNCT
ghmj-960	215	22	n.	n.	NOUN
ghmj-960	215	23	(	(	PUNCT
ghmj-960	215	24	2021	2021	NUM
ghmj-960	215	25	)	)	PUNCT
ghmj-960	215	26	.	.	PUNCT
ghmj-960	216	1	cutaneous	cutaneous	ADJ
ghmj-960	216	2	reactions	reaction	NOUN
ghmj-960	216	3	following	follow	VERB
ghmj-960	216	4	coronavac	coronavac	VERB
ghmj-960	216	5	covid-19	covid-19	PROPN
ghmj-960	216	6	vaccination	vaccination	NOUN
ghmj-960	216	7	:	:	PUNCT
ghmj-960	216	8	a	a	DET
ghmj-960	216	9	case	case	NOUN
ghmj-960	216	10	series	series	NOUN
ghmj-960	216	11	of	of	ADP
ghmj-960	216	12	six	six	NUM
ghmj-960	216	13	healthcare	healthcare	NOUN
ghmj-960	216	14	workers	worker	NOUN
ghmj-960	216	15	from	from	ADP
ghmj-960	216	16	a	a	DET
ghmj-960	216	17	single	single	ADJ
ghmj-960	216	18	centre	centre	NOUN
ghmj-960	216	19	.	.	PUNCT
ghmj-960	217	1	journal	journal	NOUN
ghmj-960	217	2	of	of	ADP
ghmj-960	217	3	the	the	DET
ghmj-960	217	4	european	european	PROPN
ghmj-960	217	5	academy	academy	PROPN
ghmj-960	217	6	of	of	ADP
ghmj-960	217	7	dermatology	dermatology	NOUN
ghmj-960	217	8	and	and	CCONJ
ghmj-960	217	9	venereology	venereology	NOUN
ghmj-960	217	10	:	:	PUNCT
ghmj-960	217	11	jeadv	jeadv	NOUN
ghmj-960	217	12	,	,	PUNCT
ghmj-960	217	13	35(12	35(12	NUM
ghmj-960	217	14	)	)	PUNCT
ghmj-960	217	15	,	,	PUNCT
ghmj-960	217	16	e861	e861	PROPN
ghmj-960	217	17	–	–	PUNCT
ghmj-960	217	18	e864	e864	PROPN
ghmj-960	217	19	.	.	PUNCT
ghmj-960	218	1	https://doi.org/10.1111/jdv.17592	https://doi.org/10.1111/jdv.17592	PROPN
ghmj-960	218	2	almuhizi	almuhizi	NOUN
ghmj-960	218	3	,	,	PUNCT
ghmj-960	218	4	f.	f.	PROPN
ghmj-960	218	5	,	,	PUNCT
ghmj-960	218	6	ton	ton	PROPN
ghmj-960	218	7	-	-	PUNCT
ghmj-960	218	8	leclerc	leclerc	NOUN
ghmj-960	218	9	,	,	PUNCT
ghmj-960	218	10	s.	s.	PROPN
ghmj-960	218	11	,	,	PUNCT
ghmj-960	218	12	fein	fein	PROPN
ghmj-960	218	13	,	,	PUNCT
ghmj-960	218	14	m.	m.	NOUN
ghmj-960	218	15	,	,	PUNCT
ghmj-960	218	16	tsoukas	tsoukas	PROPN
ghmj-960	218	17	,	,	PUNCT
ghmj-960	218	18	c.	c.	PROPN
ghmj-960	218	19	,	,	PUNCT
ghmj-960	218	20	garvey	garvey	PROPN
ghmj-960	218	21	,	,	PUNCT
ghmj-960	218	22	l.h	l.h	PROPN
ghmj-960	218	23	.	.	PROPN
ghmj-960	218	24	,	,	PUNCT
ghmj-960	218	25	lee	lee	PROPN
ghmj-960	218	26	,	,	PUNCT
ghmj-960	218	27	d.	d.	PROPN
ghmj-960	218	28	,et	,et	PUNCT
ghmj-960	218	29	al	al	PROPN
ghmj-960	218	30	.	.	PROPN
ghmj-960	218	31	(	(	PUNCT
ghmj-960	218	32	2022	2022	NUM
ghmj-960	218	33	)	)	PUNCT
ghmj-960	218	34	.	.	PUNCT
ghmj-960	219	1	successful	successful	ADJ
ghmj-960	219	2	desensitization	desensitization	NOUN
ghmj-960	219	3	to	to	ADP
ghmj-960	219	4	mrna	mrna	PROPN
ghmj-960	219	5	covid-19	covid-19	PROPN
ghmj-960	219	6	vaccine	vaccine	NOUN
ghmj-960	219	7	in	in	ADP
ghmj-960	219	8	a	a	DET
ghmj-960	219	9	case	case	NOUN
ghmj-960	219	10	series	series	NOUN
ghmj-960	219	11	of	of	ADP
ghmj-960	219	12	patients	patient	NOUN
ghmj-960	219	13	with	with	ADP
ghmj-960	219	14	a	a	DET
ghmj-960	219	15	history	history	NOUN
ghmj-960	219	16	of	of	ADP
ghmj-960	219	17	anaphylaxis	anaphylaxis	NOUN
ghmj-960	219	18	to	to	ADP
ghmj-960	219	19	the	the	DET
ghmj-960	219	20	first	first	ADJ
ghmj-960	219	21	vaccine	vaccine	NOUN
ghmj-960	219	22	dose	dose	PROPN
ghmj-960	219	23	.	.	PUNCT
ghmj-960	220	1	front	front	PROPN
ghmj-960	220	2	.	.	PUNCT
ghmj-960	221	1	allergy	allergy	NOUN
ghmj-960	221	2	,	,	PUNCT
ghmj-960	221	3	02	02	NUM
ghmj-960	221	4	february	february	NOUN
ghmj-960	221	5	2022	2022	NUM
ghmj-960	221	6	.	.	PUNCT
ghmj-960	222	1	https://doi.org/10.3389/falgy.2022.825164	https://doi.org/10.3389/falgy.2022.825164	PROPN
ghmj-960	222	2	bermingham	bermingham	NOUN
ghmj-960	222	3	,	,	PUNCT
ghmj-960	222	4	w.h	w.h	PROPN
ghmj-960	222	5	.	.	PROPN
ghmj-960	222	6	,	,	PUNCT
ghmj-960	222	7	ardern	ardern	ADJ
ghmj-960	222	8	-	-	PUNCT
ghmj-960	222	9	jones	jones	PROPN
ghmj-960	222	10	,	,	PUNCT
ghmj-960	222	11	m.r	m.r	PROPN
ghmj-960	222	12	.	.	PROPN
ghmj-960	222	13	,	,	PUNCT
ghmj-960	222	14	huissoon	huissoon	NOUN
ghmj-960	222	15	,	,	PUNCT
ghmj-960	222	16	a.p	a.p	PROPN
ghmj-960	222	17	.	.	PROPN
ghmj-960	222	18	,	,	PUNCT
ghmj-960	222	19	krishna	krishna	PROPN
ghmj-960	222	20	,	,	PUNCT
ghmj-960	222	21	m.t	m.t	PROPN
ghmj-960	222	22	.	.	PROPN
ghmj-960	222	23	(	(	PUNCT
ghmj-960	222	24	2021	2021	NUM
ghmj-960	222	25	)	)	PUNCT
ghmj-960	222	26	.	.	PUNCT
ghmj-960	223	1	forewarned	forewarned	PROPN
ghmj-960	223	2	is	be	AUX
ghmj-960	223	3	forearmed	forearmed	ADJ
ghmj-960	223	4	:	:	PUNCT
ghmj-960	223	5	chronic	chronic	ADJ
ghmj-960	223	6	spontaneous	spontaneous	ADJ
ghmj-960	223	7	urticaria	urticaria	NOUN
ghmj-960	223	8	as	as	ADP
ghmj-960	223	9	a	a	DET
ghmj-960	223	10	potential	potential	ADJ
ghmj-960	223	11	risk	risk	NOUN
ghmj-960	223	12	to	to	ADP
ghmj-960	223	13	effective	effective	ADJ
ghmj-960	223	14	sars	sar	NOUN
ghmj-960	223	15	-	-	PUNCT
ghmj-960	223	16	cov-2	cov-2	NOUN
ghmj-960	223	17	vaccine	vaccine	NOUN
ghmj-960	223	18	uptake	uptake	VERB
ghmj-960	223	19	and	and	CCONJ
ghmj-960	223	20	global	global	ADJ
ghmj-960	223	21	public	public	ADJ
ghmj-960	223	22	health	health	NOUN
ghmj-960	223	23	.	.	PUNCT
ghmj-960	224	1	british	british	ADJ
ghmj-960	224	2	journal	journal	PROPN
ghmj-960	224	3	of	of	ADP
ghmj-960	224	4	dermatology	dermatology	NOUN
ghmj-960	224	5	(	(	PUNCT
ghmj-960	224	6	2021)185	2021)185	PROPN
ghmj-960	224	7	,	,	PUNCT
ghmj-960	224	8	pp838–839	pp838–839	NOUN
ghmj-960	224	9	.	.	PUNCT
ghmj-960	225	1	https://doi.org/10.1111/bjd.20495	https://doi.org/10.1111/bjd.20495	PROPN
ghmj-960	225	2	bernstein	bernstein	PROPN
ghmj-960	225	3	,	,	PUNCT
ghmj-960	225	4	j.a	j.a	PROPN
ghmj-960	225	5	.	.	PROPN
ghmj-960	225	6	,	,	PUNCT
ghmj-960	225	7	singh	singh	PROPN
ghmj-960	225	8	,	,	PUNCT
ghmj-960	225	9	u.	u.	PROPN
ghmj-960	225	10	,	,	PUNCT
ghmj-960	225	11	rao	rao	PROPN
ghmj-960	225	12	,	,	PUNCT
ghmj-960	225	13	m.b	m.b	PROPN
ghmj-960	225	14	.	.	PROPN
ghmj-960	225	15	,	,	PUNCT
ghmj-960	225	16	berendts	berendts	ADJ
ghmj-960	225	17	,	,	PUNCT
ghmj-960	225	18	k.	k.	PROPN
ghmj-960	225	19	,	,	PUNCT
ghmj-960	225	20	zhang	zhang	PROPN
ghmj-960	225	21	,	,	PUNCT
ghmj-960	225	22	x.	x.	PROPN
ghmj-960	225	23	,	,	PUNCT
ghmj-960	225	24	mutasim	mutasim	NOUN
ghmj-960	225	25	,	,	PUNCT
ghmj-960	225	26	d.	d.	PROPN
ghmj-960	225	27	(	(	PUNCT
ghmj-960	225	28	2020	2020	NUM
ghmj-960	225	29	)	)	PUNCT
ghmj-960	225	30	.	.	PUNCT
ghmj-960	226	1	benralizumab	benralizumab	NOUN
ghmj-960	226	2	for	for	ADP
ghmj-960	226	3	chronic	chronic	ADJ
ghmj-960	226	4	spontaneous	spontaneous	ADJ
ghmj-960	226	5	urticaria	urticaria	NOUN
ghmj-960	226	6	.	.	PUNCT
ghmj-960	227	1	n	n	PROPN
ghmj-960	227	2	engl	engl	PROPN
ghmj-960	227	3	j	j	PROPN
ghmj-960	227	4	med	med	PROPN
ghmj-960	227	5	2020	2020	NUM
ghmj-960	227	6	;	;	PUNCT
ghmj-960	227	7	383:1389	383:1389	NUM
ghmj-960	227	8	-	-	SYM
ghmj-960	227	9	1391	1391	NUM
ghmj-960	227	10	.	.	PUNCT
ghmj-960	228	1	doi	doi	NOUN
ghmj-960	228	2	:	:	PUNCT
ghmj-960	228	3	10.1056	10.1056	NUM
ghmj-960	228	4	/	/	SYM
ghmj-960	228	5	nejmc2016395	nejmc2016395	PROPN
ghmj-960	228	6	bianchi	bianchi	PROPN
ghmj-960	228	7	,	,	PUNCT
ghmj-960	228	8	l.	l.	PROPN
ghmj-960	228	9	,	,	PUNCT
ghmj-960	228	10	biondi	biondi	PROPN
ghmj-960	228	11	,	,	PUNCT
ghmj-960	228	12	f.	f.	PROPN
ghmj-960	228	13	,	,	PUNCT
ghmj-960	228	14	hansel	hansel	PROPN
ghmj-960	228	15	,	,	PUNCT
ghmj-960	228	16	k.	k.	PROPN
ghmj-960	228	17	,	,	PUNCT
ghmj-960	228	18	murgia	murgia	PROPN
ghmj-960	228	19	,	,	PUNCT
ghmj-960	228	20	n.	n.	PROPN
ghmj-960	228	21	,	,	PUNCT
ghmj-960	228	22	tramontana	tramontana	PROPN
ghmj-960	228	23	,	,	PUNCT
ghmj-960	228	24	m.	m.	NOUN
ghmj-960	228	25	,	,	PUNCT
ghmj-960	228	26	stingeni	stingeni	NOUN
ghmj-960	228	27	,	,	PUNCT
ghmj-960	228	28	l.	l.	PROPN
ghmj-960	228	29	(	(	PUNCT
ghmj-960	228	30	2021	2021	NUM
ghmj-960	228	31	)	)	PUNCT
ghmj-960	228	32	.	.	PUNCT
ghmj-960	229	1	skin	skin	NOUN
ghmj-960	229	2	tests	test	NOUN
ghmj-960	229	3	in	in	ADP
ghmj-960	229	4	urticaria	urticaria	NOUN
ghmj-960	229	5	/	/	SYM
ghmj-960	229	6	angioedema	angioedema	NOUN
ghmj-960	229	7	and	and	CCONJ
ghmj-960	229	8	flushing	flush	VERB
ghmj-960	229	9	to	to	ADP
ghmj-960	229	10	pfizer‐biontech	pfizer‐biontech	NOUN
ghmj-960	229	11	sars‐cov‐2	sars‐cov‐2	PROPN
ghmj-960	229	12	vaccine	vaccine	NOUN
ghmj-960	229	13	:	:	PUNCT
ghmj-960	229	14	limits	limit	NOUN
ghmj-960	229	15	of	of	ADP
ghmj-960	229	16	intradermal	intradermal	ADJ
ghmj-960	229	17	testing	testing	NOUN
ghmj-960	229	18	.	.	PUNCT
ghmj-960	230	1	wiley	wiley	PROPN
ghmj-960	230	2	allergy	allergy	PROPN
ghmj-960	230	3	.	.	PUNCT
ghmj-960	231	1	2021	2021	NUM
ghmj-960	231	2	apr	apr	NOUN
ghmj-960	231	3	22	22	NUM
ghmj-960	231	4	:	:	SYM
ghmj-960	231	5	10.1111	10.1111	NUM
ghmj-960	231	6	/	/	SYM
ghmj-960	231	7	all.14839	all.14839	PROPN
ghmj-960	231	8	.	.	PUNCT
ghmj-960	231	9	doi	doi	NOUN
ghmj-960	231	10	:	:	PUNCT
ghmj-960	231	11	10.1111	10.1111	NUM
ghmj-960	231	12	/	/	SYM
ghmj-960	231	13	all.14839	all.14839	NUM
ghmj-960	231	14	brooks	brooks	NOUN
ghmj-960	231	15	,	,	PUNCT
ghmj-960	231	16	s.g	s.g	PROPN
ghmj-960	231	17	.	.	PROPN
ghmj-960	231	18	,	,	PUNCT
ghmj-960	231	19	de	de	PROPN
ghmj-960	231	20	jong	jong	PROPN
ghmj-960	231	21	,	,	PUNCT
ghmj-960	231	22	a.m.	a.m.	ADV
ghmj-960	231	23	,	,	PUNCT
ghmj-960	231	24	abbaslou	abbaslou	PROPN
ghmj-960	231	25	,	,	PUNCT
ghmj-960	231	26	m.	m.	NOUN
ghmj-960	231	27	,	,	PUNCT
ghmj-960	231	28	sussman	sussman	NOUN
ghmj-960	231	29	,	,	PUNCT
ghmj-960	231	30	g.	g.	PROPN
ghmj-960	231	31	(	(	PUNCT
ghmj-960	231	32	2022	2022	NUM
ghmj-960	231	33	)	)	PUNCT
ghmj-960	231	34	.	.	PUNCT
ghmj-960	232	1	chronic	chronic	ADJ
ghmj-960	232	2	spontaneous	spontaneous	ADJ
ghmj-960	232	3	urticaria	urticaria	NOUN
ghmj-960	232	4	triggered	trigger	VERB
ghmj-960	232	5	by	by	ADP
ghmj-960	232	6	the	the	DET
ghmj-960	232	7	astrazeneca	astrazeneca	PROPN
ghmj-960	232	8	/	/	SYM
ghmj-960	232	9	oxford	oxford	PROPN
ghmj-960	232	10	covid-19	covid-19	PROPN
ghmj-960	232	11	vaccine	vaccine	NOUN
ghmj-960	232	12	with	with	ADP
ghmj-960	232	13	achieved	achieve	VERB
ghmj-960	232	14	remission	remission	NOUN
ghmj-960	232	15	:	:	PUNCT
ghmj-960	232	16	a	a	DET
ghmj-960	232	17	case	case	NOUN
ghmj-960	232	18	report	report	NOUN
ghmj-960	232	19	.	.	PUNCT
ghmj-960	233	1	sage	sage	NOUN
ghmj-960	233	2	allergy	allergy	PROPN
ghmj-960	233	3	&	&	CCONJ
ghmj-960	233	4	rhinology	rhinology	PROPN
ghmj-960	233	5	volume	volume	NOUN
ghmj-960	233	6	13	13	NUM
ghmj-960	233	7	:	:	PUNCT
ghmj-960	233	8	1–2	1–2	NUM
ghmj-960	233	9	.	.	PUNCT
ghmj-960	234	1	https://doi.org/10.1177/21526567211068458	https://doi.org/10.1177/21526567211068458	ADJ
ghmj-960	234	2	bruusgaard	bruusgaard	NOUN
ghmj-960	234	3	-	-	PUNCT
ghmj-960	234	4	mouritsen	mouritsen	NOUN
ghmj-960	234	5	,	,	PUNCT
ghmj-960	234	6	m.	m.	NOUN
ghmj-960	234	7	,	,	PUNCT
ghmj-960	234	8	jensen	jensen	PROPN
ghmj-960	234	9	,	,	PUNCT
ghmj-960	234	10	b.m	b.m	PROPN
ghmj-960	234	11	.	.	PROPN
ghmj-960	234	12	,	,	PUNCT
ghmj-960	234	13	poulsen	poulsen	PROPN
ghmj-960	234	14	,	,	PUNCT
ghmj-960	234	15	l.k	l.k	PROPN
ghmj-960	234	16	.	.	PROPN
ghmj-960	234	17	,	,	PUNCT
ghmj-960	234	18	johansen	johansen	PROPN
ghmj-960	234	19	,	,	PUNCT
ghmj-960	234	20	j.d	j.d	PROPN
ghmj-960	234	21	.	.	PROPN
ghmj-960	234	22	,	,	PUNCT
ghmj-960	234	23	garvey	garvey	PROPN
ghmj-960	234	24	,	,	PUNCT
ghmj-960	234	25	l.h	l.h	PROPN
ghmj-960	234	26	.	.	PROPN
ghmj-960	234	27	(	(	PUNCT
ghmj-960	234	28	2022	2022	NUM
ghmj-960	234	29	)	)	PUNCT
ghmj-960	234	30	.	.	PUNCT
ghmj-960	235	1	optimizing	optimize	VERB
ghmj-960	235	2	investigation	investigation	NOUN
ghmj-960	235	3	of	of	ADP
ghmj-960	235	4	suspected	suspect	VERB
ghmj-960	235	5	allergy	allergy	NOUN
ghmj-960	235	6	to	to	ADP
ghmj-960	235	7	polyethylene	polyethylene	NOUN
ghmj-960	235	8	glycols	glycol	NOUN
ghmj-960	235	9	.	.	PUNCT
ghmj-960	236	1	journal	journal	PROPN
ghmj-960	236	2	of	of	ADP
ghmj-960	236	3	allergy	allergy	PROPN
ghmj-960	236	4	and	and	CCONJ
ghmj-960	236	5	clinical	clinical	ADJ
ghmj-960	236	6	immunology	immunology	NOUN
ghmj-960	236	7	volume	volume	NOUN
ghmj-960	236	8	149	149	NUM
ghmj-960	236	9	,	,	PUNCT
ghmj-960	236	10	issue	issue	NOUN
ghmj-960	236	11	1	1	NUM
ghmj-960	236	12	,	,	PUNCT
ghmj-960	236	13	january	january	PROPN
ghmj-960	236	14	2022	2022	NUM
ghmj-960	236	15	,	,	PUNCT
ghmj-960	236	16	pages	page	NOUN
ghmj-960	236	17	168	168	NUM
ghmj-960	236	18	-	-	PUNCT
ghmj-960	236	19	175.e4	175.e4	NUM
ghmj-960	236	20	.	.	PUNCT
ghmj-960	237	1	https://doi.org/10.1016/j.jaci.2021.05.020	https://doi.org/10.1016/j.jaci.2021.05.020	NOUN
ghmj-960	237	2	burlando	burlando	NOUN
ghmj-960	237	3	,	,	PUNCT
ghmj-960	237	4	m.	m.	NOUN
ghmj-960	237	5	,	,	PUNCT
ghmj-960	237	6	herzum	herzum	PROPN
ghmj-960	237	7	,	,	PUNCT
ghmj-960	237	8	a.	a.	NOUN
ghmj-960	237	9	,	,	PUNCT
ghmj-960	237	10	cozzani	cozzani	PROPN
ghmj-960	237	11	,	,	PUNCT
ghmj-960	237	12	e.	e.	PROPN
ghmj-960	237	13	,	,	PUNCT
ghmj-960	237	14	parodi	parodi	PROPN
ghmj-960	237	15	,	,	PUNCT
ghmj-960	237	16	a.	a.	NOUN
ghmj-960	237	17	(	(	PUNCT
ghmj-960	237	18	2021	2021	NUM
ghmj-960	237	19	)	)	PUNCT
ghmj-960	237	20	.	.	PUNCT
ghmj-960	238	1	acute	acute	PROPN
ghmj-960	238	2	urticarial	urticarial	ADJ
ghmj-960	238	3	rash	rash	NOUN
ghmj-960	238	4	after	after	ADP
ghmj-960	238	5	covid-19	covid-19	PROPN
ghmj-960	238	6	vaccination	vaccination	NOUN
ghmj-960	238	7	containing	contain	VERB
ghmj-960	238	8	polysorbate	polysorbate	NOUN
ghmj-960	238	9	80	80	NUM
ghmj-960	238	10	.	.	PUNCT
ghmj-960	239	1	korean	korean	ADJ
ghmj-960	239	2	vaccine	vaccine	NOUN
ghmj-960	239	3	society	society	NOUN
ghmj-960	239	4	clinical	clinical	ADJ
ghmj-960	239	5	experimental	experimental	ADJ
ghmj-960	239	6	vaccine	vaccine	NOUN
ghmj-960	239	7	research	research	NOUN
ghmj-960	239	8	2021	2021	NUM
ghmj-960	239	9	sep	sep	PROPN
ghmj-960	239	10	;	;	PUNCT
ghmj-960	239	11	10(3	10(3	NUM
ghmj-960	239	12	):	):	PUNCT
ghmj-960	239	13	298–300	298–300	NUM
ghmj-960	239	14	.	.	PUNCT
ghmj-960	240	1	https://doi.org/10.7774/cevr.2021.10.3.298	https://doi.org/10.7774/cevr.2021.10.3.298	PROPN
ghmj-960	240	2	burlando	burlando	NOUN
ghmj-960	240	3	,	,	PUNCT
ghmj-960	240	4	m.	m.	NOUN
ghmj-960	240	5	,	,	PUNCT
ghmj-960	240	6	herzum	herzum	PROPN
ghmj-960	240	7	,	,	PUNCT
ghmj-960	240	8	a.	a.	NOUN
ghmj-960	240	9	,	,	PUNCT
ghmj-960	240	10	micalizzi	micalizzi	PROPN
ghmj-960	240	11	,	,	PUNCT
ghmj-960	240	12	c.	c.	PROPN
ghmj-960	240	13	,	,	PUNCT
ghmj-960	240	14	cozzani	cozzani	PROPN
ghmj-960	240	15	,	,	PUNCT
ghmj-960	240	16	e.	e.	PROPN
ghmj-960	240	17	,	,	PUNCT
ghmj-960	240	18	parodi	parodi	PROPN
ghmj-960	240	19	,	,	PUNCT
ghmj-960	240	20	a.	a.	NOUN
ghmj-960	240	21	(	(	PUNCT
ghmj-960	240	22	2021	2021	NUM
ghmj-960	240	23	)	)	PUNCT
ghmj-960	240	24	.	.	PUNCT
ghmj-960	241	1	cutaneous	cutaneous	ADJ
ghmj-960	241	2	reactions	reaction	NOUN
ghmj-960	241	3	to	to	ADP
ghmj-960	241	4	covid-19	covid-19	PROPN
ghmj-960	241	5	vaccine	vaccine	NOUN
ghmj-960	241	6	at	at	ADP
ghmj-960	241	7	the	the	DET
ghmj-960	241	8	dermatology	dermatology	NOUN
ghmj-960	241	9	primary	primary	ADJ
ghmj-960	241	10	care	care	NOUN
ghmj-960	241	11	.	.	PUNCT
ghmj-960	242	1	wileyimmunity	wileyimmunity	NOUN
ghmj-960	242	2	,	,	PUNCT
ghmj-960	242	3	inflammation	inflammation	NOUN
ghmj-960	242	4	and	and	CCONJ
ghmj-960	242	5	diseasevolume	diseasevolume	PROPN
ghmj-960	242	6	10	10	NUM
ghmj-960	242	7	,	,	PUNCT
ghmj-960	242	8	issue	issue	NOUN
ghmj-960	242	9	2	2	NUM
ghmj-960	242	10	p.	p.	NOUN
ghmj-960	242	11	265	265	NUM
ghmj-960	242	12	-	-	SYM
ghmj-960	242	13	271	271	NUM
ghmj-960	242	14	.	.	PUNCT
ghmj-960	243	1	https://doi.org/10.1002/iid3.568	https://doi.org/10.1002/iid3.568	PROPN
ghmj-960	243	2	català	català	PROPN
ghmj-960	243	3	a	a	PROPN
ghmj-960	243	4	,	,	PUNCT
ghmj-960	243	5	muñoz	muñoz	PROPN
ghmj-960	243	6	-	-	PUNCT
ghmj-960	243	7	santos	santos	PROPN
ghmj-960	243	8	c	c	PROPN
ghmj-960	243	9	,	,	PUNCT
ghmj-960	243	10	galván	galván	NOUN
ghmj-960	243	11	-	-	PUNCT
ghmj-960	243	12	casas	casas	PROPN
ghmj-960	243	13	cr	cr	PROPN
ghmj-960	243	14	,	,	PUNCT
ghmj-960	243	15	riesco	riesco	PROPN
ghmj-960	243	16	mr	mr	PROPN
ghmj-960	243	17	,	,	PUNCT
ghmj-960	243	18	nebreda	nebreda	PROPN
ghmj-960	243	19	d	d	PROPN
ghmj-960	243	20	,	,	PUNCT
ghmj-960	243	21	solá	solá	NOUN
ghmj-960	243	22	-	-	PUNCT
ghmj-960	243	23	truyolsa	truyolsa	NOUN
ghmj-960	243	24	,	,	PUNCT
ghmj-960	243	25	et	et	PROPN
ghmj-960	243	26	al	al	PROPN
ghmj-960	243	27	.	.	PROPN
ghmj-960	243	28	(	(	PUNCT
ghmj-960	243	29	2022	2022	NUM
ghmj-960	243	30	)	)	PUNCT
ghmj-960	243	31	.	.	PUNCT
ghmj-960	244	1	cutaneous	cutaneous	ADJ
ghmj-960	244	2	reactions	reaction	NOUN
ghmj-960	244	3	after	after	ADP
ghmj-960	244	4	sars	sars	PROPN
ghmj-960	244	5	-	-	PUNCT
ghmj-960	244	6	cov-2	cov-2	PART
ghmj-960	244	7	vaccination	vaccination	NOUN
ghmj-960	244	8	:	:	PUNCT
ghmj-960	244	9	a	a	DET
ghmj-960	244	10	cross	cross	ADJ
ghmj-960	244	11	sectional	sectional	ADJ
ghmj-960	244	12	spanish	spanish	ADJ
ghmj-960	244	13	nationwide	nationwide	ADJ
ghmj-960	244	14	study	study	NOUN
ghmj-960	244	15	of	of	ADP
ghmj-960	244	16	405	405	NUM
ghmj-960	244	17	cases	case	NOUN
ghmj-960	244	18	.	.	PUNCT
ghmj-960	245	1	dermatologists	dermatologists	PROPN
ghmj-960	245	2	british	british	PROPN
ghmj-960	245	3	journal	journal	PROPN
ghmj-960	245	4	of	of	ADP
ghmj-960	245	5	dermatology	dermatology	NOUN
ghmj-960	245	6	(	(	PUNCT
ghmj-960	245	7	2022)186	2022)186	PROPN
ghmj-960	245	8	,	,	PUNCT
ghmj-960	245	9	pp142–152	pp142–152	X
ghmj-960	245	10	..	..	PUNCT
ghmj-960	246	1	https://doi.org/10.1111/bjd.20639	https://doi.org/10.1111/bjd.20639	PROPN
ghmj-960	246	2	cugno	cugno	PROPN
ghmj-960	246	3	,	,	PUNCT
ghmj-960	246	4	m.	m.	NOUN
ghmj-960	246	5	,	,	PUNCT
ghmj-960	246	6	consonni	consonni	PROPN
ghmj-960	246	7	,	,	PUNCT
ghmj-960	246	8	d.	d.	PROPN
ghmj-960	246	9	,	,	PUNCT
ghmj-960	246	10	lombardi	lombardi	PROPN
ghmj-960	246	11	,	,	PUNCT
ghmj-960	246	12	a.	a.	NOUN
ghmj-960	246	13	,	,	PUNCT
ghmj-960	246	14	bono	bono	X
ghmj-960	246	15	,	,	PUNCT
ghmj-960	246	16	p.	p.	NOUN
ghmj-960	246	17	,	,	PUNCT
ghmj-960	246	18	oggioni	oggioni	ADJ
ghmj-960	246	19	,	,	PUNCT
ghmj-960	246	20	m.	m.	NOUN
ghmj-960	246	21	,	,	PUNCT
ghmj-960	246	22	renteria	renteria	PROPN
ghmj-960	246	23	,	,	PUNCT
ghmj-960	246	24	s.u	s.u	PROPN
ghmj-960	246	25	.	.	PROPN
ghmj-960	246	26	,	,	PUNCT
ghmj-960	246	27	et	et	PROPN
ghmj-960	246	28	al	al	PROPN
ghmj-960	246	29	.	.	PROPN
ghmj-960	246	30	(	(	PUNCT
ghmj-960	246	31	2021	2021	NUM
ghmj-960	246	32	)	)	PUNCT
ghmj-960	246	33	.	.	PUNCT
ghmj-960	247	1	increased	increase	VERB
ghmj-960	247	2	risk	risk	NOUN
ghmj-960	247	3	of	of	ADP
ghmj-960	247	4	urticaria	urticaria	NOUN
ghmj-960	247	5	/	/	SYM
ghmj-960	247	6	angioedema	angioedema	NOUN
ghmj-960	247	7	after	after	ADP
ghmj-960	247	8	bnt162b2mrna	bnt162b2mrna	NUM
ghmj-960	247	9	covid-19	covid-19	PROPN
ghmj-960	247	10	vaccine	vaccine	NOUN
ghmj-960	247	11	in	in	ADP
ghmj-960	247	12	health	health	NOUN
ghmj-960	247	13	care	care	NOUN
ghmj-960	247	14	workers	worker	NOUN
ghmj-960	247	15	taking	take	VERB
ghmj-960	247	16	ace	ace	ADJ
ghmj-960	247	17	inhibitors	inhibitor	NOUN
ghmj-960	247	18	.	.	PUNCT
ghmj-960	248	1	vaccines	vaccine	NOUN
ghmj-960	248	2	2021	2021	NUM
ghmj-960	248	3	,	,	PUNCT
ghmj-960	248	4	9(9	9(9	NUM
ghmj-960	248	5	)	)	PUNCT
ghmj-960	248	6	,	,	PUNCT
ghmj-960	248	7	1011	1011	NUM
ghmj-960	248	8	;	;	PUNCT
ghmj-960	248	9	https://doi.org/10.3390/vaccines9091011	https://doi.org/10.3390/vaccines9091011	PROPN
ghmj-960	248	10	durmaz	durmaz	PROPN
ghmj-960	248	11	,	,	PUNCT
ghmj-960	248	12	k.	k.	PROPN
ghmj-960	248	13	,	,	PUNCT
ghmj-960	248	14	aykut	aykut	PROPN
ghmj-960	248	15	temiz	temiz	PROPN
ghmj-960	248	16	,	,	PUNCT
ghmj-960	248	17	s.	s.	PROPN
ghmj-960	248	18	,	,	PUNCT
ghmj-960	248	19	metin	metin	PROPN
ghmj-960	248	20	,	,	PUNCT
ghmj-960	248	21	z.	z.	PROPN
ghmj-960	248	22	,	,	PUNCT
ghmj-960	248	23	dursun	dursun	NOUN
ghmj-960	248	24	,	,	PUNCT
ghmj-960	248	25	r.	r.	PROPN
ghmj-960	248	26	,	,	PUNCT
ghmj-960	248	27	&	&	CCONJ
ghmj-960	248	28	abdelmaksoud	abdelmaksoud	PROPN
ghmj-960	248	29	,	,	PUNCT
ghmj-960	248	30	a.	a.	NOUN
ghmj-960	248	31	(	(	PUNCT
ghmj-960	248	32	2022	2022	NUM
ghmj-960	248	33	)	)	PUNCT
ghmj-960	248	34	.	.	PUNCT
ghmj-960	249	1	allergic	allergic	ADJ
ghmj-960	249	2	and	and	CCONJ
ghmj-960	249	3	cutaneous	cutaneous	ADJ
ghmj-960	249	4	reactions	reaction	NOUN
ghmj-960	249	5	following	follow	VERB
ghmj-960	249	6	inactivated	inactivated	ADJ
ghmj-960	249	7	sars	sar	NOUN
ghmj-960	249	8	-	-	PUNCT
ghmj-960	249	9	cov-2	cov-2	PART
ghmj-960	249	10	vaccine	vaccine	NOUN
ghmj-960	249	11	(	(	PUNCT
ghmj-960	249	12	coronavac	coronavac	PROPN
ghmj-960	249	13	®	®	PROPN
ghmj-960	249	14	)	)	PUNCT
ghmj-960	249	15	in	in	ADP
ghmj-960	249	16	healthcare	healthcare	NOUN
ghmj-960	249	17	workers	worker	NOUN
ghmj-960	249	18	.	.	PUNCT
ghmj-960	250	1	clinical	clinical	ADJ
ghmj-960	250	2	and	and	CCONJ
ghmj-960	250	3	experimental	experimental	ADJ
ghmj-960	250	4	dermatology	dermatology	NOUN
ghmj-960	250	5	,	,	PUNCT
ghmj-960	250	6	47(1	47(1	NUM
ghmj-960	250	7	)	)	PUNCT
ghmj-960	250	8	,	,	PUNCT
ghmj-960	250	9	171–173	171–173	NUM
ghmj-960	250	10	.	.	PUNCT
ghmj-960	251	1	https://doi.org/10.1111/ced.14896	https://doi.org/10.1111/ced.14896	PROPN
ghmj-960	251	2	farinazzo	farinazzo	NOUN
ghmj-960	251	3	,	,	PUNCT
ghmj-960	251	4	e.	e.	PROPN
ghmj-960	251	5	,	,	PUNCT
ghmj-960	251	6	ponis	ponis	PROPN
ghmj-960	251	7	,	,	PUNCT
ghmj-960	251	8	g.	g.	PROPN
ghmj-960	251	9	,	,	PUNCT
ghmj-960	251	10	zelin	zelin	PROPN
ghmj-960	251	11	,	,	PUNCT
ghmj-960	251	12	e.	e.	PROPN
ghmj-960	251	13	,	,	PUNCT
ghmj-960	251	14	errichetti	errichetti	PROPN
ghmj-960	251	15	,	,	PUNCT
ghmj-960	251	16	e.	e.	PROPN
ghmj-960	251	17	,	,	PUNCT
ghmj-960	251	18	stinco	stinco	PROPN
ghmj-960	251	19	,	,	PUNCT
ghmj-960	251	20	g.	g.	PROPN
ghmj-960	251	21	,	,	PUNCT
ghmj-960	251	22	pinzani	pinzani	PROPN
ghmj-960	251	23	,	,	PUNCT
ghmj-960	251	24	c.	c.	PROPN
ghmj-960	251	25	,	,	PUNCT
ghmj-960	251	26	et	et	PROPN
ghmj-960	251	27	al	al	PROPN
ghmj-960	251	28	.	.	PROPN
ghmj-960	251	29	(	(	PUNCT
ghmj-960	251	30	2021	2021	NUM
ghmj-960	251	31	)	)	PUNCT
ghmj-960	251	32	.	.	PUNCT
ghmj-960	252	1	cutaneous	cutaneous	ADJ
ghmj-960	252	2	adverse	adverse	ADJ
ghmj-960	252	3	reactions	reaction	NOUN
ghmj-960	252	4	after	after	ADP
ghmj-960	252	5	m	m	NOUN
ghmj-960	252	6	-	-	ADJ
ghmj-960	252	7	rna	rna	ADJ
ghmj-960	252	8	covid-19	covid-19	PROPN
ghmj-960	252	9	vaccine	vaccine	NOUN
ghmj-960	252	10	:	:	PUNCT
ghmj-960	252	11	early	early	ADJ
ghmj-960	252	12	reports	report	NOUN
ghmj-960	252	13	from	from	ADP
ghmj-960	252	14	northeast	northeast	PROPN
ghmj-960	252	15	italy	italy	PROPN
ghmj-960	252	16	.	.	PUNCT
ghmj-960	253	1	journal	journal	PROPN
ghmj-960	253	2	of	of	ADP
ghmj-960	253	3	the	the	DET
ghmj-960	253	4	european	european	PROPN
ghmj-960	253	5	academy	academy	PROPN
ghmj-960	253	6	of	of	ADP
ghmj-960	253	7	dermatology	dermatology	NOUN
ghmj-960	253	8	and	and	CCONJ
ghmj-960	253	9	venereology	venereology	NOUN
ghmj-960	253	10	:	:	PUNCT
ghmj-960	253	11	jeadv	jeadv	NOUN
ghmj-960	253	12	,	,	PUNCT
ghmj-960	253	13	35(9	35(9	NUM
ghmj-960	253	14	)	)	PUNCT
ghmj-960	253	15	,	,	PUNCT
ghmj-960	253	16	e548	e548	PROPN
ghmj-960	253	17	–	–	PUNCT
ghmj-960	253	18	e551	e551	NUM
ghmj-960	253	19	.	.	PUNCT
ghmj-960	254	1	https://doi.org/10.1111/jdv.17343	https://doi.org/10.1111/jdv.17343	PROPN
ghmj-960	254	2	grieco	grieco	PROPN
ghmj-960	254	3	,	,	PUNCT
ghmj-960	254	4	t.	t.	PROPN
ghmj-960	254	5	,	,	PUNCT
ghmj-960	254	6	ambrosio	ambrosio	PROPN
ghmj-960	254	7	,	,	PUNCT
ghmj-960	254	8	l.	l.	PROPN
ghmj-960	254	9	,	,	PUNCT
ghmj-960	254	10	trovato	trovato	PROPN
ghmj-960	254	11	,	,	PUNCT
ghmj-960	254	12	f.	f.	PROPN
ghmj-960	254	13	,	,	PUNCT
ghmj-960	254	14	vitiello	vitiello	PROPN
ghmj-960	254	15	,	,	PUNCT
ghmj-960	254	16	m.	m.	NOUN
ghmj-960	254	17	,	,	PUNCT
ghmj-960	254	18	demofonte	demofonte	PROPN
ghmj-960	254	19	,	,	PUNCT
ghmj-960	254	20	i.	i.	PROPN
ghmj-960	254	21	,	,	PUNCT
ghmj-960	254	22	fanto	fanto	ADV
ghmj-960	254	23	,	,	PUNCT
ghmj-960	254	24	m.	m.	NOUN
ghmj-960	254	25	,	,	PUNCT
ghmj-960	254	26	et	et	PROPN
ghmj-960	254	27	al	al	PROPN
ghmj-960	254	28	.	.	PROPN
ghmj-960	254	29	(	(	PUNCT
ghmj-960	254	30	2022	2022	NUM
ghmj-960	254	31	)	)	PUNCT
ghmj-960	254	32	.	.	PUNCT
ghmj-960	255	1	effects	effect	NOUN
ghmj-960	255	2	of	of	ADP
ghmj-960	255	3	vaccination	vaccination	NOUN
ghmj-960	255	4	against	against	ADP
ghmj-960	255	5	covid-19	covid-19	PROPN
ghmj-960	255	6	in	in	ADP
ghmj-960	255	7	chronic	chronic	ADJ
ghmj-960	255	8	spontaneous	spontaneous	ADJ
ghmj-960	255	9	and	and	CCONJ
ghmj-960	255	10	inducible	inducible	ADJ
ghmj-960	255	11	urticaria	urticaria	NOUN
ghmj-960	255	12	(	(	PUNCT
ghmj-960	255	13	csu	csu	NOUN
ghmj-960	255	14	/	/	SYM
ghmj-960	255	15	ciu	ciu	ADJ
ghmj-960	255	16	)	)	PUNCT
ghmj-960	255	17	patients	patient	NOUN
ghmj-960	255	18	:	:	PUNCT
ghmj-960	255	19	a	a	DET
ghmj-960	255	20	monocentric	monocentric	ADJ
ghmj-960	255	21	study	study	NOUN
ghmj-960	255	22	.	.	PUNCT
ghmj-960	256	1	journal	journal	NOUN
ghmj-960	256	2	of	of	ADP
ghmj-960	256	3	clinical	clinical	ADJ
ghmj-960	256	4	medicine	medicine	NOUN
ghmj-960	256	5	.	.	PUNCT
ghmj-960	257	1	2022	2022	NUM
ghmj-960	257	2	;	;	PUNCT
ghmj-960	258	1	11(7):1822	11(7):1822	NUM
ghmj-960	258	2	.	.	PUNCT
ghmj-960	259	1	https://doi.org/10.3390/jcm11071822	https://doi.org/10.3390/jcm11071822	NOUN
ghmj-960	259	2	https://doi.org/10.1111/jdv.17592	https://doi.org/10.1111/jdv.17592	PROPN
ghmj-960	259	3	https://doi.org/10.3389/falgy.2022.825164	https://doi.org/10.3389/falgy.2022.825164	PROPN
ghmj-960	259	4	https://doi.org/10.1111/bjd.20495	https://doi.org/10.1111/bjd.20495	ADJ
ghmj-960	259	5	https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8251329/	https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8251329/	NOUN
ghmj-960	259	6	https://dx.doi.org/10.1111%2fall.14839	https://dx.doi.org/10.1111%2fall.14839	NOUN
ghmj-960	259	7	https://doi.org/10.1177%2f21526567211068458	https://doi.org/10.1177%2f21526567211068458	PROPN
ghmj-960	259	8	https://www.sciencedirect.com/journal/journal-of-allergy-and-clinical-immunology	https://www.sciencedirect.com/journal/journal-of-allergy-and-clinical-immunology	PRON
ghmj-960	260	1	https://www.sciencedirect.com/journal/journal-of-allergy-and-clinical-immunology/vol/149/issue/1	https://www.sciencedirect.com/journal/journal-of-allergy-and-clinical-immunology/vol/149/issue/1	NUM
ghmj-960	260	2	https://doi.org/10.1016/j.jaci.2021.05.020	https://doi.org/10.1016/j.jaci.2021.05.020	PROPN
ghmj-960	260	3	https://doi.org/10.7774/cevr.2021.10.3.298	https://doi.org/10.7774/cevr.2021.10.3.298	PROPN
ghmj-960	260	4	https://onlinelibrary.wiley.com/journal/20504527	https://onlinelibrary.wiley.com/journal/20504527	PROPN
ghmj-960	260	5	https://onlinelibrary.wiley.com/journal/20504527	https://onlinelibrary.wiley.com/journal/20504527	PROPN
ghmj-960	260	6	https://onlinelibrary.wiley.com/toc/20504527/2022/10/2	https://onlinelibrary.wiley.com/toc/20504527/2022/10/2	PROPN
ghmj-960	260	7	https://doi.org/10.1002/iid3.568	https://doi.org/10.1002/iid3.568	PROPN
ghmj-960	260	8	https://doi.org/10.1111/bjd.20639	https://doi.org/10.1111/bjd.20639	PROPN
ghmj-960	260	9	https://doi.org/10.3390/vaccines9091011	https://doi.org/10.3390/vaccines9091011	VERB
ghmj-960	260	10	https://doi.org/10.1111/ced.14896	https://doi.org/10.1111/ced.14896	INTJ
ghmj-960	260	11	https://doi.org/10.1111/jdv.17343	https://doi.org/10.1111/jdv.17343	VERB
ghmj-960	260	12	https://doi.org/10.3390/jcm11071822	https://doi.org/10.3390/jcm11071822	NOUN
ghmj-960	260	13	65	65	NUM
ghmj-960	260	14	ghmj	ghmj	NOUN
ghmj-960	260	15	(	(	PUNCT
ghmj-960	260	16	global	global	ADJ
ghmj-960	260	17	health	health	PROPN
ghmj-960	260	18	management	management	NOUN
ghmj-960	260	19	journal	journal	PROPN
ghmj-960	260	20	)	)	PUNCT
ghmj-960	260	21	2023	2023	NUM
ghmj-960	260	22	,	,	PUNCT
ghmj-960	260	23	vol	vol	NOUN
ghmj-960	260	24	.	.	PROPN
ghmj-960	260	25	6	6	NUM
ghmj-960	260	26	,	,	PUNCT
ghmj-960	260	27	no	no	NOUN
ghmj-960	260	28	.	.	NOUN
ghmj-960	260	29	2	2	NUM
ghmj-960	260	30	nugrahaeni	nugrahaeni	PROPN
ghmj-960	260	31	&	&	CCONJ
ghmj-960	260	32	budiyanti	budiyanti	PROPN
ghmj-960	260	33	gronbeck	gronbeck	PROPN
ghmj-960	260	34	,	,	PUNCT
ghmj-960	260	35	c.	c.	PROPN
ghmj-960	260	36	and	and	CCONJ
ghmj-960	260	37	grant	grant	NOUN
ghmj-960	260	38	-	-	PUNCT
ghmj-960	260	39	kels	kel	NOUN
ghmj-960	260	40	,	,	PUNCT
ghmj-960	260	41	j.	j.	PROPN
ghmj-960	260	42	m.	m.	PROPN
ghmj-960	260	43	(	(	PUNCT
ghmj-960	260	44	2021	2021	NUM
ghmj-960	260	45	)	)	PUNCT
ghmj-960	260	46	.	.	PUNCT
ghmj-960	261	1	attention	attention	NOUN
ghmj-960	261	2	all	all	DET
ghmj-960	261	3	anti	anti	NOUN
ghmj-960	261	4	-	-	NOUN
ghmj-960	261	5	vaccinators	vaccinator	NOUN
ghmj-960	261	6	:	:	PUNCT
ghmj-960	261	7	the	the	DET
ghmj-960	261	8	cutaneous	cutaneous	ADJ
ghmj-960	261	9	adverse	adverse	ADJ
ghmj-960	261	10	events	event	NOUN
ghmj-960	261	11	from	from	ADP
ghmj-960	261	12	the	the	DET
ghmj-960	261	13	mrna	mrna	PROPN
ghmj-960	261	14	covid-19	covid-19	PROPN
ghmj-960	261	15	vaccines	vaccine	NOUN
ghmj-960	261	16	are	be	AUX
ghmj-960	261	17	not	not	PART
ghmj-960	261	18	an	an	DET
ghmj-960	261	19	excuse	excuse	NOUN
ghmj-960	261	20	to	to	PART
ghmj-960	261	21	avoid	avoid	VERB
ghmj-960	261	22	them	they	PRON
ghmj-960	261	23	.	.	PUNCT
ghmj-960	262	1	clinics	clinic	NOUN
ghmj-960	262	2	in	in	ADP
ghmj-960	262	3	dermatology	dermatology	NOUN
ghmj-960	262	4	volume	volume	NOUN
ghmj-960	262	5	39	39	NUM
ghmj-960	262	6	,	,	PUNCT
ghmj-960	262	7	issue	issue	NOUN
ghmj-960	262	8	4	4	NUM
ghmj-960	262	9	,	,	PUNCT
ghmj-960	262	10	july	july	PROPN
ghmj-960	262	11	–	–	PUNCT
ghmj-960	262	12	august	august	PROPN
ghmj-960	262	13	2021	2021	NUM
ghmj-960	262	14	,	,	PUNCT
ghmj-960	262	15	pages	page	NOUN
ghmj-960	262	16	674	674	NUM
ghmj-960	262	17	-	-	SYM
ghmj-960	262	18	687	687	NUM
ghmj-960	262	19	.	.	PUNCT
ghmj-960	263	1	https://doi.org/10.1016/j.clindermatol.2021.05.027	https://doi.org/10.1016/j.clindermatol.2021.05.027	PROPN
ghmj-960	263	2	kaya	kaya	PROPN
ghmj-960	263	3	,	,	PUNCT
ghmj-960	263	4	l.	l.	PROPN
ghmj-960	263	5	,	,	PUNCT
ghmj-960	263	6	and	and	CCONJ
ghmj-960	263	7	kaya	kaya	PROPN
ghmj-960	263	8	,	,	PUNCT
ghmj-960	263	9	z.	z.	PROPN
ghmj-960	263	10	(	(	PUNCT
ghmj-960	263	11	2022	2022	NUM
ghmj-960	263	12	)	)	PUNCT
ghmj-960	263	13	.	.	PUNCT
ghmj-960	264	1	a	a	DET
ghmj-960	264	2	case	case	NOUN
ghmj-960	264	3	report	report	NOUN
ghmj-960	264	4	of	of	ADP
ghmj-960	264	5	a	a	DET
ghmj-960	264	6	nurse	nurse	NOUN
ghmj-960	264	7	who	who	PRON
ghmj-960	264	8	received	receive	VERB
ghmj-960	264	9	the	the	DET
ghmj-960	264	10	covid-19	covid-19	PROPN
ghmj-960	264	11	vaccine	vaccine	NOUN
ghmj-960	264	12	.	.	PUNCT
ghmj-960	265	1	international	international	ADJ
ghmj-960	265	2	journal	journal	NOUN
ghmj-960	265	3	of	of	ADP
ghmj-960	265	4	pharmata	pharmata	ADJ
ghmj-960	265	5	2022	2022	NUM
ghmj-960	265	6	;	;	PUNCT
ghmj-960	265	7	2(2	2(2	NUM
ghmj-960	265	8	):	):	PUNCT
ghmj-960	265	9	9	9	NUM
ghmj-960	265	10	-	-	SYM
ghmj-960	265	11	14	14	NUM
ghmj-960	265	12	.	.	PUNCT
ghmj-960	266	1	macy	macy	PROPN
ghmj-960	266	2	,	,	PUNCT
ghmj-960	266	3	e.	e.	PROPN
ghmj-960	266	4	,	,	PUNCT
ghmj-960	266	5	pandya	pandya	PROPN
ghmj-960	266	6	,	,	PUNCT
ghmj-960	266	7	s.	s.	PROPN
ghmj-960	266	8	,	,	PUNCT
ghmj-960	266	9	sheikh	sheikh	PROPN
ghmj-960	266	10	,	,	PUNCT
ghmj-960	266	11	j.	j.	PROPN
ghmj-960	266	12	,	,	PUNCT
ghmj-960	266	13	brunette	brunette	PROPN
ghmj-960	266	14	,	,	PUNCT
ghmj-960	266	15	a.	a.	NOUN
ghmj-960	266	16	,	,	PUNCT
ghmj-960	266	17	m.shi	m.shi	PROPN
ghmj-960	266	18	,	,	PUNCT
ghmj-960	266	19	j.	j.	PROPN
ghmj-960	266	20	,	,	PUNCT
ghmj-960	266	21	chung	chung	PROPN
ghmj-960	266	22	,	,	PUNCT
ghmj-960	266	23	j.	j.	PROPN
ghmj-960	266	24	,et	,et	PUNCT
ghmj-960	266	25	al	al	PROPN
ghmj-960	266	26	.	.	PROPN
ghmj-960	266	27	(	(	PUNCT
ghmj-960	266	28	2022	2022	NUM
ghmj-960	266	29	)	)	PUNCT
ghmj-960	266	30	.	.	PUNCT
ghmj-960	267	1	population	population	NOUN
ghmj-960	267	2	based	base	VERB
ghmj-960	267	3	incidence	incidence	NOUN
ghmj-960	267	4	,	,	PUNCT
ghmj-960	267	5	severity	severity	NOUN
ghmj-960	267	6	,	,	PUNCT
ghmj-960	267	7	and	and	CCONJ
ghmj-960	267	8	risk	risk	NOUN
ghmj-960	267	9	factors	factor	NOUN
ghmj-960	267	10	associated	associate	VERB
ghmj-960	267	11	with	with	ADP
ghmj-960	267	12	treated	treat	VERB
ghmj-960	267	13	acute	acute	NOUN
ghmj-960	267	14	-	-	PUNCT
ghmj-960	267	15	onset	onset	NOUN
ghmj-960	267	16	covid-19	covid-19	PROPN
ghmj-960	267	17	mrna	mrna	PROPN
ghmj-960	267	18	vaccinationassociated	vaccinationassociate	VERB
ghmj-960	267	19	hypersensitivity	hypersensitivity	NOUN
ghmj-960	267	20	reactions	reaction	NOUN
ghmj-960	267	21	.	.	PUNCT
ghmj-960	268	1	the	the	DET
ghmj-960	268	2	journal	journal	PROPN
ghmj-960	268	3	of	of	ADP
ghmj-960	268	4	allergy	allergy	NOUN
ghmj-960	268	5	and	and	CCONJ
ghmj-960	268	6	clinical	clinical	ADJ
ghmj-960	268	7	immunology	immunology	NOUN
ghmj-960	268	8	:	:	PUNCT
ghmj-960	268	9	in	in	ADP
ghmj-960	268	10	practice	practice	NOUN
ghmj-960	268	11	volume	volume	NOUN
ghmj-960	268	12	10	10	NUM
ghmj-960	268	13	,	,	PUNCT
ghmj-960	268	14	issue	issue	NOUN
ghmj-960	268	15	3	3	NUM
ghmj-960	268	16	,	,	PUNCT
ghmj-960	268	17	march	march	PROPN
ghmj-960	268	18	2022	2022	NUM
ghmj-960	268	19	,	,	PUNCT
ghmj-960	268	20	pages	page	NOUN
ghmj-960	268	21	827	827	NUM
ghmj-960	268	22	-	-	SYM
ghmj-960	268	23	836	836	NUM
ghmj-960	268	24	.	.	PUNCT
ghmj-960	269	1	https://doi.org/10.1016/j.jaip.2021.12.021	https://doi.org/10.1016/j.jaip.2021.12.021	NOUN
ghmj-960	269	2	magro	magro	NOUN
ghmj-960	269	3	,	,	PUNCT
ghmj-960	269	4	c.	c.	PROPN
ghmj-960	269	5	,	,	PUNCT
ghmj-960	269	6	crowson	crowson	PROPN
ghmj-960	269	7	,	,	PUNCT
ghmj-960	269	8	n.	n.	NOUN
ghmj-960	269	9	,	,	PUNCT
ghmj-960	269	10	franks	frank	NOUN
ghmj-960	269	11	,	,	PUNCT
ghmj-960	269	12	l.	l.	PROPN
ghmj-960	269	13	,	,	PUNCT
ghmj-960	269	14	schaffer	schaffer	PROPN
ghmj-960	269	15	,	,	PUNCT
ghmj-960	269	16	p.r	p.r	PROPN
ghmj-960	269	17	.	.	PROPN
ghmj-960	269	18	,	,	PUNCT
ghmj-960	269	19	whelan	whelan	PROPN
ghmj-960	269	20	,	,	PUNCT
ghmj-960	269	21	p.	p.	PROPN
ghmj-960	269	22	nuovo	nuovo	PROPN
ghmj-960	269	23	,	,	PUNCT
ghmj-960	269	24	g.	g.	PROPN
ghmj-960	269	25	(	(	PUNCT
ghmj-960	269	26	2021	2021	NUM
ghmj-960	269	27	)	)	PUNCT
ghmj-960	269	28	.	.	PUNCT
ghmj-960	270	1	the	the	DET
ghmj-960	270	2	histologic	histologic	NOUN
ghmj-960	270	3	and	and	CCONJ
ghmj-960	270	4	moleculer	moleculer	PROPN
ghmj-960	270	5	correlates	correlate	VERB
ghmj-960	270	6	of	of	ADP
ghmj-960	270	7	covid-19	covid-19	PROPN
ghmj-960	270	8	vaccine	vaccine	NOUN
ghmj-960	270	9	-	-	PUNCT
ghmj-960	270	10	induced	induce	VERB
ghmj-960	270	11	in	in	ADP
ghmj-960	270	12	the	the	DET
ghmj-960	270	13	skin	skin	NOUN
ghmj-960	270	14	.	.	PUNCT
ghmj-960	271	1	clinics	clinic	NOUN
ghmj-960	271	2	in	in	ADP
ghmj-960	271	3	dermatology	dermatology	NOUN
ghmj-960	271	4	volume	volume	NOUN
ghmj-960	271	5	39	39	NUM
ghmj-960	271	6	,	,	PUNCT
ghmj-960	271	7	issue	issue	NOUN
ghmj-960	271	8	6	6	NUM
ghmj-960	271	9	,	,	PUNCT
ghmj-960	271	10	november	november	PROPN
ghmj-960	271	11	–	–	PUNCT
ghmj-960	271	12	december	december	PROPN
ghmj-960	271	13	2021	2021	NUM
ghmj-960	271	14	,	,	PUNCT
ghmj-960	271	15	pages	page	VERB
ghmj-960	271	16	966	966	NUM
ghmj-960	271	17	-	-	SYM
ghmj-960	271	18	984	984	NUM
ghmj-960	271	19	.	.	PUNCT
ghmj-960	272	1	https://doi.org/10.1016/j.clindermatol.2021.07.011	https://doi.org/10.1016/j.clindermatol.2021.07.011	NOUN
ghmj-960	272	2	magro	magro	NOUN
ghmj-960	272	3	,	,	PUNCT
ghmj-960	272	4	c.	c.	PROPN
ghmj-960	272	5	,	,	PUNCT
ghmj-960	272	6	nuovo	nuovo	PROPN
ghmj-960	272	7	,	,	PUNCT
ghmj-960	272	8	g.	g.	PROPN
ghmj-960	272	9	,	,	PUNCT
ghmj-960	272	10	mulvey	mulvey	PROPN
ghmj-960	272	11	,	,	PUNCT
ghmj-960	272	12	j.	j.	PROPN
ghmj-960	272	13	,	,	PUNCT
ghmj-960	272	14	laurence	laurence	PROPN
ghmj-960	272	15	,	,	PUNCT
ghmj-960	272	16	j.	j.	PROPN
ghmj-960	272	17	,	,	PUNCT
ghmj-960	272	18	harp	harp	PROPN
ghmj-960	272	19	,	,	PUNCT
ghmj-960	272	20	j.	j.	PROPN
ghmj-960	272	21	,	,	PUNCT
ghmj-960	272	22	crowson	crowson	PROPN
ghmj-960	272	23	,	,	PUNCT
ghmj-960	272	24	a.n	a.n	PROPN
ghmj-960	272	25	.	.	PROPN
ghmj-960	272	26	(	(	PUNCT
ghmj-960	272	27	2021	2021	NUM
ghmj-960	272	28	)	)	PUNCT
ghmj-960	272	29	.	.	PUNCT
ghmj-960	273	1	the	the	DET
ghmj-960	273	2	skin	skin	NOUN
ghmj-960	273	3	as	as	ADP
ghmj-960	273	4	a	a	DET
ghmj-960	273	5	critical	critical	ADJ
ghmj-960	273	6	window	window	NOUN
ghmj-960	273	7	in	in	ADP
ghmj-960	273	8	unveiling	unveil	VERB
ghmj-960	273	9	the	the	DET
ghmj-960	273	10	pathophysiologic	pathophysiologic	ADJ
ghmj-960	273	11	principles	principle	NOUN
ghmj-960	273	12	of	of	ADP
ghmj-960	273	13	covid-19	covid-19	PROPN
ghmj-960	273	14	.	.	PUNCT
ghmj-960	273	15	elsevierclinics	elsevierclinic	NOUN
ghmj-960	273	16	in	in	ADP
ghmj-960	273	17	dermatology	dermatology	NOUN
ghmj-960	273	18	volume	volume	NOUN
ghmj-960	273	19	39	39	NUM
ghmj-960	273	20	,	,	PUNCT
ghmj-960	273	21	issue	issue	NOUN
ghmj-960	273	22	6	6	NUM
ghmj-960	273	23	,	,	PUNCT
ghmj-960	273	24	november	november	PROPN
ghmj-960	273	25	–	–	PUNCT
ghmj-960	273	26	december	december	PROPN
ghmj-960	273	27	2021	2021	NUM
ghmj-960	273	28	,	,	PUNCT
ghmj-960	273	29	pages	page	NOUN
ghmj-960	273	30	934	934	NUM
ghmj-960	273	31	-	-	SYM
ghmj-960	273	32	965	965	NUM
ghmj-960	273	33	.	.	PUNCT
ghmj-960	274	1	https://doi.org/10.1016/j.clindermatol.2021.07.001	https://doi.org/10.1016/j.clindermatol.2021.07.001	NOUN
ghmj-960	274	2	namazi	namazi	NOUN
ghmj-960	274	3	,	,	PUNCT
ghmj-960	274	4	n.	n.	NOUN
ghmj-960	274	5	,	,	PUNCT
ghmj-960	274	6	diab	diab	PROPN
ghmj-960	274	7	,	,	PUNCT
ghmj-960	274	8	r.	r.	PROPN
ghmj-960	274	9	,	,	PUNCT
ghmj-960	274	10	mardani	mardani	PROPN
ghmj-960	274	11	,	,	PUNCT
ghmj-960	274	12	g.	g.	PROPN
ghmj-960	274	13	,	,	PUNCT
ghmj-960	274	14	jamali	jamali	PROPN
ghmj-960	274	15	,	,	PUNCT
ghmj-960	274	16	e.	e.	PROPN
ghmj-960	274	17	,	,	PUNCT
ghmj-960	274	18	kaddah	kaddah	PROPN
ghmj-960	274	19	,	,	PUNCT
ghmj-960	274	20	a.	a.	NOUN
ghmj-960	274	21	(	(	PUNCT
ghmj-960	274	22	2022	2022	NUM
ghmj-960	274	23	)	)	PUNCT
ghmj-960	274	24	.	.	PUNCT
ghmj-960	275	1	figurate	figurate	VERB
ghmj-960	275	2	purpuric	purpuric	ADJ
ghmj-960	275	3	eruption	eruption	NOUN
ghmj-960	275	4	post	post	ADJ
ghmj-960	275	5	-	-	ADJ
ghmj-960	275	6	covid-19	covid-19	ADJ
ghmj-960	275	7	vaccination	vaccination	NOUN
ghmj-960	275	8	.	.	PUNCT
ghmj-960	276	1	dermatologic	dermatologic	ADJ
ghmj-960	276	2	therapy.2022;35	therapy.2022;35	NOUN
ghmj-960	276	3	:	:	PUNCT
ghmj-960	276	4	e15360	e15360	NUM
ghmj-960	276	5	.	.	PUNCT
ghmj-960	277	1	https://doi.org/10.1111/dth.15360	https://doi.org/10.1111/dth.15360	PROPN
ghmj-960	277	2	pitlick	pitlick	PROPN
ghmj-960	277	3	,	,	PUNCT
ghmj-960	277	4	m.m	m.m	PROPN
ghmj-960	277	5	.	.	PROPN
ghmj-960	277	6	,	,	PUNCT
ghmj-960	277	7	joshi	joshi	PROPN
ghmj-960	277	8	,	,	PUNCT
ghmj-960	277	9	a.y	a.y	PROPN
ghmj-960	277	10	.	.	PROPN
ghmj-960	277	11	,	,	PUNCT
ghmj-960	277	12	gonzalez	gonzalez	PROPN
ghmj-960	277	13	-	-	PUNCT
ghmj-960	277	14	estrada	estrada	PROPN
ghmj-960	277	15	,	,	PUNCT
ghmj-960	277	16	a.	a.	NOUN
ghmj-960	277	17	,	,	PUNCT
ghmj-960	277	18	chiarella	chiarella	PROPN
ghmj-960	277	19	,	,	PUNCT
ghmj-960	277	20	s.e	s.e	PROPN
ghmj-960	277	21	.	.	PROPN
ghmj-960	277	22	(	(	PUNCT
ghmj-960	277	23	2022	2022	NUM
ghmj-960	277	24	)	)	PUNCT
ghmj-960	277	25	.	.	PUNCT
ghmj-960	278	1	delayed	delay	VERB
ghmj-960	278	2	systematic	systematic	ADJ
ghmj-960	278	3	urticarial	urticarial	ADJ
ghmj-960	278	4	reactions	reaction	NOUN
ghmj-960	278	5	following	follow	VERB
ghmj-960	278	6	mrna	mrna	PROPN
ghmj-960	278	7	covid-19	covid-19	PROPN
ghmj-960	278	8	vaccination	vaccination	NOUN
ghmj-960	278	9	.	.	PUNCT
ghmj-960	279	1	allergy	allergy	NOUN
ghmj-960	279	2	and	and	CCONJ
ghmj-960	279	3	asthma	asthma	PROPN
ghmj-960	279	4	proceedings	proceeding	NOUN
ghmj-960	279	5	,	,	PUNCT
ghmj-960	279	6	volume	volume	NOUN
ghmj-960	279	7	43	43	NUM
ghmj-960	279	8	,	,	PUNCT
ghmj-960	279	9	number	number	NOUN
ghmj-960	279	10	1	1	NUM
ghmj-960	279	11	,	,	PUNCT
ghmj-960	279	12	1	1	NUM
ghmj-960	279	13	january	january	NOUN
ghmj-960	279	14	2022	2022	NUM
ghmj-960	279	15	,	,	PUNCT
ghmj-960	279	16	pp	pp	ADJ
ghmj-960	279	17	.	.	PUNCT
ghmj-960	280	1	40	40	NUM
ghmj-960	280	2	-	-	PUNCT
ghmj-960	280	3	43(4	43(4	NOUN
ghmj-960	280	4	)	)	PUNCT
ghmj-960	280	5	.	.	PUNCT
ghmj-960	281	1	https://doi.org/10.2500/aap.2022.43.210101	https://doi.org/10.2500/aap.2022.43.210101	NOUN
ghmj-960	281	2	pourani	pourani	VERB
ghmj-960	281	3	,	,	PUNCT
ghmj-960	281	4	mr	mr	PROPN
ghmj-960	281	5	,	,	PUNCT
ghmj-960	281	6	shahidi	shahidi	PROPN
ghmj-960	281	7	dadras	dadras	PROPN
ghmj-960	281	8	,	,	PUNCT
ghmj-960	281	9	m	m	NOUN
ghmj-960	281	10	,	,	PUNCT
ghmj-960	281	11	salari	salari	ADJ
ghmj-960	281	12	,	,	PUNCT
ghmj-960	281	13	m	m	PROPN
ghmj-960	281	14	,	,	PUNCT
ghmj-960	281	15	diab	diab	PROPN
ghmj-960	281	16	,	,	PUNCT
ghmj-960	281	17	r	r	NOUN
ghmj-960	281	18	,	,	PUNCT
ghmj-960	281	19	namazi	namazi	NOUN
ghmj-960	281	20	,	,	PUNCT
ghmj-960	281	21	n	n	CCONJ
ghmj-960	281	22	,	,	PUNCT
ghmj-960	281	23	abdollahimajd	abdollahimajd	ADV
ghmj-960	281	24	,	,	PUNCT
ghmj-960	281	25	f.	f.	PROPN
ghmj-960	281	26	(	(	PUNCT
ghmj-960	281	27	2022	2022	NUM
ghmj-960	281	28	)	)	PUNCT
ghmj-960	281	29	.	.	PUNCT
ghmj-960	282	1	cutaneous	cutaneous	ADJ
ghmj-960	282	2	adverse	adverse	ADJ
ghmj-960	282	3	events	event	NOUN
ghmj-960	282	4	related	relate	VERB
ghmj-960	282	5	to	to	ADP
ghmj-960	282	6	covid-19	covid-19	PROPN
ghmj-960	282	7	vaccines	vaccine	NOUN
ghmj-960	282	8	:	:	PUNCT
ghmj-960	282	9	a	a	DET
ghmj-960	282	10	cross	cross	ADJ
ghmj-960	282	11	-	-	ADJ
ghmj-960	282	12	sectional	sectional	ADJ
ghmj-960	282	13	questionnaire	questionnaire	NOUN
ghmj-960	282	14	-	-	PUNCT
ghmj-960	282	15	based	base	VERB
ghmj-960	282	16	study	study	NOUN
ghmj-960	282	17	of	of	ADP
ghmj-960	282	18	867	867	NUM
ghmj-960	282	19	patients	patient	NOUN
ghmj-960	282	20	.	.	PUNCT
ghmj-960	283	1	dermatologic	dermatologic	ADJ
ghmj-960	283	2	therapy	therapy	NOUN
ghmj-960	283	3	.	.	PUNCT
ghmj-960	284	1	2022	2022	NUM
ghmj-960	284	2	;	;	PUNCT
ghmj-960	284	3	35	35	NUM
ghmj-960	284	4	(	(	PUNCT
ghmj-960	284	5	2):e15223	2):e15223	NUM
ghmj-960	284	6	.	.	PUNCT
ghmj-960	285	1	doi:10.1111	doi:10.1111	ADJ
ghmj-960	285	2	/	/	SYM
ghmj-960	285	3	dth.15223	dth.15223	PROPN
ghmj-960	285	4	rerknimitr	rerknimitr	NOUN
ghmj-960	285	5	,	,	PUNCT
ghmj-960	285	6	p.	p.	NOUN
ghmj-960	285	7	,	,	PUNCT
ghmj-960	285	8	puaratanaarunkon	puaratanaarunkon	PROPN
ghmj-960	285	9	,	,	PUNCT
ghmj-960	285	10	t.	t.	PROPN
ghmj-960	285	11	,	,	PUNCT
ghmj-960	285	12	wongtada	wongtada	PROPN
ghmj-960	285	13	,	,	PUNCT
ghmj-960	285	14	c.	c.	PROPN
ghmj-960	285	15	,	,	PUNCT
ghmj-960	285	16	wittayabusarakam	wittayabusarakam	NOUN
ghmj-960	285	17	,	,	PUNCT
ghmj-960	285	18	n.	n.	NOUN
ghmj-960	285	19	,	,	PUNCT
ghmj-960	285	20	krithin	krithin	PROPN
ghmj-960	285	21	,	,	PUNCT
ghmj-960	285	22	s.	s.	PROPN
ghmj-960	285	23	,	,	PUNCT
ghmj-960	285	24	paitoonpong	paitoonpong	PROPN
ghmj-960	285	25	,	,	PUNCT
ghmj-960	285	26	l.	l.	PROPN
ghmj-960	285	27	,	,	PUNCT
ghmj-960	285	28	et	et	PROPN
ghmj-960	285	29	al	al	PROPN
ghmj-960	285	30	.	.	PROPN
ghmj-960	285	31	(	(	PUNCT
ghmj-960	285	32	2022	2022	NUM
ghmj-960	285	33	)	)	PUNCT
ghmj-960	285	34	,	,	PUNCT
ghmj-960	285	35	cutaneous	cutaneous	ADJ
ghmj-960	285	36	adverse	adverse	ADJ
ghmj-960	285	37	reactions	reaction	NOUN
ghmj-960	285	38	from	from	ADP
ghmj-960	285	39	35,229	35,229	NUM
ghmj-960	285	40	doses	dose	NOUN
ghmj-960	285	41	of	of	ADP
ghmj-960	285	42	sinovac	sinovac	NOUN
ghmj-960	285	43	and	and	CCONJ
ghmj-960	285	44	astrazeneca	astrazeneca	NOUN
ghmj-960	285	45	covid-19	covid-19	PROPN
ghmj-960	285	46	vaccination	vaccination	NOUN
ghmj-960	285	47	:	:	PUNCT
ghmj-960	285	48	a	a	DET
ghmj-960	285	49	prospective	prospective	ADJ
ghmj-960	285	50	cohort	cohort	NOUN
ghmj-960	285	51	study	study	NOUN
ghmj-960	285	52	in	in	ADP
ghmj-960	285	53	healthcare	healthcare	NOUN
ghmj-960	285	54	workers	worker	NOUN
ghmj-960	285	55	.	.	PUNCT
ghmj-960	286	1	j	j	PROPN
ghmj-960	286	2	eur	eur	PROPN
ghmj-960	286	3	acad	acad	PROPN
ghmj-960	286	4	dermatol	dermatol	NOUN
ghmj-960	286	5	venereol	venereol	NOUN
ghmj-960	286	6	,	,	PUNCT
ghmj-960	286	7	36	36	NUM
ghmj-960	286	8	:	:	PUNCT
ghmj-960	286	9	e158e161	e158e161	X
ghmj-960	286	10	.	.	PUNCT
ghmj-960	287	1	https://doi.org/10.1111/jdv.17761	https://doi.org/10.1111/jdv.17761	PROPN
ghmj-960	287	2	smola	smola	PROPN
ghmj-960	287	3	,	,	PUNCT
ghmj-960	287	4	a.	a.	NOUN
ghmj-960	287	5	,	,	PUNCT
ghmj-960	287	6	samadzadeh	samadzadeh	PROPN
ghmj-960	287	7	,	,	PUNCT
ghmj-960	287	8	s.	s.	PROPN
ghmj-960	287	9	,	,	PUNCT
ghmj-960	287	10	müller	müller	PROPN
ghmj-960	287	11	,	,	PUNCT
ghmj-960	287	12	l.	l.	PROPN
ghmj-960	287	13	,	,	PUNCT
ghmj-960	287	14	adams	adams	PROPN
ghmj-960	287	15	,	,	PUNCT
ghmj-960	287	16	o.	o.	NOUN
ghmj-960	287	17	,	,	PUNCT
ghmj-960	287	18	homey	homey	ADJ
ghmj-960	287	19	,	,	PUNCT
ghmj-960	287	20	b.	b.	PROPN
ghmj-960	287	21	,	,	PUNCT
ghmj-960	287	22	albrecht	albrecht	PROPN
ghmj-960	287	23	,	,	PUNCT
ghmj-960	287	24	p.	p.	PROPN
ghmj-960	287	25	,et	,et	PUNCT
ghmj-960	288	1	al	al	PROPN
ghmj-960	288	2	.	.	PROPN
ghmj-960	288	3	(	(	PUNCT
ghmj-960	288	4	2021	2021	NUM
ghmj-960	288	5	)	)	PUNCT
ghmj-960	288	6	.	.	PUNCT
ghmj-960	289	1	omalizumab	omalizumab	NOUN
ghmj-960	289	2	prevents	prevent	VERB
ghmj-960	289	3	anaphylactoid	anaphylactoid	ADJ
ghmj-960	289	4	reactions	reaction	NOUN
ghmj-960	289	5	to	to	ADP
ghmj-960	289	6	mrna	mrna	PROPN
ghmj-960	289	7	covid-19	covid-19	PROPN
ghmj-960	289	8	vaccine	vaccine	NOUN
ghmj-960	289	9	.	.	PUNCT
ghmj-960	290	1	journal	journal	NOUN
ghmj-960	290	2	of	of	ADP
ghmj-960	290	3	the	the	DET
ghmj-960	290	4	european	european	PROPN
ghmj-960	290	5	academy	academy	PROPN
ghmj-960	290	6	of	of	ADP
ghmj-960	290	7	dermatology	dermatology	NOUN
ghmj-960	290	8	and	and	CCONJ
ghmj-960	290	9	venereology	venereology	NOUN
ghmj-960	290	10	:	:	PUNCT
ghmj-960	290	11	jeadv	jeadv	NOUN
ghmj-960	290	12	,	,	PUNCT
ghmj-960	290	13	35(11	35(11	NUM
ghmj-960	290	14	)	)	PUNCT
ghmj-960	290	15	,	,	PUNCT
ghmj-960	290	16	e743	e743	PROPN
ghmj-960	290	17	–	–	PUNCT
ghmj-960	290	18	e745	e745	PROPN
ghmj-960	290	19	.	.	PUNCT
ghmj-960	291	1	https://doi.org/10.1111/jdv.17549	https://doi.org/10.1111/jdv.17549	PROPN
ghmj-960	291	2	suan	suan	PROPN
ghmj-960	291	3	,	,	PUNCT
ghmj-960	291	4	d.	d.	PROPN
ghmj-960	291	5	,	,	PUNCT
ghmj-960	291	6	and	and	CCONJ
ghmj-960	291	7	lee	lee	PROPN
ghmj-960	291	8	,	,	PUNCT
ghmj-960	291	9	a.y.s	a.y.s	PROPN
ghmj-960	291	10	.	.	PUNCT
ghmj-960	291	11	(	(	PUNCT
ghmj-960	291	12	2022	2022	NUM
ghmj-960	291	13	)	)	PUNCT
ghmj-960	291	14	.	.	PUNCT
ghmj-960	292	1	chronic	chronic	ADJ
ghmj-960	292	2	spontaneous	spontaneous	ADJ
ghmj-960	292	3	urticaria	urticaria	NOUN
ghmj-960	292	4	following	follow	VERB
ghmj-960	292	5	chadox1	chadox1	ADJ
ghmj-960	292	6	-	-	PUNCT
ghmj-960	292	7	scovid-19	scovid-19	PROPN
ghmj-960	292	8	vaccination	vaccination	NOUN
ghmj-960	292	9	.	.	PUNCT
ghmj-960	293	1	springer	springer	NOUN
ghmj-960	293	2	allergo	allergo	PROPN
ghmj-960	293	3	j	j	PROPN
ghmj-960	293	4	int	int	NOUN
ghmj-960	293	5	.	.	PUNCT
ghmj-960	294	1	(	(	PUNCT
ghmj-960	294	2	2022	2022	NUM
ghmj-960	294	3	)	)	PUNCT
ghmj-960	294	4	.	.	PUNCT
ghmj-960	295	1	https://doi.org/10.1007/s40629-022-00204-x	https://doi.org/10.1007/s40629-022-00204-x	INTJ
ghmj-960	295	2	triwatcharikorn	triwatcharikorn	VERB
ghmj-960	295	3	,	,	PUNCT
ghmj-960	295	4	j.	j.	PROPN
ghmj-960	295	5	,	,	PUNCT
ghmj-960	295	6	puaratana	puaratana	NOUN
ghmj-960	295	7	-	-	PUNCT
ghmj-960	295	8	arunkon	arunkon	PROPN
ghmj-960	295	9	,	,	PUNCT
ghmj-960	295	10	t.	t.	NOUN
ghmj-960	295	11	,	,	PUNCT
ghmj-960	295	12	punyaratabandhu	punyaratabandhu	NOUN
ghmj-960	295	13	,	,	PUNCT
ghmj-960	295	14	p.	p.	PROPN
ghmj-960	295	15	,	,	PUNCT
ghmj-960	295	16	mongkolpathumrat	mongkolpathumrat	NOUN
ghmj-960	295	17	,	,	PUNCT
ghmj-960	295	18	p.	p.	NOUN
ghmj-960	295	19	,	,	PUNCT
ghmj-960	295	20	palapinyo	palapinyo	PROPN
ghmj-960	295	21	,	,	PUNCT
ghmj-960	295	22	s.	s.	PROPN
ghmj-960	295	23	,	,	PUNCT
ghmj-960	295	24	buranapraditkul	buranapraditkul	PROPN
ghmj-960	295	25	,	,	PUNCT
ghmj-960	295	26	s.	s.	PROPN
ghmj-960	295	27	,	,	PUNCT
ghmj-960	295	28	et	et	PROPN
ghmj-960	295	29	al	al	PROPN
ghmj-960	295	30	.	.	PROPN
ghmj-960	296	1	(	(	PUNCT
ghmj-960	296	2	2022	2022	NUM
ghmj-960	296	3	)	)	PUNCT
ghmj-960	296	4	,	,	PUNCT
ghmj-960	296	5	acute	acute	ADJ
ghmj-960	296	6	urticaria	urticaria	NOUN
ghmj-960	296	7	alone	alone	ADV
ghmj-960	296	8	after	after	ADP
ghmj-960	296	9	coronavac	coronavac	NOUN
ghmj-960	296	10	covid-19	covid-19	PROPN
ghmj-960	296	11	vaccination	vaccination	NOUN
ghmj-960	296	12	should	should	AUX
ghmj-960	296	13	not	not	PART
ghmj-960	296	14	be	be	AUX
ghmj-960	296	15	a	a	DET
ghmj-960	296	16	contraindication	contraindication	NOUN
ghmj-960	296	17	for	for	ADP
ghmj-960	296	18	revaccination	revaccination	NOUN
ghmj-960	296	19	.	.	PUNCT
ghmj-960	297	1	clin	clin	PROPN
ghmj-960	297	2	exp	exp	NOUN
ghmj-960	297	3	dermatol	dermatol	NOUN
ghmj-960	297	4	,	,	PUNCT
ghmj-960	297	5	47	47	NUM
ghmj-960	297	6	:	:	PUNCT
ghmj-960	297	7	735	735	NUM
ghmj-960	297	8	-	-	SYM
ghmj-960	297	9	738	738	NUM
ghmj-960	297	10	.	.	PUNCT
ghmj-960	298	1	https://doi.org/10.1111/ced.14962	https://doi.org/10.1111/ced.14962	PROPN
ghmj-960	298	2	worm	worm	PROPN
ghmj-960	298	3	,	,	PUNCT
ghmj-960	298	4	m.	m.	NOUN
ghmj-960	298	5	,	,	PUNCT
ghmj-960	298	6	bauer	bauer	PROPN
ghmj-960	298	7	,	,	PUNCT
ghmj-960	298	8	a.	a.	PROPN
ghmj-960	298	9	,	,	PUNCT
ghmj-960	298	10	wedi	wedi	PROPN
ghmj-960	298	11	,	,	PUNCT
ghmj-960	298	12	b.	b.	PROPN
ghmj-960	298	13	,	,	PUNCT
ghmj-960	298	14	treudler	treudler	PROPN
ghmj-960	298	15	,	,	PUNCT
ghmj-960	298	16	r.	r.	PROPN
ghmj-960	298	17	,	,	PUNCT
ghmj-960	298	18	pfuetzner	pfuetzner	NOUN
ghmj-960	298	19	,	,	PUNCT
ghmj-960	298	20	w.	w.	PROPN
ghmj-960	298	21	,	,	PUNCT
ghmj-960	298	22	brockow	brockow	NOUN
ghmj-960	298	23	,	,	PUNCT
ghmj-960	298	24	k.	k.	PROPN
ghmj-960	298	25	,	,	PUNCT
ghmj-960	298	26	et	et	PROPN
ghmj-960	298	27	al	al	PROPN
ghmj-960	298	28	.	.	PROPN
ghmj-960	298	29	(	(	PUNCT
ghmj-960	298	30	2021	2021	NUM
ghmj-960	298	31	)	)	PUNCT
ghmj-960	298	32	.	.	PUNCT
ghmj-960	299	1	practical	practical	ADJ
ghmj-960	299	2	recommendations	recommendation	NOUN
ghmj-960	299	3	for	for	ADP
ghmj-960	299	4	the	the	DET
ghmj-960	299	5	allergological	allergological	ADJ
ghmj-960	299	6	risk	risk	NOUN
ghmj-960	299	7	assessment	assessment	NOUN
ghmj-960	299	8	of	of	ADP
ghmj-960	299	9	the	the	DET
ghmj-960	299	10	covid-19	covid-19	PROPN
ghmj-960	299	11	vaccination	vaccination	NOUN
ghmj-960	299	12	a	a	DET
ghmj-960	299	13	harmonized	harmonized	ADJ
ghmj-960	299	14	statement	statement	NOUN
ghmj-960	299	15	of	of	ADP
ghmj-960	299	16	allergy	allergy	NOUN
ghmj-960	299	17	centers	center	NOUN
ghmj-960	299	18	in	in	ADP
ghmj-960	299	19	germany	germany	PROPN
ghmj-960	299	20	.	.	PUNCT
ghmj-960	300	1	allergologie	allergologie	PROPN
ghmj-960	300	2	select	select	ADJ
ghmj-960	300	3	,	,	PUNCT
ghmj-960	300	4	5	5	NUM
ghmj-960	300	5	,	,	PUNCT
ghmj-960	300	6	72–76	72–76	NUM
ghmj-960	300	7	.	.	PUNCT
ghmj-960	301	1	https://doi.org/10.5414/alx02225e	https://doi.org/10.5414/alx02225e	PROPN
ghmj-960	301	2	zuberbier	zuberbier	NOUN
ghmj-960	301	3	,	,	PUNCT
ghmj-960	301	4	t.	t.	PROPN
ghmj-960	301	5	,	,	PUNCT
ghmj-960	301	6	hamzah	hamzah	PROPN
ghmj-960	301	7	,	,	PUNCT
ghmj-960	301	8	a.	a.	PROPN
ghmj-960	301	9	l.	l.	PROPN
ghmj-960	301	10	,	,	PUNCT
ghmj-960	301	11	abuzakouk	abuzakouk	PROPN
ghmj-960	301	12	,	,	PUNCT
ghmj-960	301	13	m.	m.	NOUN
ghmj-960	301	14	aquailina	aquailina	PROPN
ghmj-960	301	15	,	,	PUNCT
ghmj-960	301	16	s.	s.	PROPN
ghmj-960	301	17	,	,	PUNCT
ghmj-960	301	18	asero	asero	PROPN
ghmj-960	301	19	,	,	PUNCT
ghmj-960	301	20	r.	r.	PROPN
ghmj-960	301	21	,	,	PUNCT
ghmj-960	301	22	et	et	PROPN
ghmj-960	301	23	al	al	PROPN
ghmj-960	301	24	.	.	PROPN
ghmj-960	301	25	(	(	PUNCT
ghmj-960	301	26	2022	2022	NUM
ghmj-960	301	27	)	)	PUNCT
ghmj-960	301	28	.	.	PUNCT
ghmj-960	302	1	the	the	DET
ghmj-960	302	2	international	international	PROPN
ghmj-960	302	3	eaaci	eaaci	PROPN
ghmj-960	302	4	/	/	SYM
ghmj-960	302	5	ga²len	ga²len	PROPN
ghmj-960	302	6	/	/	SYM
ghmj-960	302	7	euroguiderm	euroguiderm	NOUN
ghmj-960	302	8	/	/	SYM
ghmj-960	302	9	apaaaci	apaaaci	NOUN
ghmj-960	302	10	guideline	guideline	NOUN
ghmj-960	302	11	for	for	ADP
ghmj-960	302	12	the	the	DET
ghmj-960	302	13	definition	definition	NOUN
ghmj-960	302	14	,	,	PUNCT
ghmj-960	302	15	classification	classification	NOUN
ghmj-960	302	16	,	,	PUNCT
ghmj-960	302	17	diagnosis	diagnosis	NOUN
ghmj-960	302	18	,	,	PUNCT
ghmj-960	302	19	and	and	CCONJ
ghmj-960	302	20	management	management	NOUN
ghmj-960	302	21	of	of	ADP
ghmj-960	302	22	urticaria	urticaria	PROPN
ghmj-960	302	23	.	.	PUNCT
ghmj-960	303	1	wileyallergy	wileyallergy	PROPN
ghmj-960	303	2	2022;77:734–766	2022;77:734–766	NUM
ghmj-960	303	3	.	.	PUNCT
ghmj-960	304	1	https://doi.org/10.1111/all.15090	https://doi.org/10.1111/all.15090	PROPN
ghmj-960	304	2	cite	cite	VERB
ghmj-960	304	3	this	this	DET
ghmj-960	304	4	article	article	NOUN
ghmj-960	304	5	as	as	ADP
ghmj-960	304	6	:	:	PUNCT
ghmj-960	304	7	nugrahaeni	nugrahaeni	ADJ
ghmj-960	304	8	,	,	PUNCT
ghmj-960	304	9	a.	a.	PROPN
ghmj-960	304	10	&	&	CCONJ
ghmj-960	304	11	budiyanti	budiyanti	PROPN
ghmj-960	304	12	,	,	PUNCT
ghmj-960	304	13	r.t	r.t	PROPN
ghmj-960	304	14	.	.	PROPN
ghmj-960	304	15	(	(	PUNCT
ghmj-960	304	16	2023	2023	NUM
ghmj-960	304	17	)	)	PUNCT
ghmj-960	304	18	.	.	PUNCT
ghmj-960	305	1	prevalence	prevalence	NOUN
ghmj-960	305	2	,	,	PUNCT
ghmj-960	305	3	pathophysiology	pathophysiology	NOUN
ghmj-960	305	4	,	,	PUNCT
ghmj-960	305	5	and	and	CCONJ
ghmj-960	305	6	treatment	treatment	NOUN
ghmj-960	305	7	of	of	ADP
ghmj-960	305	8	urticaria	urticaria	NOUN
ghmj-960	305	9	postcovid-19	postcovid-19	PROPN
ghmj-960	305	10	vaccination	vaccination	NOUN
ghmj-960	305	11	:	:	PUNCT
ghmj-960	305	12	a	a	DET
ghmj-960	305	13	systematic	systematic	ADJ
ghmj-960	305	14	review	review	NOUN
ghmj-960	305	15	.	.	PUNCT
ghmj-960	306	1	ghmj	ghmj	PROPN
ghmj-960	306	2	(	(	PUNCT
ghmj-960	306	3	global	global	ADJ
ghmj-960	306	4	health	health	PROPN
ghmj-960	306	5	management	management	NOUN
ghmj-960	306	6	journal	journal	PROPN
ghmj-960	306	7	)	)	PUNCT
ghmj-960	306	8	,	,	PUNCT
ghmj-960	306	9	6(2	6(2	NUM
ghmj-960	306	10	)	)	PUNCT
ghmj-960	306	11	.	.	PUNCT
ghmj-960	307	1	57–65	57–65	NUM
ghmj-960	307	2	https://doi.org/10.35898/ghmj-62960	https://doi.org/10.35898/ghmj-62960	PROPN
ghmj-960	307	3	https://www.sciencedirect.com/journal/clinics-in-dermatology	https://www.sciencedirect.com/journal/clinics-in-dermatology	PROPN
ghmj-960	307	4	https://www.sciencedirect.com/journal/clinics-in-dermatology/vol/39/issue/4	https://www.sciencedirect.com/journal/clinics-in-dermatology/vol/39/issue/4	PROPN
ghmj-960	307	5	https://doi.org/10.1016/j.clindermatol.2021.05.027	https://doi.org/10.1016/j.clindermatol.2021.05.027	PROPN
ghmj-960	307	6	https://doi.org/10.1016/j.jaip.2021.12.021	https://doi.org/10.1016/j.jaip.2021.12.021	PROPN
ghmj-960	307	7	https://www.sciencedirect.com/journal/clinics-in-dermatology	https://www.sciencedirect.com/journal/clinics-in-dermatology	NOUN
ghmj-960	307	8	https://www.sciencedirect.com/journal/clinics-in-dermatology/vol/39/issue/6	https://www.sciencedirect.com/journal/clinics-in-dermatology/vol/39/issue/6	ADJ
ghmj-960	307	9	https://doi.org/10.1016/j.clindermatol.2021.07.011	https://doi.org/10.1016/j.clindermatol.2021.07.011	NOUN
ghmj-960	307	10	https://www.sciencedirect.com/journal/clinics-in-dermatology	https://www.sciencedirect.com/journal/clinics-in-dermatology	NOUN
ghmj-960	307	11	https://doi.org/10.1016/j.clindermatol.2021.07.001	https://doi.org/10.1016/j.clindermatol.2021.07.001	NOUN
ghmj-960	307	12	https://doi.org/10.1111/dth.15360	https://doi.org/10.1111/dth.15360	PROPN
ghmj-960	307	13	https://doi.org/10.2500/aap.2022.43.210101	https://doi.org/10.2500/aap.2022.43.210101	PROPN
ghmj-960	307	14	https://doi.org/10.1111/dth.15223	https://doi.org/10.1111/dth.15223	PROPN
ghmj-960	307	15	https://doi.org/10.1111/jdv.17761	https://doi.org/10.1111/jdv.17761	VERB
ghmj-960	307	16	https://doi.org/10.1111/jdv.17549	https://doi.org/10.1111/jdv.17549	PROPN
ghmj-960	307	17	https://doi.org/10.1007/s40629-022-00204-x	https://doi.org/10.1007/s40629-022-00204-x	PROPN
ghmj-960	307	18	https://doi.org/10.1111/ced.14962	https://doi.org/10.1111/ced.14962	PROPN
ghmj-960	307	19	https://doi.org/10.5414/alx02225e	https://doi.org/10.5414/alx02225e	PROPN
ghmj-960	307	20	https://doi.org/10.1111/all.15090	https://doi.org/10.1111/all.15090	PROPN
ghmj-960	307	21	https://doi.org/10.35898/ghmj-62960	https://doi.org/10.35898/ghmj-62960	PROPN